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ABSTRACT 
 
 
 
Autotaxin in Central Nervous System Development and Disease 
 
By Natalie A. Wheeler 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2016 
 
Advisor: Babette Fuss, Ph.D., Professor, Department of Anatomy and 
Neurobiology 
 
During development, oligodendrocytes (OLGs), the myelinating cells of the central 
nervous system (CNS), undergo a stepwise progression during which OLG progenitors, 
specified from neural stem/progenitor cells, differentiate into fully mature myelinating 
OLGs. This progression along the OLG lineage is characterized by well-synchronized 
changes in morphology and gene expression patterns. The studies presented in this 
dissertation identified the extracellular factor Autotaxin (ATX) as a novel upstream 
signal modulating HDAC1/2 activity and gene expression in cells of the OLG lineage. 
Using the zebrafish as an in vivo model system, as well as rodent primary OLG cultures, 
this functional property of ATX was found to be mediated by its lysoPLD activity, which 
has been well-characterized to generate the lipid signaling molecule lysophosphatidic 
acid (LPA). LPA binds to Gprotein-coupled LPA receptors (LPARs) on the surface of 
OLGs to initiate downstream signaling events. ATX’s lysoPLD activity was found to 
modulate HDAC1/2 regulated gene expression during a time window coinciding with the 
transition from OLG progenitor to early differentiating OLG. When looking further 
downstream of the ATX-LPA axis, down-regulation of LPA receptor 6 (LPA6) was found 
	 	 	
		
	 	 				xi		
to reduce the expression of OLG differentiation genes as well as the overall process 
network area of OLGs. Thus, LPA6 plays a role in both the gene expression and 
morphology changes seen in OLG differentiation. These findings prove useful for future 
therapeutic targets needed for demyelinating diseases of the CNS such as Multiple 
Sclerosis (MS), in which OLGs fail to differentiate into mature OLGs, needed for 
remyelination.  
Additionally, white matter injury has been frequently reported in HIV+ patients. 
Previous studies showed that HIV-1 Tat (transactivator of transcription), a viral protein 
that is produced and secreted by HIV-infected cells, is a toxic factor to OLGs. We show 
here that Tat treatment reduces the expression of OLG differentiation genes and the 
overall process network area of OLGs. Additionally, Tat-treated OLGs have reduced 
ATX lysoPLD activity and there is a physical interaction between Tat and ATX. 
Together, these data strongly suggest functional implications of Tat blocking ATX’s 
lysoPLD activities and thus the ATX-LPA signaling axis proves to play a significant role 
in the development of OLGs. 
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CHAPTER 1 
 
Introduction to Myelin, Oligodendrocytes and Influential factors 
 
Myelin and its functional significance 
 
Communication throughout the brain relies on electrical signals between 
neurons. Just as wires need insulation, neurons require the lipid rich multilamellar 
myelin membrane for proper conduction. The highly insulated myelin membrane 
provides support for brain conductivity and can be considered a defining characteristic 
of vertebrates, though myelin-like sheaths have been found in invertebrates. 
Oligodendrocytes (OLGs) and Schwann cells are the cells responsible for producing 
myelin in the central nervous system (CNS) and peripheral nervous system (PNS), 
respectively.  
To ensure electrical signals are maintained and transmitted throughout the body, 
ions pass through axons at areas of myelin gaps or so called “nodes of Ranvier.” This 
passage of ions helps to retain electrical signals, as they appear to “jump” from one 
node to another, and is therefore termed, saltatory conduction (Baumann and Pham-
Dinh, 2001). Evolutionarily, myelin was one of the later structures of the nervous system 
to evolve (Baumann and Pham-Dinh, 2001; Hartline and Colman, 2007). As animals 
developed more sophisticated behaviors, the ability to act fast to capture or escape prey 
was needed and rapid conductance of nerve impulses became a high priority for the 
nervous systems of animals (Hartline and Colman, 2007). To allow for increased speed 
of conductance, larger axons could be used to decrease the overall resistance of the 
electrical signal and allow for faster conduction. This proves to be an impractical 
solution for mammals, however, as the conduction speed needed would result in a large 
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distribution of nerve fibers that would be disproportionate to their body size. The myelin 
membrane proved to circumvent this problem by allowing insulation to the axons, 
thereby increasing the resistance of the electrical field (Hartline and Colman, 2007). The 
myelin membrane serves as an integral part of the nervous system. Additionally, not 
only does myelin act as an insulator of axons, it is now known that myelin also provides 
axonal support (Saab et al., 2013). This idea becomes important when considering the 
consequences of myelin loss on axons in pathology. The significance of myelin 
becomes increasingly evident in pathological conditions where the myelin membrane is 
disrupted, such as in the demyelinating disease Multiple Sclerosis (MS).  
Multiple Sclerosis (MS) 
Multiple Sclerosis (MS) is the most common demyelinating disease, for which 
there is no present cure, and is usually seen in patients ranging from 20 to 50 years old, 
although it has been reported in individuals as young as 2 and as old as 75. Currently, 
there are approximately 2.3 million people worldwide affected by MS (Multiple Sclerosis 
Society, 2016). MS proves to be the leading cause of non-traumatic disability with 
symptoms encompassing vision loss, pain, fatigue, cognitive dysfunction and impaired 
coordination (Fox et al., 2006). Both the diagnosis and treatment of MS is difficult as the 
symptoms, severity and duration of MS can vary from person to person.  
It is not clear as to the cause of MS, however, both genetic and environmental 
factors have been argued to play a role in the development of the disease (Hauser and 
Oksenberg, 2006). One of the environmental factors that may contribute to the disease 
is a deficiency in vitamin D, which is produced when the body is exposed to natural 
sunlight. The idea of a vitamin D deficiency in relation to MS was initially theorized when 
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an epidemiological study showed that MS cases tend to occur less frequently in 
populations of people living closer to the equator. This goes along with the idea that by 
living closer to the equator, a person would have more sun exposure and thus would 
make more vitamin D than those living farther away from the equator (Freedman et al., 
2000; Raghuwanshi et al., 2008).  
The genetic prolife of MS remains unknown and has not been strictly linked to 
heredity. Those who have a first-degree relative (parent or sibling) with MS, however, 
are more at risk of developing MS than the general population. Researchers have also 
speculated that individuals can be born with a genetic predisposition that makes them 
more sensitive to environmental agents that can cause the disease (Multiple Sclerosis 
Society, 2016). Genome-wide association studies have identified over a hundred 
polymorphisms with modest individual effects in MS susceptibility and confirmed the 
main individual effect of the Major Histocompatibility Complex (Burrell et al., 2011; 
Hoppenbrouwers and Hintzen, 2011). Additional immunological relevant genes were 
found significantly overexpressed (Gutierrez-Arcelus et al., 2016). These studies, 
however, involve patients diagnosed with MS and as such use blood or cerebrospinal 
fluid (CSF), thus, the result obtained cannot be used to address any potential genetic 
associations with parenchymal gene expression. Nonetheless, it is generally accepted 
that the genetic contribution to MS susceptibility remains to be defined. Additionally, 
there are certain risk factors including age, sex, race, smoking, infections, etc., that 
have been linked to MS (Mayo Clinic, 2016). Though the exact cause of MS is 
unknown, it is plausible that responsibility lies on the combination of genetic and 
environmental risk factors.  
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There are four main clinically defined forms of MS that can be classified as: 
relapsing remitting, primary progressive, secondary progressive and progressive-
relapsing. RRMS is the most common form as 85% of patients start with this disease 
course. Patients with RRMS have periods of MS “attacks,” called relapses, followed by 
partial or complete recovery periods, known as remission. During remission, patients 
display improved symptoms with no apparent progression of the disease. Interestingly, 
patients suffering from RRMS have more brain lesions (plaques or scars) containing 
inflammatory cells. As time progresses, patients with RRMS may transition to secondary 
progressive MS (SPMS) (Multiple Sclerosis Society, 2016).  Another form of MS, 
primary progressive MS (PPMS) is seen in roughly 10-15% of patients. PPMS is 
characterized by a steady, but gradual, worsening of neurologic functioning, without any 
distinct relapses or periods of recovery. People with PPMS tend to have more spinal 
cord lesions than cortical lesions (Multiple Sclerosis Society, 2016). Lastly the rarest 
form of MS is progressive relapsing (PRMS), with only 5% occurrence in the population. 
PRMS is characterized by a steady worsening disease course from onset with 
additional attacks of more severe neurological symptoms. Some PRMS patients 
experience times of remission, although this is not true for all patients (Multiple 
Sclerosis Society, 2016). Due to the capricious symptoms, severity and progression of 
MS, it is sometimes difficult to classify as well as treat patients with MS.  
As MS is classified as an autoimmune disease, current therapies target the 
inflammation side of the disease. These therapies, however, fail to treat the loss of 
myelin or any axonal damage caused by the disease. Though these treatments help 
patients short term, remyelination by OLGs and axonal repair is needed to correctly 
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cure the disease. In this therapeutic paradigm, remyelination of axons, by OLGs, will 
reinstate the proper neural circuitry needed for normal brain activity. Interestingly, OLG 
progenitor cells (OPCs) are found in MS lesions, however, they are limited in their ability 
to remyelinate or remyelinate sufficiently (Bradl and Lassmann, 2010; Chang et al., 
2002a; Goldschmidt et al., 2009). Therefore, with the notion that regeneration of the 
myelin sheath follows the same mechanisms present during development, obtaining a 
better understanding of OLG development from a progenitor cell to a fully myelinating 
cell is integral to target specific mechanisms that are altered in demyelinated conditions.  
Oligodendrocyte specification in the Central Nervous System (CNS)  
OLGs were originally discovered by Rio Hortega in 1921 (Iglesias-Rozas and 
Garrosa, 2012). Though the cellular origins of this myelinating cell in the brain and 
spinal cord have been debated, research advances using transgenic mouse models 
have given us insight into OLG specification (Richardson et al., 2006). CNS cell 
initiation and proliferation develops within distinct layers and zones, of neuroectodermal 
origin, where each zone comprises distinct cell types and morphologies (Brazel et al., 
2003; Marshall et al., 2003; Pringle et al., 1996; Richardson et al., 2006; Woodruff et al., 
2001). The ventricular zone of the brain is the first to develop and houses the origin of 
neurons, as well as some astrocytes. This zone is made of pseudostratified epithelial-
like tissue consisting of neuroectodermal tissue (Kettenmann and Ransom, 2013). As 
development progresses, a new proliferative area, the subventricular zone, begins to 
thicken and remains actively proliferative during early postnatal development (Brazel et 
al., 2003). Cortical progenitor cells follow a developmental sequence in which cell types 
develop in temporally distinct, yet overlapping patterns beginning with neuronal 
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development, followed by astrocyte development, and lastly OLG development 
(Sauvageot and Stiles, 2002; Spassky et al., 1998, 2000). 
 During development, OPCs are generated in sequential waves from specific 
germinal regions. OPCs arise from the ventricular zone of the spinal cord and the 
ventral forebrain of the developing brain (Baracskay et al., 2007; Brazel et al., 2003; 
Kettenmann and Ransom, 2013; Levison et al., 1993; Marshall et al., 2003; Privat and 
Leblond, 1972) (Kessaris et al., 2006). Research conducted in the rat elucidated that 
there are multiple areas along the ventral and dorsal axes of the spinal cord that 
produce OLGs and that OLGs originate in subventral regions and later move to more 
dorsal regions. Starting around E12.5, the pMN (motor neuron progenitor) domain of the 
spinal cord produces 85-90% of the OPCs (Miller, 1996; Pringle and Richardson, 1993; 
Pringle et al., 1996; Richardson et al., 1988, 2006; Woodruff et al., 2001). This is 
followed by a second wave of OPC genesis emanating from more dorsal progenitor 
domains starting at E15.5 (Cai et al., 2005a; Fogarty et al., 2005). Dorsally-derived 
progenitors only contribute 10-15% of adult OLGs.  
 In the developing forebrain, OPCs also migrate in a series of waves. At about 
E12.5 in mice (E5-6 in chicks), the initial wave of OPC production unfolds in the medial 
ganglionic eminence and the closely associated enteropeduncular area of the ventral 
telencephalon (Olivier et al., 2001; Spassky et al., 2001; Tekki-Kessaris et al., 2001). 
These ventrally-derived OPCs then migrate into the cortex (Kessaris et al., 2006; 
Richardson et al., 2006) and can be observed throughout the cortex around E18 
(Kessaris et al., 2006; Richardson et al., 2006; Woodruff et al., 2001). The second and 
third wave of OPCs emanating from the lateral and caudal ganglionic eminences, at 
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E15.5 and from the cortex after birth, give rise to the majority of adult OLGs in mice 
(Brazel et al., 2003; Kessaris et al., 2006; Richardson et al., 2006; Woodruff et al., 
2001). Additionally, OLGs origin in the brain surfaces in the medial and lateral 
ganglionic eminences, which are considered to be transient and only appear present 
during embryonic development (Brazel et al., 2003; de Castro and Bribián, 2005; 
Kessaris et al., 2006; Richardson et al., 2006; Woodruff et al., 2001). Though some 
differences are seen, the overall spatiotemporal specification of OLGs originate in the 
ventral regions of the brain and spinal cord, and as development continues, these cells 
migrate in a radial dorsolateral migration pattern (Cai et al., 2005b; Emery, 2010; 
Fogarty et al., 2005; Richardson et al., 2006; Vallstedt et al., 2005). Specification of 
OPCs is highly regulated and requires the expression of essential transcription factors. 
Sox9 and Olig2 are two early transcription factors that are necessary for specification 
into the OLG lineage (Ben-Hur et al., 2003; Stolt et al., 2003; Zhou and Anderson, 
2002). Olig2 then induces the expression of Sox10, Nkx2.2, and platelet-derived growth 
factor (PDGFR)-alpha (Cai et al., 2005b; Liu et al., 2007; Vallstedt et al., 2005; Zhou et 
al., 2001). 
 OLG specification, development and myelination in the zebrafish share many 
similarities with the mammalian system (Buckley et al., 2008; Czopka, 2016; Preston 
and Macklin, 2015; Sidik and Talbot, 2015). The development of the transient, 
embryonic midline structure, the notochord, is essential for OLG specification in the 
spinal cord (Stemple, 2005). The notochord is required for the formation of the dorsal-
ventral axis of the overlying neural tube, which includes the specification of the floor 
plate, the ventral-most portion of the spinal cord (Dodd et al., 1998; Placzek and 
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Briscoe, 2005; van Straaten and Hekking, 1991; van Straaten et al., 1989). OPCs are 
generated adjacent to the floor plate in the same location that gives rise to motor 
neurons, named the motor neuron progenitor domain (Noll and Miller, 1993; Pringle and 
Richardson, 1993; Warf et al., 1991; Yu et al., 1994) and specification of OPCs begins 
when motor neuron production has ended (Park et al., 2004; Zhou and Anderson, 
2002). 
Oligodendrocyte development  
 OLG differentiation is an essential part of overall OLG development, with the 
notion that many progenitor cells are present at lesion sites in MS, but fail to properly 
differentiate and develop further along the lineage (Kuhlmann et al., 2008a). This crucial 
step is highlighted throughout my dissertation, as it is the main focus of my studies 
regarding overall OLG development. OLG development can be characterized by four 
different stages identified by both the expression of specific cell markers (surface 
antigens, transcription factors, etc.) as well as changes in cellular morphology 
(Baumann and Pham-Dinh, 2001; Bradl and Lassmann, 2010; Pfeiffer et al., 1993). 
These markers display specific functions and are needed for proper development along 
the lineage (Fig.1.1) 
 Early stages of OLG development can be recognized by the presence of certain 
genes, cell surface gangliosides, as well as mitogens. Both Olig2 and Sox10 are 
expressed early in OLG development and remain expressed throughout the lineage in 
rodents (Liu et al., 2007). In addition to these early markers, in the rodent model 
system, the antibody A2B5 can be used to identify cell surface gangliosides found on 
OPCs. The lipids recognized by A2B5 are down-regulated as the cell differentiates into 
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a more mature OLG (Baracskay et al., 2007; Baumann and Pham-Dinh, 2001; Bradl 
and Lassmann, 2010; Pfeiffer et al., 1993; Raff et al., 1983, 1984). In the early stages of 
OLG development, mitogens, specifically platelet-derived growth factor (PDGF) and 
basic fibroblast growth factor (bFGF), are present in order to increase cell survival, aid 
in cell migration and proliferation, and prevent cell differentiation (Fok-Seang and Miller, 
1994; Gard and Pfeiffer, 1993; Hart et al., 1989a, 1989b; Pringle and Richardson, 1993; 
Richardson et al., 1988). Platelet derived growth factor receptor alpha (PDGFRα) is 
specifically expressed in immature OPCs, but its expression is rapidly extinguished as 
OPCs undergo terminal differentiation (Gard and Pfeiffer, 1993; Pringle and Richardson, 
1993; Richardson et al., 1988).  
 As OLG development progresses, there is a decline in mitogenic factors and 
OLGs are instead introduced to the differentiating factor thyroid hormone (TH). Both the 
removal of mitogens and TH are necessary for OPC differentiation (Barres et al., 1994; 
Franco et al., 2008). At this stage, OLGs start to display a multipolar morphology that 
can be identified by the mouse monoclonal antibody O4, which binds to an 
uncharacterized surface antigen (POA) and sulfatide (Bansal et al., 1989, 1992). Cnp, 
Ugt8, Mbp and Plp are induced immediately after mitogen withdrawal and TH exposure 
(Dugas et al., 2006). CNP (2',3'-cyclic nucleotide 3'-phosphodiesterase) activity appears 
to be one of the earliest events in OLG differentiation and thought to play a critical role 
in the events leading to myelination. It has also been seen in uncompact myelin in the 
paranodal loops (Nave and Trapp, 2008; Wells and Sprinkle, 1981). When CNP is 
overexpressed in mice, premature and abnormal myelination is observed and when 
overexpressed in vitro, it promotes process outgrowth (Lee et al., 2005; Nave and 
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Trapp, 2008). Cnp1 null mutant mice, although fully myelinated, develop progressive 
axonopathy and die prematurely (Edgar et al., 2009; Lappe-Siefke et al., 2003), thereby 
suggesting its role in axonal support. UGT8 (UDP- galactose ceramide 
galactosyltransferase 8) is an endoplasmic reticulum-localized enzyme (Kapitonov and 
Yu, 1997; Schulte and Stoffel, 1993; Sprong et al., 1998) that is responsible for the 
synthesis of galactosylceramide, the major glycosphingolipid of myelin produced by 
OLGs (Marcus and Popko, 2002). A knock-out (KO) mouse model lacking UGT8 
revealed that galactosylceramide, together with sulfatide, is involved in myelin function 
and stability, but not in myelin biogenesis (Bosio et al., 1996; Coetzee et al., 1996; 
Dupree et al., 1999).   
 Two extensively studied myelin genes that encode major myelin protein 
components in the CNS are Mbp (myelin basic protein) and Plp (proteolipid protein). 
Membrane associated MBP is abundant in myelin, representing 30% of the total myelin 
protein and is significantly involved in the compaction and binding of opposing 
cytoplasmic myelin membranes (Readhead et al., 1990). In the shiverer mouse line, in 
which MBP is absent, hypomyelination and the formation of uncompact myelin is 
apparent in the CNS (Readhead and Hood, 1990; Readhead et al., 1990; Shine et al., 
1990), therefore solidifying its significance in the generation of myelin. PLP, a 4-pass 
transmembrane protein, is thought to mediate adhesion between the outer membranes 
of the myelin sheath (Baumann and Pham-Dinh, 2001; Popot et al., 1991). Interestingly, 
PLP has a splice variant with the name DM20 (Campagnoni, 1988; Nave and Trapp, 
2008; Timsit et al., 1995) that is expressed earlier in OLG development and is later 
followed by the expression of PLP (Timsit et al., 1995). Mice harboring the jimpy 
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mutation, the first Plp mutation identified, express a reduction in OLGs and display thin 
myelin, ultimately leading to premature death (Duncan et al., 1989; Knapp et al., 1986). 
The phenotypic response seen in the jimpy mice is a result of protein misfolding in the 
mutant PLP (Griffiths et al., 1998a, 1998b). Conversely, and similar to what is seen in 
Cnp1 null mutant mice, Plp1-null mice, in which the Plp1 gene is inactivated, show no 
signs of OLG or myelin loss, however, older age mutant mice develop progressive 
axonopathy throughout the CNS, with transport defects, swellings and widespread 
axonal degeneration. Since the prominent axonal transport defects in Plp1 null mutant 
mice (Edgar et al., 2004) resemble those observed in mitochondrial disorders 
(Ferreirinha et al., 2004; Tarrade et al., 2006), it is suggested that OLGs require PLP to 
support the axonal energy metabolism.  
OLG development in the zebrafish  
 As seen in the mammalian system, gene regulation plays a large role in the timely 
development and differentiation of OLGs. To start, olig1 and olig2 are expressed in cells 
of the motor neuron domain, containing both OPCs and motor neurons (Zhou and 
Anderson, 2002; Zhou et al., 2001). It has been shown, in both mice and zebrafish, that 
olig2 is necessary for the specification of both motor neurons and OLGs (Park et al., 
2002; Takebayashi et al., 2002; Zhou and Anderson, 2002). Additionally, olig1 
expression in the zebrafish is important in OLG differentiation and can activate MBP 
transcription as seen in the mouse (Li et al., 2007; Xin et al., 2005). Near the end of 
embryogenesis and during postnatal stages, many OPCs stop dividing and differentiate 
to become mature myelinating cells, whereas others persist as nonmyelinating cells. 
The expression of nkx2.2a (NK2 transcription factor 2a) was found to be a prominent 
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factor in this fate determining step as OPCs that express nkx2.2a were found to 
differentiate as OLGs, whereas those that did not express the gene mostly remained 
nonmyelinating OPCs (Kucenas et al., 2008). Thus, nkx2.2a promotes the specification 
and differentiation of a myelinating subset of OLG lineage cells (Kucenas et al., 2008). 
  In order for differentiation of OLGs to occur in the zebrafish, the expression of 
genes such as cldnk (claudink) and plp1b (proteolipid protein) are needed. Genechip 
analysis studies revealed cldnk and plp1b to be among 119 genes predicted to be 
expressed at elevated levels in differentiating OLGs (Takada and Appel, 2010). 
Additionally, microarray screen analysis studies indicated that these genes are highly 
elevated in mature OLGs (Chung et al., 2011). Thus, both genes prove important in the 
crucial differentiation stage of OLG development, and remain expressed into mature 
stages. The relevance of cldnk in OLG maturation can be inferred as it encodes a 
protein that is a member of a family of tight junction components and is expressed 
specifically in OLGs and Schwann cells associated with the lateral line (Takada and 
Appel, 2010). Likewise, plp1b encodes proteolipid protein 1b, whose importance has 
been extensively studied in the mammalian system with regards to OLG development 
and myelination. In addition to these genes, mbp and p0 appear later in OLG 
development showing initial expression at 48hpf in cells of the ventral medial hindbrain 
and at 72hpf in cells of the spinal cord (Brösamle and Halpern, 2002; Buckley et al., 
2010). The overall functions of the above stated genes have not been thoroughly 
studied in the zebrafish, however, conservation of their predicted protein sequences 
with those of the mammalian sequences and their overall expression patterns make it 
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likely to predict they serve similar functions (Brösamle and Halpern, 2002; Buckley et 
al., 2008, 2010).  
All together, in both mammalian and zebrafish systems there are many steps 
along the developmental pathway of OLGs. The timing of gene expression and 
extracellular factors alike contribute to the precise maturation of these cells. It is crucial 
that the mechanisms behind each stage of development be understood to the highest 
degree, so that progenitor cell maturation can be obtained. As previously discussed, 
OPCs are present and recruited to MS lesions initially, however, they become depleted 
over time and fail to develop into mature cells (Kuhlmann et al., 2008b). The limitations 
of remyelination seen in MS lesions suggests that though myelination is possible, OPCs 
need to be stimulated in order to become fully myelinating cells and this action must 
remain consistent. One molecule known to stimulate OLG differentiation is the 
extracellular protein, Autotaxin (ATX) (Dennis et al., 2005, 2008; Fox et al., 2003; Fuss 
et al., 1997; Nogaroli et al., 2009a; Yuelling and Fuss, 2008; Yuelling et al., 2012). Its 
importance in MS became increasing interesting when ATX expression was found 
reduced in MS lesions (Comabella and Martin, 2007). Thus, further investigation of this 
extracellular protein in OLG development could pave the way towards potential targets 
for MS treatment. 
Autotaxin 
 
 Autotaxin (ATX), also known as ecto-nucleotide 
pyrophoshatase/phosphodiesterase (ENPP)2, was first introduced as a cell motility-
stimulating factor in human melanoma cells (Stracke et al., 1992), and has since been 
extensively studied in different areas of research. Though initially ATX did not exhibit 
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any significant homologies to characterized motility and growth factors, ATX was found 
to contain a domain that displayed high homology with the enzymatically active domain 
of proteins known to possess nucleotide phosphodiesterase and pyrophosphatase 
activity (Buckley et al., 1990; Culp and Butler, 1985; van Driel and Goding, 1987; 
Murata et al., 1994). It was later discovered, through recombinant forms of ATX, that the 
catalytic domain of ATX is crucial for motility stimulation (Lee et al., 1996). This 
enzymatic activity led to the inclusion of ATX into the family of nucleotide 
pyrophosphatase/phosphodiesterase (NPP)-type ectophosphodiesterases and was 
additionally termed (E)NPP2 (Bollen et al., 2000; Goding et al., 2003; Stefan et al., 
2005). The idea that ATX possessed enzymatic activity prompted the finding that all 
(E)NPPs hydrolyze both pyrophosphate and phosphodiester bonds present in 
nucleotides and their derivatives (Bollen et al., 2000). Although at the time the 
physiological substrates of (E)NPPs remained unidentified, it was later uncovered that, 
though structurally related, (E)NPPs differ in their enzymatic substrate specificities 
(Cimpean et al., 2004; Gijsbers et al., 2001; Stefan et al., 2005). A turning point in 
research related to ATX later revealed that ATX’s enzymatic activity catalyzed the 
conversion of extracellular lysophosphatidylcholine (LPC) to the lipid mediator, 
lysophosphatidic acid (LPA), and displayed molecular identity to the extracellular 
lysoPLD (Ferry et al., 2003; Tokumura et al., 2002; Umezu-Goto et al., 2002; Xie and 
Meier, 2004). Moreover, the affinity for ATX towards LPC was significantly greater than 
its affinity towards nucleotides (Tokumura et al., 2002; Umezu-Goto et al., 2002). 
Currently, the phosphodiesterase activity of ATX is considered unlikely (Gijsbers et al., 
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2003; van Meeteren et al., 2006). The lysoPLD properties of ATX remain the focus of 
my research with regard to the effects of ATX on OLG differentiation in the CNS. 
 ATX is synthesized as a pre-pro-enzyme and, after N-glycosylation and 
proteolytic maturation, is secreted as an active lysoPLD along the classical secretory 
route (Jansen et al., 2005; Koike et al., 2006). Additionally, ATX is seen present in the 
circulation where it accounts for maintaining plasma LPA levels. This circulating ATX 
has a short half-life as it is rapidly cleared by the liver (Jansen et al., 2009). The brain 
displays relatively high expression levels of ATX, especially in the choroid plexus, along 
with the spinal cord, ovary, lung, intestines, kidney and lymphoid organs, and CSF 
(Kanda et al., 2008; Koike et al., 2010; van Meeteren et al., 2006; Nakamura et al., 
2009; Nakasaki et al., 2008; Tanaka et al., 2006). Currently, three splice 
variants/isoforms of ATX have been identified in both human and mouse, referred to as 
ATX α, β, and γ, that do not seem to display any major functional isoform differences, 
although show characteristic expression patterns (Fuss et al., 1997; Giganti et al., 2008; 
Lee et al., 1996).  
It wasn’t until the creation of ATX knockout (KO) mice (Enpp2-/-mutants) that the 
physiological importance of ATX was revealed. Enpp2-/- mice displayed embryonic 
lethality (E9.5–E11.5) due to prominent vasculature and neural tube defects (van 
Meeteren et al., 2006; Tanaka et al., 2006). Intriguingly, mice expressing ATX with 
inactivated lysoPLD activity displayed the same embryonic lethality that was previously 
observed in Enpp2-/- mice (Ferry et al., 2007). Heterozygote Enpp2-/+ mice survived until 
adulthood and, interestingly, revealed to have LPA plasma levels that were half that of 
wild-type mice; thus confirming the notion that ATX activity is the major source of LPA in 
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plasma. Accordingly, the ATX-LPA signaling axis is essential for the formation of the 
vasculature and neural tube and proper embryonic development, though these effects 
may be secondary to the vasculature effects.  
ATX: enzymatic activity via the catalytic lysoPLD active site 
 
The cell motility effect of ATX was originally thought to be due to ATX’s reported 
function as a nucleotide phosphodiesterase (Bollen et al., 2000), however, it later 
became clear that the cell motility-stimulating activity of ATX is mediated, at least in 
part, via the production of LPA and its action on its respective LPA receptors (Hama et 
al., 2004; Lee et al., 1996; Okudaira et al., 2010). ATX's NPP activity was known to be 
dependent on a single threonine residue located within the enzymatic active site (Clair 
et al., 1997), which was ultimately found to be the same residue critical for ATX’s 
lysoPLD activity (Gijsbers et al., 2003; Koh et al., 2003). In addition to the threonine 
residue, it was revealed that the lysoPLD activity was also stringent upon sequences 
within the N- and C-terminal domains of ATX, a finding unique to ATX (Cimpean et al., 
2004; Gijsbers et al., 2003; Stefan et al., 2005). Since these initial findings, a number of 
studies have set forth to further characterize the functions of ATX’s lysoPLD active site. 
ATX’s enzymatic lysoPLD activity has been shown to play a large role in 
biological processes related to development, as well as those in pathological conditions. 
The best-known cellular responses to LPA include the stimulation of cell migration, 
proliferation, and survival, although inhibitory responses have also been implicated 
(Jongsma et al., 2011; Oda et al., 2013). The ATX-LPA signaling axis has been 
implicated in a variety of physiological and pathological processes, including lymphocyte 
homing, pulmonary fibrosis, neuropathic pain, cardiovascular disease, cholestatic 
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pruritus, tumor progression, Alzheimer's disease, chronic Hepatitis C, obesity and 
rheumatoid arthritis, and as outlined in this dissertation, Multiple Sclerosis (Bai et al., 
2013; Boucher et al., 2005; Ferry et al., 2003; Hammack et al., 2004; Inoue et al., 2011, 
2004, 2008a, 2008b; Kanda et al., 2008; Kremer et al., 2010; Oikonomou et al., 2012; 
Santos et al., 1996; Smyth et al., 2014; Tager et al., 2008; Watanabe et al., 2007a, 
2007b; Zhang et al., 2012; Zhao et al., 2008). Importantly, LPA has also been described 
to be a regulator of epigenetic modifications, specifically histone deacetylase (HDAC) 
regulation, at least in cancer cell lines (Ishdorj et al., 2008). In an attempt to link ATX’s 
lysoPLD activity with the known epigenetic changes seen throughout OLG 
development, I investigated the gene regulatory mechanisms controlled by ATX’s 
lysoPLD activity during OLG differentiation.  
Epigenetic Regulation in OLG Development  
Epigenetics refers to the study of changes in gene expression, that may or may 
not be heritable, without changing the sequence of DNA. Epigenetic modifications 
include DNA methylation, post-translational modification of histone tails, nucleosomal 
remodeling, and modifications by small non-coding RNAs (Berger, 2007; Goldberg et 
al., 2007). Post-translational modifications include acetylation/deacetylation, methylation 
(Shilatifard, 2006), phosphorylation of serine and threonine residues (Dyson et al., 
2005), sumoylation (Iñiguez-Lluhí, 2006), ubiquitination of lysine residues(Shilatifard, 
2006; Weake and Workman, 2008), and citrullination of arginine residues (Mastronardi 
et al., 2006), as well as ADP- ribosylation and isomerization of prolines (Kouzarides, 
2007). These modifications make up the “histone code” that is cell-type specific. A 
dynamic balance of these modifications dictates the transcriptional state of chromatin, 
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as some histone changes confer a more open and transcriptionally competent state and 
others silence gene activation by chromatin compaction.  
Epigenetic regulation of gene expression during OLG development has recently 
been recognized as a fundamental contributing player in (re)myelination. It is anticipated 
that insights into the epigenetic regulation of myelin formation and repair will provide 
novel targets for therapeutic intervention (Copray et al., 2009). OLGs need to go 
through several steps of development before ultimately producing myelin. A large 
network of transcriptional activators and repressors are known to control each stage 
(Miller, 2002; Wegner, 2008). With regard to differentiation, Olig1, Olig2, Sox10 and 
more recently myelin gene regulatory factor (Myrf) are needed in order to terminally 
differentiate and activate myelin protein expression (Ben-Hur et al., 2003; Emery et al., 
2009; Liu et al., 2007; Stolt et al., 2002; Xin et al., 2005). In addition, inhibitors of OLG 
differentiation are needed in order to fine-tune this transcriptional network and prevent 
precocious differentiation. These inhibitors include Hes5 (Kondo and Raff, 2000a; Liu et 
al., 2006), Sox11 and Tcf4 (He et al., 2007a), and Id2 and Id4 (Kondo and Raff, 2000b; 
Marin-Husstege et al., 2002; Samanta and Kessler, 2004). Selective expression or 
silencing of genes at each stage of OLG development is ultimately controlled by 
epigenetic regulatory mechanisms, which determine the accessibility of the 
transcriptional machinery to the chromosomal territories containing the specific genes 
(Copray et al., 2009). 
Though increasing evidence points to the substantial role for HDACs in OLG 
development, which will be further elucidated, methylation serves to play a fascinating 
role as well. Histone methyltransferases (HMTases) are histone-modifying enzymes that 
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catalyze the transfer of methyl groups to lysine and arginine residues. Distinct enzymes 
mediate methylation of specific residues. A prominent HMTase that catalyzes histone 
H3 lysine 27 trimethylation (H3K27me3) is enhancer of zeste homologue 2 (Ezh2). It 
has been shown that methylation at H3K27 by Ezh2 plays a role in the specification of 
the OLG lineage. Ezh2 is completely down-regulated during specification towards 
neurons and astrocytes allowing transcription of these programs (Sher et al., 2012). 
Ezh2 expression is present in the early proliferating OPCs up to the stage of 
premyelinating OLGs. Ezh2 expression is down-regulated, however, in mature OLGs at 
the onset of myelination  
Introduction to HATs and HDACs 
One of the best-characterized histone modifications that modulate OLG 
development is the equilibrium between histone acetylation and deacetylation (Copray 
et al., 2009). Histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
finely tune cellular acetylation, targeting not only histones, but also numerous proteins 
with key roles in cell metabolism, signaling and death (Kazantsev and Thompson, 2008; 
Langley et al., 2005; Saha and Pahan, 2006). HATs provide for acetylation of the 
conserved N-terminal histone tails, resulting in relaxation of the nucleosomes by 
decreasing the interaction of the positively charged histone tails with the negatively 
charged phosphate backbone of DNA. HATs have been shown to play an important role 
in neural stem cell differentiation (Asklund et al., 2004; Hsieh et al., 2004; Song and 
Ghosh, 2004), however, the role of HATs in OLG differentiation is less pronounced. In 
fact, deacetylation by HDACs has been shown to play a more critical role in the 
progression of progenitor cells toward the OLG lineage. 
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In most cases, HDACs remove the acetyl groups from histone lysine residues 
favoring condensed chromatin that prevents access of transcriptional activators to their 
target sites and results in transcriptional repression. The mammalian members of the 
HDAC family are, based on their structures, subdivided into four main classes: Class I 
(HDAC1, 2, 3, and 8), Class II (HDAC4, 5, 6, 7, 9, and 10), Class III (SIRT1-7) and 
Class IV (HDAC11). The classical, class I, II and IV, HDACs are structurally related and 
need the presence of Zn+2 to be active (de Ruijter et al., 2003), whereas class III 
HDACs, the sirtuins, are a group of enzymes dependent on NAD+ and are structurally 
unrelated to the classical HDACs (Michan and Sinclair, 2007).  
OLG specification is unique in that it is initiated by a global histone deacetylation 
program. During the early stages of OLG specification, HDACs mediate the suppression 
of alternative lineages and, later in development, regulate the repression of inhibitors of 
myelin specific genes. HDAC inhibition by trichostatin A (TSA) in neural stem cells 
favors the neuronal fate, while inhibiting specification into OPCs. The loss of HDACs 
also reprograms OPCs into neural stem-like cells capable of neurogenesis (Aixiao Liu, 
2007; Kondo and Raff, 2004; Lyssiotis et al., 2007a). More specifically, HDACs block 
critical transcription factors of alternative lineages such as the stem cell marker Sox2 
(Lyssiotis et al., 2007a; Shen and Casaccia-Bonnefil, 2008). Taken together, HDAC 
inhibition results in the reactivation of other genes that mark the stem cell state, along 
with the silencing of OLG lineage-specific genes (Lyssiotis et al., 2007b). The 
importance of histone deacetylation in determining the direction of neural stem cell 
specification is further supported by evidence in which HDAC inhibitors cause a 
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noticeable reduction in OPCs on the account of a larger population of astrocytes and 
neurons (Aixiao Liu, 2007; He et al., 2007a; Siebzehnrubl et al., 2007; Ye et al., 2009).  
Once specification has taken place, HDACs continue to serve a crucial role in the 
differentiation stage of OLG development. The timely differentiation of progenitor cells is 
indispensable for development. With that in mind, investigators demonstrated 
deacetylation of histone H3 is a critical mechanism for myelination onset in vivo as it is 
required for the down-regulation of differentiation inhibitors and early progenitor 
markers. During the first 10 postnatal days in rats, administration of valproic acid (VPA, 
a Class I HDAC inhibitor) resulted in significant hypomyelination, while administration of 
VPA after onset of myelination had no effect on myelin gene expression. During the 
time after the onset of myelination, a more stable repression of the transcriptional 
inhibitors of the myelin genes is carried out by methylation at H3K9 (Shen and 
Casaccia-Bonnefil, 2008). This methylation is coupled with increased association of 
HP1, a protein that directs chromatin compaction by binding to adjacent H3K9 sites. 
These results thereby indicate that histone deacetylation is the molecular link of the 
transition between cell cycle exit and differentiation onset (Shen and Casaccia-Bonnefil, 
2008). Additionally, pharmacological inhibitors of HDACs increase histone acetylation 
and prevent differentiation of OLG progenitors in vitro (Hsieh et al., 2004; Marin-
Husstege et al., 2002) and in vivo (Aixiao Liu, 2007; Shen et al., 2005). Accordingly, in 
the rodent model, HDACs prove to be necessary for OLG development, not only for 
OPC specification, but also for differentiation.   
As just described, HDAC inhibition is correlated with the induction of Sox2 and 
increased neurogenic capacity from treated OPCs (Kondo and Raff, 2004; Lyssiotis et 
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al., 2007a). Unlike rodent OPCs, however, acutely isolated human OPCs express both 
Sox2 protein and mRNA (Sim et al., 2011) and are neurogenic in the absence of 
reprogramming (Tripathi et al., 2010). These observations led to the idea that the role of 
HDACs on OLG development may differ between species. This was further tested by 
treatment with HDAC inhibitors, TSA and sodium butyrate, on human primary OPCs. 
HDAC inhibition (HDACi) resulted in significant dose-dependent inhibition of O4+ OLG 
cell differentiation, reduction of OLG morphological maturation and down-regulation of 
Mbp mRNA (Conway et al., 2012). Along with these results, HDACi treatment prevented 
down-regulation of Sox2, Id4 and Tcf4/Tcf7l2 mRNAs, but did not regulate Hes5 
(Conway et al., 2012). Thus, suggesting that HDAC activity plays an essential role in the 
specification of OPCs (rodent), as well as the differentiation of progenitor cells into 
OLGs (rodent, human). Interestingly, studies describing the role of the ATX-LPA axis in 
epigenetic modulation of OLGs, presented in this dissertation, are limited to OPCs 
committed to the lineage and have no effect on specification. These data parallel what 
is seen in the human and further signifies the importance of ATX in OLG differentiation. 
Pharmacological inhibition of HDACs provided for a clear proof of concept that histone 
deacetylation is crucial for OLG development, however, the identification of individual 
members of the HDAC family was, and partly remains, the next step into understanding 
the role of HDACs in OLG differentiation.  
Regulation by HDAC1 and HDAC2  
HDAC1 and HDAC2 are of particular interest in OLG development as they have 
been reported to be recruited to the promoters of inhibitory molecules of myelin specific 
genes to initiate OLG differentiation (Dewald et al., 2011; He et al., 2007a; Shen and 
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Casaccia-Bonnefil, 2008; Ye et al., 2009). The RE1-silencing transcription factor 
(REST) recruits HDAC1 and HDAC2 to stimulate OPC differentiation by repressing 
several neuronal genes and thereby favoring glial cell specification (Dewald et al., 
2011). In mice, conditional ablation of Hdac1 and Hdac2 results in the stabilization and 
nuclear translocation of β-catenin, which negatively regulates OLG specification by 
repressing Olig2 expression (Ye et al., 2009). A severe impairment in the formation and 
differentiation of OPCs was observed in these double KO mice. Furthermore, mouse 
genetic approaches identified Yin Yang1 (YY1) as the essential transcription factor that 
facilitates the recruitment of HDAC1 to the promoters of the transcriptional inhibitors, 
Tcf4 and Id4, allowing for expression of myelin specific genes (He et al., 2007a). These 
data indicate that HDAC1 and HDAC2 are required for both specification and 
differentiation of OPCs.  
Moreover, the role of HDAC1 activity in OLG development appears to be conserved 
across a wide range of species. In hdac1 zebrafish mutants, specification of OPCs fails, 
but persistence of neural progenitors in the hindbrain ventricular zone is independent of 
hdac1 activity (Cunliffe and Casaccia-Bonnefil, 2006). zHDAC-1 null neural stem cells 
continue to express Sox2 and fail to express Olig2 required for specification into the 
OLG lineage. In addition, sonic hedgehog (Shh) is normally expressed in the zHDAC-1 
mutant hindbrain, however, it’s signaling is inefficient in inducing Olig2 expression 
(Cunliffe and Casaccia-Bonnefil, 2006). Thus, the global deacetylation program initiated 
by HDACs, especially specific isoforms of Class I HDACs, enables expression of the 
OLG transcriptional profile.  
In a different study, Nkx2.2 recruited the HDAC1/mSin3a complex to repress the 
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MBP promoter in immature OLGs (Wei et al., 2005). In addition, Nkx2.2 binds to and 
represses the promoter of the class III HDAC Sirt2 in CG4 cells, an oligodendroglial 
precursor cell line, and Sirt2 promoted the differentiation of CG4 cells (Ji et al., 2011). 
Similarly, HDAC1/2 heterodimers, in association with Sin3B, were detected in complex 
with Myt-1 on the proximal region of the PLP promoter (Romm et al., 2005). These 
results may appear contradictory to the described functions of HDAC1 in promoting 
OLG differentiation, however, it is also conceivable that tightly regulated repression of 
precocious differentiation may be a prerequisite to adequate OLG lineage progression 
(Jacob et al., 2011). 
The Role of Histone Deacetylation on Later Stages of Oligodendrocyte 
Development 
Not only do HDACS play a crucial role in the actual generation and differentiation of 
early OLGs, but they also act on immature OLGs (after established lineage choice) up 
to the onset of myelination. Histone deacetylase 11, HDAC11, plays a distinct role in 
OLG development. HDAC11 catalyzes deacetylation of lysine 9 and 14 on histone H3 
(H3K9; H3K14) and it has been proposed to activate the expression of both, MBP and 
PLP genes, possibly by modulating specific regulatory regions (Liu et al., 2009). Indeed, 
disruption of HDAC11 expression increased acetylation at the promoter region of both 
MBP and PLP and led to a subsequent decrease in their transcript levels (Liu et al., 
2009). In accordance to these studies, in the mouse brain, HDAC11 shows strong 
expression in OLGs that increases during postnatal development (Liu et al., 2008). 
These studies support an important function of HDAC11 in OLG terminal differentiation 
and myelination. 
			
	
25	
Histone modifications have been shown to display an important role in OLG 
development along the lineage and have such been studied in a more clinical 
standpoint by examining modifications in patients suffering from MS. Brain samples 
revealed that there is a shift toward histone acetylation in the white matter of the frontal 
lobes of aged subjects and in patients with chronic MS (Pedre et al., 2011). These 
changes were associated with high levels of transcriptional inhibitors of OLG 
differentiation, TCF7l2, ID2 and SOX2, and higher HAT transcript levels, CBP and 
P300, in female MS patients compared with non-neurological control and correlated with 
disease duration (Pedre et al., 2011). These data suggest that histone deacetylation is a 
process that occurs at the early stages of the disease, and displays decreased 
efficiency with disease duration. The role of HDACs on OLG development is 
increasingly critical to understand, as it proves to be involved in essential stages and 
plays a role in disease pathology.  
Conclusions 
There are many mechanisms that regulate both the specification and 
development of OLGs. With regards to MS, it is imperative that we gain a better 
understanding of these mechanism in order to stimulate the specification of OPCs or, 
and more suitable for lesions in which adult OPCs are present, drive differentiation of 
progenitor cells into cells with the capacity to (re)myelinate. To achieve functional 
maturity of OLGs needed for (re)myelination, there must be a dynamic chemistry 
between extrinsic and intrinsic signals. Epigenetic modifications have been shown to 
play a large role in OLG development. The rate and type of these modifications in OLGs 
is controlled by many factors and depends on the developmental stage and health of 
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the cells (Copray et al., 2009).  
The data presented in this dissertation reveal the discovery of the first 
extracellular signal, ATX, that regulates HDAC activity in the transition from progenitor 
cells to OLGs (differentiation), which is indispensable for proper OLG development. As 
OPCs are found in MS lesions, but are limited in their ability to differentiate, this step 
becomes a crucial area of investigation when searching for therapeutic advances. The 
novel finding that ATX, through its ability to form LPA via the lysoPLD active site, 
regulates the epigenetic modifications needed for proper OLG differentiation is a turning 
point in the field, and further shows its importance in OLG development.  The role that 
the ATX-LPA- epigenetic regulatory pathway plays in relation to MS is so impacting, 
they may offer to be future therapeutic targets.  
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Figure 1.1. The oligodendrocyte lineage. This figure depicts both the changes in 
morphology and gene expression/cell surface markers that OLGs undergo as they 
develop. OPCs are specified (neural progenitor cell to OPC) in restricted regions of the 
central nervous system where they migrate from and proliferate extensively, populating 
the brain and spinal cord. Once they have reached their destination, they begin to 
develop a complex process network and eventually form membranous structures which 
wrap around axons in vivo. OLG differentiation, as denoted in this schematic, is the 
main focus of this dissertation. As changes are observed morphologically, OLGs also 
undergo changes in gene expression/cell surface markers as shown underneath the 
pictures. The genes/cell surface markers listed are used to identify different stages of 
the OLG lineage and are delineated for the developing zebrafish (purple) and rat (blue): 
oligodendrocyte transcription factor 2 (olig2), ganglioside (A2B5), proteolipid protein 
(plp1b), claudink (cldnk), pro-oligodendrocyte surface antigen or sulfatide (O4), 2,3-
cyclic nucleotide 3-phosphodiesterase (Cnp) and UDP- galactose ceramide 
galactosyltransferase (Ugt8). 											 										
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Chapter 2 
 
The Autotaxin-LPA Axis Modulates Histone Acetylation and Gene Expression 
during Oligodendrocyte Differentiation 
 
(This chapter was accepted as a paper in the Journal of Neuroscience in August of 
2015. The work reported for this manuscript is based primarily on my own efforts. 
Assistance was provided by Dr. James Lister (CRISPR-Cas9 genome editing Figure 
2.1)  
Introduction 
The differentiation of the myelinating cells of the central nervous system (CNS), 
namely oligodendrocytes (OLGs), follows a step-wise program that is characterized by 
well-coordinated changes in gene expression and cellular morphology (Bauer et al., 
2009; Mitew et al., 2014; Wegner, 2008). The developmental timing of this 
progression along the OLG lineage is finely tuned by extracellular signals and 
intracellular pathways. In particular, and at the transition from OLG progenitor to 
differentiating OLG, epigenetic mechanisms associated with a progressive 
compaction of chromatin have been found to play a central role (Bischof et al., 2015; 
Copray et al., 2009; Jacob et al., 2011; Liu and Casaccia, 2010; Liu et al., 2015; 
Mori and Leblond, 1970; Shen and Casaccia-Bonnefil, 2008; Yu et al., 2013). The 
current understanding of the above mechanisms affecting the chromatin landscape 
involves histone deacetylation via the action of the class I histone deacetylase 
(HDAC) members HDAC1 and HDAC2 (Shen et al., 2005, 2008; Wu et al., 2012; Ye 
et al., 2009). In general, HDAC1/2 containing complexes are considered to remove 
acetyl groups from histone tails, thereby favoring a condensed chromatin structure 
and limiting DNA access for transcription factors (Grunstein, 1997). In the case of 
the OLG lineage, it has been demonstrated that the target genes affected by 
HDAC1/2 deacetylation include clusters of co-regulated genes implicated in 
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transcriptional repression (Swiss et al., 2011). Thus, it is deacetylation-mediated 
repression of transcriptional inhibitors of OLG differentiation, such as Egr1, Id2 and 
Sox11, that is thought to promote progression along the OLG lineage. While the 
intracellular aspects of this mechanism have been well-characterized, little is known 
about the extracellular signals that may be modulating it (Wu et al., 2012).  
In our previous studies, we identified autotaxin (ATX), also known as ENPP2, 
phosphodiesterase-Iα/ATX or lysophospholipase D (lysoPLD), as an extracellular factor 
that promotes OLG differentiation at various steps along the progression of the lineage 
and via the action of two distinct functionally active domains (Dennis et al., 2005, 2008; 
Nogaroli et al., 2009b; Yuelling and Fuss, 2008; Yuelling et al., 2012). In this regard, 
ATX’s so-called modulator of oligodendrocyte remodeling and focal adhesion 
organization (MORFO) domain was found to regulate primarily the morphological 
aspects of OLG differentiation (Dennis et al., 2008, 2012; Fox et al., 2003), while its 
lysoPLD-active site, which generates the lipid signaling molecule lysophosphatidic acid 
(LPA) (van Meeteren and Moolenaar, 2007; Nakanaga et al., 2010; Tokumura et al., 
2002; Umezu-Goto et al., 2002), may be predominantly modulating gene expression 
(Nogaroli et al., 2009b). Intriguingly, studies assessing ATX’s functions as a whole and 
in vivo in the developing zebrafish revealed a lineage promoting, and likely gene 
expression regulatory, role at the transition from OLG progenitor to differentiating 
OLG (Yuelling et al., 2012). Thus, we investigated here a possible role of, in 
particular, ATX’s lysoPLD activity in modulating histone deacetylation and gene 
expression during the early stages of the OLG lineage.  
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Materials and Methods 
Animals. Zebrafish embryos were obtained through natural matings, raised at 28.5°C 
and staged according to morphological criteria and hours post fertilization (hpf) (Kimmel 
et al., 1995). Wildtype fish were of the AB strain and Tg(nkx2.2a:megfp)vu17 (Kirby et al., 
2006; Kucenas et al., 2008), abbreviated Tg(nkx2.2a:megfp), as well as 
Tg(olig2:dsred2)vu19 (Kucenas et al., 2008), abbreviated Tg(olig2:dsred2), fish were 
kindly provided by Sarah Kucenas and Bruce Appel. Sprague Dawley female rats with 
early postnatal litters were obtained from Harlan Laboratories (Indianapolis, IN). All 
animal studies were approved by the institutional animal care and use committee at 
Virginia Commonwealth University. 
Antibodies. Supernatants from cultured hybridoma cells (clone A2B5; ATCC, 
Manassas, VA) were used for immunopanning. Anti-acetyl-Histone H3 (Lys 9) 
antibodies (Cell Signaling Technology, Inc., Danvers, MA) were used for Western blot 
analysis as well as immunocytochemistry. Anti-Histone H3 antibodies (Cell Signaling 
Technology, Inc., Danvers, MA) as well as IRDye 680RD- and 800CW-conjugated 
secondary antibodies (LI-COR Biosciences, Lincoln, NE) were used for Western blot 
analysis. Supernatants from cultured hybridoma cells (clone O4; gift from S.E. Pfeiffer), 
anti-Caspase 3, active (cleaved) form (EMD Millipore, Billerica, MA), anti-Ki67 (Leica 
Microsystems, Buffalo Grove, IL) and Alexa 488- and/or Alexa 568-conjugated 
secondary antibodies (Life Technologies, Grand Island, NY) were used for 
immunocytochemistry. 
Pharmacological compounds. Zebrafish embryos and primary cultures of 
differentiating OLGs were treated with the following compounds: ATX-lysoPLD activity 
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inhibitors S32826 and HA130 (Tocris/Bio-Techne, Minneapolis, MN), HDAC1/2/3 
inhibitor C1944 and HDAC6 inhibitor Tubastatin A (Selleckchem, Houston, TX) all of 
which were dissolved in dimethyl sulfoxide (DMSO) resulting in a final experimental 
concentration of 0.1% of DMSO, which is well tolerated in both the zebrafish as well as 
the cell culture system (Lyssiotis et al., 2007b; Maes et al., 2012). Lysophosphatidic 
acid (LPA; 18:1; Sigma, St. Louis, MO) was dissolved in DMEM containing 0.1% fatty 
acid-free bovine serum albumin. Control in all experiments where pharmacological 
compounds were used refers to vehicle treatment.  
Cell culture.  Primary OLG progenitors were isolated from postnatal day 2 (P2) rat 
brains by A2B5 immunopanning and cultured as previously described (Barres et al., 
1992; Lafrenaye and Fuss, 2010; Martinez-Lozada et al., 2014). Briefly, immunopanned 
OLG progenitors were plated onto fibronectin (10 µg/ml)-coated tissue culture dishes, 
glass coverslips or 96-well plates. Plated OLG progenitors were cultured in serum-free 
proliferation medium (Dulbecco’s modified Eagle’s medium (DMEM) containing human 
PDGF and basic fibroblast growth factor (bFGF) (Gemini Bio-Products, Sacramento, 
CA) for 24 hrs, after which cells were allowed to differentiate in serum-free medium 
(DMEM containing 40 ng/mL tri-iodo-thyronine (T3; Sigma, St. Louis, MO) and N2 
supplement (Life Technologies, Grand Island, NY); DMEM/T3/N2) over the time periods 
indicated. Differentiating OLGs were either directly analyzed or treated as indicated. 
Typically, at least three independent experiments were performed, whereby an 
independent experiment refers to an experiment in which cells were isolated from a 
separate P2 rat litter at an independent time point (day) and treated separately from all 
other independent experiments.  
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CRISPR/Cas9 genome editing. CRISPR target sequences for atx (enpp2), as 
depicted in Fig. 1, were identified using the online tools crispr.mit.edu and 
chopchop.rc.fas.harvard.edu (Montague et al., 2014). sgRNAs were generated using 
the cloning-free/short oligonucleotide approach described by Talbot and Amacher 
(2014). Briefly, short-guide oligonucleotides containing a T7 promoter and genomic 
target site were synthesized by Eurofins MWG Operon LLC (Huntsville, AL). Guide-
constant oligonucleotides were obtained from Life Technologies (Grand Island, NY). Full 
length templates for sgRNA synthesis were generated by PCR using short-guide and 
guide-constant oligonucleotides, and PCR templates were purified using ISOLATE II 
PCR cleanup columns (Bioline, Taunton, MA). The plasmid pT7tyrgRNA (Addgene 
46761; kindly provided by Wenbiao Chen) (Jao et al., 2013) was used as a template for 
the generation of the tyrosinase (tyr) control sgRNA. sgRNAs were transcribed from 
their templates using the MEGAshortscript T7 kit (Life Technologies, Grand Island, NY). 
Cas9 mRNA was synthesized from the plasmid pT3TS-nCas9n (Addgene 46757; kindly 
provided by Wenbiao Chen) (Jao et al., 2013) using the mMESSAGE mMACHINE T3 
Transcription Kit (Life Technologies, Grand Island, NY). 1 nanoliter of a mixture of Cas9 
mRNA (100 ng/µl) and sgRNA (80 ng/µl for atx-E2; 95 ng/µl for atx-E7; 100ng/µl for tyr) 
was injected per one-cell stage zebrafish embryo. Zebrafish were analyzed at 48 hpf. 
Brightfield images of whole embryos were taken using an Olympus SZX12 zoom stereo 
microscope (Olympus America Inc., Melville, NY) equipped with an Olympus DP70 
digital camera system.  
Genomic DNA analysis. Genomic DNA was isolated from control and Cas9 
mRNA/sgRNA injected embryos using the DNeasy Blood and Tissue kit (Qiagen, 
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Valencia, CA). DNA fragments spanning genomic target sites were amplified by PCR 
using the following primer pairs:  
atx-E2(ZDB-GENE-040426-1156): forward (5’ AAATTGTTGAAACCATATGCGA 3’), reverse (5’ 
GCATCCTACTTTTTGAGAGCGA) 
 atx-E7(ZDB-GENE-040426-1156): forward (5’ TGTTTAGGTGTGTGCTTAGTGC 3’), reverse (5’ 
AATCTGCAATTAATACATACCGTTG 3’).  
To assess for indels generated by CRISPR/Cas9 genome editing, PCR fragments were 
sequenced (VCU’s Nucleic Acid Research Facilities) and the Surveyor Mutation 
Detection Kit (Integrated DNA Technologies, Inc., Coralville, IA) was used.  
ATX-lysoPLD activity assay. ATX-lysoPLD activity was determined using the 
fluorogenic assay as described by Ferguson et al. (Ferguson et al., 2006). Whole 
zebrafish homogenates diluted in 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 
5 mM Tris/HCl (pH 8.0), 1 mg/ml fatty acid-free BSA (Sigma-Aldrich, St. Louis, MO) or 
concentrated (40x) conditioned medium from primary OLG cultures grown in phenol-
red-free DMEM were incubated with 2.5 μM FS-3 substrate (Echelon Biosciences Inc., 
Salt Lake City, UT) for 4 hrs at 37°C. Increase in fluorescence with time was measured 
at an excitation wavelength of 485 nm and an emission wavelength of 520 nm using a 
PHERAstar multimode microplate reader (BMG LABTECH Inc. Cary, NC.). 
RNA isolation and real-time RT-qPCR Analysis. For the isolation of RNA from whole 
zebrafish embryos or cultured rodent OLGs, samples were collected in Trizol 
(Invitrogen, Carlsbad, CA) and immediately homogenized. RNA was extracted as 
described by Chomczynski and Sacci (1987) (Chomczynski and Sacchi, 1987). For the 
isolation of RNA from FACS-isolated cells, cells were collected directly in Trizol and 
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then immediately processed using the RNeasy Micro Kit from Qiagen (Valencia, CA). All 
RNA samples were treated with DNase (DNA-Free Kit; Applied Biosystems/Ambion, 
Austin, TX). RNA concentrations were determined using a Nanodrop ND 1000 
Spectrophotometer (Thermo Scientific/NanoDrop, Wilmington, DE) and purity was 
assessed by the ratio of absorbance at 260 and 280 nm (OD260/280 ≥ 1.8). Oligo(dT)-
primed cDNAs were synthesized from 50 ng to 1 µg of RNA using the Omniscript or 
Sensiscript RT Kit (Qiagen, Valencia, CA) according to the manufacturer’s guidelines. 
RNA samples were normalized to the same approximate concentration and the same 
amount of RNA was used for all conditions of an individual independent experiment. As 
control, cDNA reactions without reverse transcriptase were performed for all samples. 
PCR reactions performed with such no-reverse-transcriptase cDNAs as template 
yielded quantitation cycle (Cq) numbers that were at least 5 cycles below the lowest Cq 
for any of the experimental samples (unknowns), whereby Cq values for unknowns 
were within the linear quantifiable range as determined by calibration curves. Gene-
specific primers were designed and in silico tested for specificity using NCBI/Primer-
BLAST (Ye et al., 2012). All primers were designed to amplify all known splice variants.  
For each primer pair listed below, amplicon length is noted in bp.  In addition, PCR 
efficiencies are given in % and correlation coefficients (r2 values) as single numbers, 
whereby the latter were determined from calibration curves using RNA samples derived 
from species and tissue/cell type equivalent sources.   
The following unmodified zebrafish gene-specific primer pairs were used:  
atx/enpp2(ZDB-GENE-040426-1156): forward (5’-CAATGTATGCAGCATTCAAACGAGTG-3’, 
exon 22), reverse (5’CACCATTTTTCTCACTAGCGTAACG-3’, exon 23), 79 bp, 107%, 
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0.996 
plp1b(ZDB-GENE-030710-6): forward (5’TGCCATGCCAGGGGTTGTTTGTGGA-3, exon 5), 
reverse (5’-GGCGACCATGTAAACGAACAGGGC-3, exon 6/7); 143 bp, 96%, 1,000 
cldnk(ZDB-GENE-040801-201): forward (5’-TGGCATTTCGGCTCAAGCTCTGGA-3’, exon 1), 
reverse: (5’GGTACAGACTGGGCAATGGACCTGA-3, exon 2); 135 bp, 93%, 0.999 
inab (gefiltin)(ZDB-GENE-990415-83): forward: 5’-CTCTCCATCCCGGCTGAGCAGCT -3’, exon 
1), reverse: (5’AGCCTGGGATGTTGGGGCGGTT-3’, exon 1); 74 bp, 105%, 0,997 
gfap(ZDB-GENE-990914-3): forward (5’-TGAGACAAGCGAAGCAGGAGGCCA-3’, exon 5), 
reverse (5’GGCGCTCCAGGGACTCATTAGACCC-3’, exon5/6); 102 bp, 101%, 0.997 
prph (plasticin)(ZDB-GENE-990415-207): forward (5’-ACTCCTACCGCACCTCTCACCACCG -3’, 
exon 1), reverse (5’-TAGCGGCCCCCGATGCGACTG-3’, exon 1); 70 bp, 93%, 0.997 
sox10(ZDB-GENE-011207-1): forward (5’-TGGACACCACCCTCACGCTA-3’, exon 3), reverse 
(5’-CTGCAGTTCCGTCTTGGGGG-3’, exon 4); 76 bp, 94%, 0.966 
β-actin (actb2(ZDB-GENE-000329-3)) (Buckley et al., 2010) was used as reference gene (60bp, 
95%, 0.999); eef1a1/1(ZDB-GENE-990415-52) has been assessed as additional reference gene 
for the analysis of RNA derived from the developing zebrafish and no pronounced 
differences were noted (Yuelling et al., 2012). 
The following unmodified rat gene-specific primer pairs were used:  
Cnp(NM_012809.2): forward (5’-ATGCCCAACAGGATGTGGTG-3’, exon 3/4), reverse 
(5’-AGGGCTTGTCCAGGTCACTT-3’, exon 4); 150 bp, 103%, 0.990 
Ugt8(NM_019276.3): forward (5’-AGGAGCTCTGGGGAGATTGC-3’, exon 3), reverse 
(5’-TTTGAATGGCCAAGCAGGTCA-3’, exon 4/5); 126 bp, 108%, 0.960 
Egr1(NM_012551.2): forward (5’-CCTGACCACAGAGTCCTTTTCT-3’, exon 1/2), reverse 
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(5’-AAAGTGTTGCCACTGTTGGG-3’, exon 2); 150 bp, 93%, 0.996 
Pgk1(NM_053291.3) (as reference gene): forward (5’-ATGCAAAGACTGGCCAAGCTAC-3’, 
exon 8), reverse (5’-AGCCACAGCCTCAGCATATTTC-3’, exon 9), 103 bp, 103%, 0.997 
Pgk1 was used as reference gene due to its previously established expression stability 
in rat OLGs (Nelissen et al., 2010). In addition, Ppia(NM_017101.1) has been assessed as 
additional reference gene for the analysis of RNA derived from differentiating OLG 
cultures and no pronounced differences were noted.  
RT-qPCR reactions with at least 2 technical replicates per sample were performed on a 
CFX96 real-time PCR detection system (BioRad, Hercules, CA) using the iQ SYBR 
Green Supermix (BioRad, Hercules, CA). PCR conditions were as follows: 95°C for 3 
min followed by 40 cycles of 95°C for 15 s, 58°C for 30 s, and 95°C for 10 s. For all 
primer pairs, melting curves were used to ensure specificity. Relative expression levels 
were determined using the ΔΔCT method (Livak and Schmittgen, 2001).  
Whole mount in situ hybridization. Zebrafish embryos were fixed in 4% 
paraformaldehyde in PBS overnight at 4°C and stored in methanol at 22°C for at least 1 
day. Colorimetric in situ hybridizations using digoxigenin-labeled antisense cRNA 
probes were performed by standard methods and as previously described (Thisse and 
Thisse, 2014, 2008; Yuelling et al., 2012). In situ hybridized embryos were mounted in 
90% glycerol/PBS and whole mount images were acquired using the extended focus 
module of the axiovision software package in combination with an Axio Observer Z.1 or 
SteREO Discovery.V20 microscope equipped with an AxioCam MRc digital camera 
(Carl Zeiss MicroImaging, Inc., Thornwood, NY). Once captured, images were imported 
into Adobe Photoshop and adjustments were limited to cropping and brightness/contrast 
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adjustments which were applied equally across the entire image and to controls. In situ-
labeled cells were counted using the Cell Counter plugin to the ImageJ software 
package (Abramoff et al., 2004).  
Isolation of OLG progenitors from zebrafish embryos using fluorescent activated cell-
sorting (FACS). Tg(nkx2.2a:megfp;olig2:dsred2) zebrafish embryos (up to 300 per 
sample) were anesthetized with tricaine methanesulfonate (MS-222;  Sigma Aldrich 
Corp., St. louis, MO) and subjected to enzymatic (trypsin and DNAse) and mechanical 
(20 and 26 gauge needle) dissociation. Cell suspensions were resuspended first in 1ml 
and then in 500 µl of ice cold 5% Goat Serum in PBS after centrifugation (at 956xg for 
2 min at 4°C) and then subjected once again to mechanical dissociation (26-gauge 
needle). Cell suspensions were passed through a 40 micron filter and then through a 
fluorescence activated cell sorter (FACS Aria II, BD Biosciences, San Jose, CA) using 
an 85 µM nozzle. Cell sorting was performed at room temperature using a 488 nm laser 
(>20mW power, Coherent solid-state) for excitation and 530/30 nm and 585/42 nm 
bandpass filters for the collection of emission. Settings were carefully determined 
empirically and exactly reproduced in each experiment. Gates were demarcated to sort 
only mEGFP/DsRed2 double-positive cells. The speed of sorting (usually no more than 
1–2 drops per event) was adjusted to obtain a purity of  >95%. Cells were suspended in 
either PBS (HDAC activity assay) or Trizol (RNA isolation).  
HDAC activity assay. FACS-isolated cells were plated into 96-well plates 
(1x104 cells/well) and directly assayed. Rodent OLG progenitor cells were cultured and 
treated in fibronectin coated 96-well plates (1x105 cells/well) and then assayed. HDAC 
activity was determined using the fluorometric HDAC Activity Assay Kit from BioVision 
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Inc. (Milpitas, CA). Briefly, the cell permeable HDAC Substrate Boc-Lys(AC)-AMC was 
added and cells were incubated for 3 hrs at 37 °C. Subsequent incubation with the 
Lysine Developer (30 min at 37 °C) was used to produce a fluorophore from substrate 
sensitized through deacetylation. Fluorescence, as a measure of HDAC activity, was 
determined using a Spectra Max M5 fluorescent plate reader (Molecular Devices, 
Sunnyvale, CA) with excitation/emission at 360/460 nm. In each experiment, triplicates 
were prepared for all conditions and treatments. 
Immunocytochemistry. For immunocytochemistry using O4 hybridoma supernatants, 
cells were fixed in 4% paraformaldehyde/PBS, nonspecific binding sites were blocked in 
10% FCS/DMEM, and cells were incubated with the supernatant (1:1 diluted in 10% 
FCS/DMEM) overnight. Cells were fixed and in case of dual staining permeabilized 
using 0.5% Triton X-100/0.4 M sucrose/PBS and then incubated for 30 min in blocking 
solution (10% FCS/DMEM). Subsequently, cells were incubated overnight with anti-
acetyl-histone H3 (Lys 9), anti-Caspase 3 (active (cleaved) form) or anti-Ki67 antibodies 
overnight. Primary antibodies were detected using Alexa 488- or Alexa 568-conjugated 
secondary antibodies (Life Technologies, Grand Island, NY) and nuclei were 
counterstained using Hoechst 33342 (EMD Millipore, Billerica,MA). For the generation 
of representative images, confocal laser scanning microscopy was used (Zeiss LSM 
700, Carl Zeiss Microscopy, LLC, Thornwood, NY). Images represent 2D maximum 
projections of stacks of 0.5 µm optical sections.  
Nuclear histone acetylation analysis. Cells double-labeled for O4 and acetyl-histone 
H3 (Lys 9) were imaged using confocal laser scanning microscopy (LSM 700 Carl Zeiss 
Microscopy, LLC, Thornwood, NY). Single focal plane images were taken using a 
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40x/1.3 n.a. plan-apochromat objective lens. Images were taken from O4-positive cells 
and focused on the region of the nucleus as marked by staining with Hoechst. Laser 
intensity, detector gain and amplifier offset were optimized and kept constant throughout 
the imaging of all samples from one experiment. Fluorescence intensity, i.e. average 
pixel intensity, for the anti-acetyl histone H3 (Lys 9) signal, as a measure for the level of 
histone acetylation, was determined over the area of the nucleus using IP Lab imaging 
software (BD Biosciences Bioimaging, Rockville, MD). Unprocessed confocal images 
were used for analysis and threshold settings were kept constant once determined.  
Western blot analysis. Cells were homogenized in lysis buffer (150 mM NaCl, 10 mM 
KCl, 20 mM HEPES (pH 7.0), 1 mM MgCl2, 20% glycerol, and 1% Triton X-100) 
including the complete protease and phosphatase inhibitor cocktail (Thermo Scientific, 
Rockford, IL). 5 µg per sample were used for Western blot analysis to detect acetyl 
histone H3 (Lys 9) and total H3. Bound primary antibodies were detected using IRDye 
680RD- and 800CW-conjugated secondary antibodies (LI-COR Biosciences, Lincoln, 
NE). Signal intensities were determined using a LI-COR Odyssey infrared imaging 
system (LI-COR Biosciences, Lincoln, NE).  
Cell survival and proliferation analysis. Cells were subjected to immunostaining 
using O4 hybridoma cell supernatants and antibodies specifically recognizing the active 
(cleaved) form of caspase-3 or the Ki67 antigen. To determine the number of caspase-3 
or Ki67 immunopositive cells, images of four fields per coverslip were taken with a 
20x/0.8 n.a. plan-apochromat objective lens using a confocal laser scanning microscope 
(LSM 700 Carl Zeiss Microscopy, LLC, Thornwood, NY). Three coverslips per condition 
for each of three independent experiments were analyzed, and Hoechst 33342-positive 
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nuclei as well as caspase-3 or Ki67 immunopositive oligodendrocytes were counted 
using the Cell Counter plugin to the ImageJ software package (Abramoff et al., 2004).  
Statistical Analysis. To determine significance, GraphPad Prism (GraphPad 
Software, La Jolla, CA) or SigmaPlot (Systat Software, Inc., San Jose, CA) software 
was used. Data composed of two groups were analyzed using the two-tailed Student’s 
t-test or the Mann-Whitney U-test and presented in bar graphs depicting means ± SEM 
or box and whisker plots depicting medians and quartiles. Data compared to a set 
control value lacking variability were analyzed using the one-sample t-test (Dalgaard, 
2008; Robert R. Sokal, 2013) and presented in bar graphs.  
 
Results 
In the developing zebrafish hindbrain, ATX promotes the timely appearance of 
differentiating OLGs via its lysoPLD activity 
Our previous studies, using antisense morpholino oligonucleotide-mediated knock-
down of atx expression, revealed that in the developing zebrafish hindbrain, ATX 
promotes the timely appearance of cells committed to the OLG lineage without affecting 
the number of olig2-positive progenitor cells, the overall morphology of the axonal 
network or the differentiation of somatic abducens motor neurons (Yuelling et al., 2012). 
As recent studies have questioned the correlation between morpholino oligonucleotide-
induced and mutant phenotypes in the zebrafish (Kok et al., 2015), we used clustered 
regularly interspaced short palindromic repeats (CRISPR)/Cas9 genome editing to 
substantiate the above proposed in vivo role of ATX. For these studies, we used the 
codon-optimized Cas9 with nuclear localization signals system described by Jao et al. 
(2013). This optimized system has been described to lead to an increased frequency of 
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biallelic disruption so that injected (F0) embryos phenocopy known mutant phenotypes 
(Jao et al., 2013). As shown in Fig. 2.1A-E, injection of guide RNAs against exon 2 or 7 
of the atx (enpp2) gene and in vitro transcribed, capped, polyadenylated nls-zCas9-nls 
RNA into one-cell stage zebrafish embryos resulted in the generation of indel mutations 
over and upstream of the CRISPR targeting sequence. These mutations resulted in 
reduced levels of atx mRNA (Fig. 2.1F) (atx-E2, n=4, t-test, p=0.0038; atx-E7, n=6, t-
test, P=0.0006), an effect that was not observed when using a guide RNA against 
tyrosinase (tyr) (tyr, n=3, t-test, p=0.3468). Most importantly, the CRISPR/Cas9-
mediated reduction in atx expression was found associated with a decrease in the 
transcript levels for the later stage OLG differentiation marker genes claudin K (cldnk) 
and proteolipid protein (plp1b) (Fig, 2.1G) (cldnk atx-E2, n=4, t-test, p=0.0188; cldnk 
atx-E7, n=5, t-test, p=0.0006; plp1b atx-E2, n=6, t-test, p=0.0155; plp1b atx-E7, n=5, t-
test, p=0.0203). As shown in Fig. 2.1H, injection of Cas9 mRNA with either of the guide 
RNAs was not found to be associated with changes in the gross morphology of the 
embryos. The above described data, therefore, corroborate our earlier morpholino 
oligonucleotide-mediated knock-down results and confirm a critical in vivo role of ATX in 
the regulation of OLG differentiation.  
To assess the extent to which this functional role of ATX may be dependent on its 
lysoPLD activity, the inhibitors HA130 and S32826, which have been well-characterized 
to block ATX’s lysoPLD activity (Albers et al., 2010; Ferry et al., 2008), were used. Of 
these inhibitors, HA130 has previously been demonstrated to effectively block ATX’s 
lysoPLD activity in the developing zebrafish at concentrations similar to the ones found 
to block human ATX (Lai et al., 2012). Two experimental designs were used (see 
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Figs. 2.2A and 2.3A). First, to determine the effect of an inhibition of ATX’s lysoPLD 
activity on OLG differentiation, inhibitors were added to zebrafish embryos at 44 hrs 
post fertilization (hpf), i.e. at a time point when OLG progenitors arise in the ventral 
hindbrain and start to differentiate (Zannino and Appel, 2009)(Fig. 2.2A). Zebrafish 
embryos were analyzed at 48 hpf, a time point at which transcripts for cldnk and plp1b 
start to become detectable (Brösamle and Halpern, 2002; Münzel et al., 2012; Takada 
and Appel, 2010). As shown in Fig. 2.2B, treatment with either of the inhibitors at both 
1µM and 10µM concentrations significantly reduced ATX’s lysoPLD activity (HA130 
1µM, n=4, t-test, p=0.0166; HA130 10µM, n=4, t-test, p=0.0132; S32826 1µM, n=6, 
t-test, p=0.0008; S32826 10µM, n=5, t-test, p=0.0131). Importantly, both inhibitors 
significantly reduced the mRNA levels for cldnk and plp1b at both concentrations used 
(Fig. 2.2C,D) (cldnk: HA130 1µM, n=3, t-test, p=0.0144; HA130 10µM, n=3, t-test, 
p=0.0413; S32826 1µM, n=3, t-test, p=0.0006; S32826 10µM, n=3, t-test, p=0.0166; 
plp1b: HA130 1µM, n=5, t-test, p=0.0038; HA130 10µM, n=5, t-test, p=0.0325; S32826 
1µM, n=5, t-test, p=0.0071; S32826 10µM, n=5, t-test, p=0.0031). In contrast, there was 
no change in the number of olig2-positive progenitors (Fig. 2.2E,F) (HA130 1µM, n=5, 
t-test, p=0.7184; HA130 10µM, n=5, t-test, p=0.5050; S32826 1µM, n=5, t-test, 
p=0.7679; S32826 10µM, n=5, t-test, p=0.7277), which at 48 hpf represent early stages 
of both motor neuron and OLG lineages (Park et al., 2002; Zannino and Appel, 2009). It 
is of note that neither S32826 nor HA130 were found to exert cytotoxic effects when 
treating zebrafish embryos or cells in culture at the concentrations used here (Albers et 
al., 2010; Ferry et al., 2008; Iyer et al., 2012; Lai et al., 2012, see also description to Fig. 
2.7 below). Consistently, no gross morphological defects were noted upon the treatment 
			
	
44	
of zebrafish embryos with HA130 or S32826 (Fig. 2.2G) and no noticeable increase in 
7-aminoactinomycin D (7-AAD) staining, as a measure for increased cell death (Philpott 
et al., 1996), was detected when analyzing single cell suspensions from control and 
inhibitor treated whole fish embryos by flow cytometry (data not shown). Hence, the 
data shown in Fig. 2 suggest that ATX’s lysoPLD activity, as ATX as a whole (Yuelling 
et al., 2012), regulates the progression of olig2-positive progenitor cells into lineage 
committed and differentiating OLGs, but not the appearance of olig2-positive 
progenitors itself.  
To further confirm the above conclusion, ATX-lysoPLD inhibitors were added at a 
time point at which olig2-positive progenitors begin to arise in the hindbrain, i.e. at 
24 hpf (Zannino and Appel, 2009) (Fig. 2.3A). As shown in Fig. 2.3B-E, treatment with 
HA130 had a comparable effect in both experimental designs (ATX activity: HA130 
1µM, n=5, t-test, p=0.0051; HA130 10µM, n=4, t-test, p=0.0130; cldnk: HA130 1µM, 
n=4, t-test, p=0.0037; HA130 10µM, n=5, t-test, p=0.0167; plp1b: HA130 1µM, n=4, 
t-test, p=0.0272; HA130 10µM, n=4, t-test, p=0.0111; olig2: HA130 1µM, n=5, t-test, 
p=0.1867; HA130 10µM, n=5, t-test, p=0.8770). Interestingly, treatment with S32826, 
when applied at 24 hpf, did not cause a significant effect on ATX’s lysoPLD activity or 
cldnk/plp1b mRNA levels when used at 1µM and a much-reduced effect when used at 
10µM (Fig. 2.3B-E) (ATX activity: S32826 1µM, n=3, t-test, p=0.0566; S32826 10µM, 
n=4, t-test, p=0.0322; cldnk: S32826 1µM, n=5, t-test, p=.3999; S32826 10µM, n=5, 
t-test, p=0.0145; plp1b: S32826 1µM, n=3, t-test, p=0.9437; S32826 10µM, n=3, t-test, 
p=0.0162; olig2: S32826 1µM, n=5, t-test, p=0.2823; S32826 10µM, n=5, t-test, 
p=0.8073). This lack of effective inhibition of ATX’s lysoPLD activity is likely due to the 
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known poor in vivo stability and/or bioactivity of S32826 (Ferry et al., 2008; Gupte et al., 
2011). As in the studies to the experimental design shown in Fig. 2.2, no gross 
morphological defects (Fig. 2.3G) or noticeable increase in cell death (not shown) were 
noted.  
Taken together, the above data demonstrate that inhibition of ATX’s lysoPLD activity 
mimics the effects on the OLG lineage as seen upon morpholino oligonucleotide-
mediated knock-down of atx expression (Yuelling et al., 2012) or CRISPR/Cas9-
mediated genome editing at the atx locus (Fig. 2.1). Thus, they establish that it is ATX’s 
lysoPLD activity that is necessary for the timely appearance of differentiating OLGs in 
the developing zebrafish hindbrain.  
 
In the developing zebrafish, ATX-lysoPLD promoted progression along the early 
stages of the OLG lineage is associated with an increase in HDAC activity  
The progression along the early stages of the OLG lineage, as seen regulated by 
ATX’s lysoPLD activity, has been well-established to be associated with epigenetic 
modifications and in particular with an increase in histone deacetylation (He et al., 2007a; 
Liu and Casaccia, 2010; Marin-Husstege et al., 2002; Shen et al., 2005, 2008; Swiss et 
al., 2011; Takada and Appel, 2010). In addition, in studies unrelated to ATX, it has been 
shown that LPA, for which enzymatic lysoPLD activity represents one of the known 
biosynthetic pathways (Aoki et al., 2008a), can increase histone deacetylation in a 
number of human cancer cell lines (Ishdorj et al., 2008). Thus, and in an effort to identify 
downstream targets of ATX’s lysoPLD activity involved in the regulation of OLG 
differentiation, we focused on HDACs and their activity. For these studies, the 
experimental design as depicted in Fig. 2.4A was used. In addition, and to enable an 
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analysis of HDAC activity explicitly in cells of the OLG lineage, the double transgenic 
zebrafish line Tg(nkx2.2a:megfp;olig2:dsred2) was used in which a subset of OLG 
lineage cells can be identified by the concurrent expression of mEGFP and DsRed2 
(Kucenas et al., 2008) and thus be isolated by fluorescence-activated cell sorting 
(FACS). In agreement with an OLG lineage commitment, such sorted and double-
positive cells were characterized under control conditions by an enriched expression of 
the OLG marker gene cldnk (Fig. 2.4B) (n=5, t- test, p=0.0262, compared to whole fish 
embryo expression). In contrast, there were, if at all, only slight levels of expression 
detectable for the radial/ependymal/enteric glia marker gfap (Fig. 2.4B) (n=4, t-test, p= 
0.0023, compared to whole fish embryo expression) (Bernardos and Raymond, 2006; 
Doodnath et al., 2010; Grupp et al., 2010; Hagström and Olsson, 2010; Lam et al., 
2009) and the neuronal intermediate filament encoding genes gefiltin (inab) (Fig. 2.4B) 
(n=4, t-test, p=0.0014, compared to whole fish embryo expression) and plasticin (prph) 
(Fig. 2.4B) (n=4, t-test, p=0.0019, compared to whole fish embryo expression) (Leake et 
al., 1999). In addition, and similar to the rodent system (Savaskan et al., 2007), such 
early stages of the OLG lineage were found to express atx (Fig. 2.4B) (n=4, t-test, 
p=0.0464). It is of note that such early, and relatively low, expression during the OLG 
lineage remained undetected in our earlier studies (Yuelling et al., 2012) due to the use 
of less sensitive detection methods. Upon inhibition of ATX’s lysoPLD activity, and 
consistent with the previously observed lack of an effect on the number of olig2 
expressing progenitor cells (Fig. 2.2E,F), no change in the number of double-positive 
cells was observed (Fig. 2.4C) (HA130, n=4, t-test, p=0.4722; S32826, n=4, t-test, 
p=0.3765). To further assess potential effects of ATX-lysoPLD inhibition on progenitor 
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marker expression levels, the fluorescence intensities for mEGFP and DsRed2 were 
monitored, as they are indicators for nkx2.2a and olig2 promoter activities. A shown in 
Fig. 2.4D and E, no changes were observed (n=5, t-test, p=0.5855, mEGFP; n=5, t-test, 
p=0.6436, DsRed2). In contrast, and in agreement with our previous findings 
(Fig. 2.2C,D), the expression of sox10, which at the developmental stage analyzed 
marks olig2/nkx2.2a double-positive cells that are OLG lineage committed and 
differentiating (Kucenas et al., 2008), was found to be decreased (Fig. 2.4F) (HA130, 
n=4, t-test, p=0.0358). Importantly, such a reduction in the expression of a gene 
characteristic for recently specified and differentiating OLGs was associated with a 
reduction in overall HDAC activity (Fig. 2.4G) (HA130, n=4, t-test, p=0.0275; S32826, 
n=4, t-test, p=0.0106). This effect was found to not be associated with a noticeable 
decrease in cell viability as assessed by propidium iodide staining and flow cytometry 
(Sasaki et al., 1987) (data not shown).  
Taken together, the above data demonstrate that in the developing zebrafish, ATX, 
via its lysoPLD activity, promotes the lineage progression from an olig2/nkx2.2a 
double-positive progenitor cell to a sox10 expressing fully committed and early 
differentiating OLG by a mechanism that is associated with an increase in overall HDAC 
activity.   
 
In enriched primary cultures of rodent OLG lineage cells, ATX’s lysoPLD activity 
promotes OLG differentiation 
To more precisely define the functional correlation between ATX’s lysoPLD 
activity and changes in HDAC activity/histone acetylation and to assess evolutionary 
conservation of this mechanism, we turned to the well-established culture system of 
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enriched primary rodent OLG lineage cells. In this culture system, OLG differentiation 
follows the same sequence of events as observed in vivo but provides the advantage of 
studying intrinsic cellular mechanisms (Temple and Raff, 1985). In addition, the role of 
HDACs and histone acetylation has been well-characterized in this system (Marin-
Husstege et al., 2002; Swiss et al., 2011). More specifically, an increase in histone 
deacetylation as early as 6 hrs post-mitogen withdrawal has been found crucial for the 
transition from a proliferating OLG progenitor to a differentiating OLG (Marin-Husstege 
et al., 2002). To establish the role of ATX’s lysoPLD activity on OLG differentiation 
during this developmental time window, we, therefore, employed the experimental 
design as depicted in Fig. 2.5A. First, we established the expression profile of 
transcriptional targets previously shown to be regulated by histone deacetylation, 
namely 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (Cnp), UDP glycosyltransferase 8 
(Ugt8) and the transcriptional regulator Egr1 (Swiss et al., 2011). In agreement with the 
findings described by Swiss et al., OLG differentiation was found in our system to be 
characterized by an increase in the expression of the OLG marker genes Cnp and Ugt8 
and a decrease in the expression of Egr1 (Fig. 2.5B) (Cnp: n=5, t-test, p=0.0134; Ugt8: 
n=5, t-test, p=0.0429; Egr1: n=3, t-test, p=0.0362). In addition, there was a slight 
increase in the expression of Atx (Fig. 2.5B) (n=5, t-test, p=0.0118). As shown in 
Fig. 2.5C, treatment with either of the ATX-lysoPLD activity inhibitors, HA130 or 
S32826, significantly reduced ATX’s lysoPLD activity after 4 and 24 hrs (Fig. 2.5C) 
(HA130 10µM 28 hrs, n=4, t-test, p=0.0004; HA130 10µM 48 hrs, n=5, t-test, p=0.0001; 
S32826 10µM 28 hrs, n=4, t-test, p=0.0078; S32826 10µM 48 hrs, n=5, t-test, 
p=0.0095). This inhibition of ATX-lysoPLD activity resulted in an attenuation of both the 
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upregulation of Cnp and Ugt8 expression and the downregulation of Egr1 expression 
(Fig. 2.5D) (Cnp: HA130 10µM, n=3, t-test, p=0.0224, S32826 10µM, n=3, t-test, 
p=0.0159; Ugt8: HA130 10µM, n=3, t-test, p=0.0321, S32826 10µM, n=3, t-test, 
p=0.0063; Egr1: HA130 10µM, n=4, t-test, p=0.0051, S32826 10µM, n=3, t-test, 
p=0.0345). The above findings demonstrate that ATX, via its lysoPLD activity and 
similar to what we have seen in the developing zebrafish (Figs. 2.1-4), promotes gene 
expression changes associated with OLG differentiation in primary cultures of rodent 
OLGs.  
 
In primary cultures of rodent OLGs, ATX-lysoPLD promoted progression along 
the early stages of the OLG lineage is associated with an increase in HDAC 
activity  
The gene expression changes observed upon inhibition of ATX’s lysoPLD activity 
(Fig. 2.5D) mimicked those changes previously described to occur upon inhibition of 
HDAC activity (Swiss et al., 2011), thus suggesting that, as in the zebrafish, these 
changes may be associated with a decrease in overall HDAC activity.  To assess this 
possibility, the experimental design as shown in Fig. 2.6A was used. Indeed, HDAC 
activity was found to be decreased as early as 4 hrs and up to 24 hrs post-application of 
ATX-lysoPLD inhibitors (Fig. 2.6B) (HA130 10µM 28 hrs, n=5, t-test, p=0.0280; HA130 
10µM 48 hrs, n=7, t-test, p=0.0001; S32826 10µM 28 hrs, n=3, t-test, p=0.0004; 
S32826 10µM 48 hrs, n=5, t-test, p=0.0034). To provide further evidence for a direct link 
between ATX’s lysoPLD activity and the regulation of HDAC activity, we performed 
rescue experiments in which LPA, the enzymatic product of ATX’s lysoPLD activity, was 
added concurrent with ATX-lysoPLD inhibitors. As shown in Fig. 2.6C, addition of LPA 
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(10 µM) attenuated the effect of HA130 on HDAC activity (n=7, t-test, p=0.0003). 
Consistent with LPA’s thereby suggested HDAC activity promoting role in differentiating 
OLGs, LPA treatment alone was found to lead to an increase in HDAC activity (Fig. 
2.6D) (n=4, t-test, p=0.0052). Taken together, the above data confirm that, as in the 
developing zebrafish, progression along the early stages of the OLG lineage in rodents 
is promoted by ATX’s lysoPLD activity via the generation of LPA and a downstream 
mechanism that involves an increase in HDAC activity.  
 
ATX-lysoPLD promoted increase in HDAC activity is associated with a decrease 
in nuclear histone acetylation 
It has been previously shown that HDAC activity in differentiating OLGs is 
primarily directed to lysine residues of histones H4 and H3 including the lysine residue 
on the tail of histone H3 at position 9 (H3K9) (Swiss et al., 2011). To assess changes in 
acetylation at this site, cells treated as depicted in Fig. 2.5A were analyzed at 48 hrs by 
immunocytochemistry combined with confocal microscopy. As shown in Fig. 2.7A, 
nuclear histone acetylation can be readily detected in O4-positive differentiating OLGs 
by this method. Most importantly, inhibition of ATX’s lysoPLD activity led to a significant 
increase in the levels of H3K9 acetylation (Fig. 2.7C) (HA130: n=3, Mann-Whitney U-
test, p=0.00005; S32826: n=3, Mann-Whitney U-test, p=0.0003). This effect was not 
found to be associated with changes in cell survival or proliferation as determined by 
immunostaining using antibodies specifically recognizing the active (cleaved) form of 
caspase-3 (n=3, t-test, p=0.1355) or the Ki67 antigen (n=3, t-test, p=0.1189). In 
addition, no prominent changes in cellular morphology or nuclear appearance were 
noted (Fig. 2.7B). The above described increase in H3K9 acetylation upon ATX-
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lysoPLD inhibition could be further confirmed by Western blot analysis of cell 
homogenates (Fig. 7D) (n=3, t-test, p=0.0442). Taken together, our data so far 
demonstrate that attenuation of OLG differentiation via inhibition of ATX’s lysoPLD 
activity (Figs. 2.2, 2.3 and 2.5) is associated with a decrease in HDAC activity (Figs. 2.4 
and 2.6) and an increase in histone acetylation (Fig. 2.7).  
 
ATX-lysoPLD promoted progression along the early stages of the OLG lineage is 
dependent on the activity of HDAC1/2 but not HDAC6 
The general requirement of HDAC activity for OLG differentiation has been 
previously shown to involve particularly the class I HDAC members HDAC1 and HDAC2 
(Shen et al., 2008; Wu et al., 2012; Ye et al., 2009). To investigate the extent to which 
ATX’s lysoPLD activity may represent an upstream signal regulating especially the 
activity of the class I HDAC members HDAC1 and HDAC2, we used a pharmacological 
HDAC1/2/3 inhibitor, namely CI994 (Beckers et al., 2007; Kraker et al., 2003), in the 
experimental design as depicted in Fig. 2.8A.  It is of note that HDAC3 was found to not 
be involved in the regulation of OLG differentiation at the stages analyzed here (Shen et 
al., 2008; Wu et al., 2012). In addition, at the concentration used (2.5 µM), CI994 is 
considered to effectively inhibit HDAC1 (Beckers et al., 2007). The effectiveness of 
HDAC1/2 inhibition in our system is corroborated by the observed reduction in Ugt8 
mRNA levels (Fig. 2.8B), as its expression has been previously shown to be regulated 
by direct targets of HDAC1/2-mediated histone deacetylation (Swiss et al., 2011). 
Furthermore, and as a control, inhibition of HDAC6, which represents a class II HDAC 
member, was performed by using the inhibitor Tubastatin A (Butler et al., 2010). At the 
concentration used (5 µM), Tubastatin A is considered to effectively inhibit HDAC6 with 
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additional but only moderate activity at HDAC8 (Beckers et al., 2007). Neither HDAC6 
nor HDAC8 have been found involved in the regulation of gene expression changes 
associated with OLG differentiation (Noack et al., 2014; Shen et al., 2005, 2008; Wu et 
al., 2012), and HDAC6 has in OLGs functionally been primarily implicated in 
contributing to the clearing process of misfolded protein aggregates (Leyk et al., 2015; 
Noack et al., 2014). As indicated above and shown in Fig. 2.8, application of CI994, but 
not Tubastatin A, attenuated the expression of the OLG differentiation genes Ugt8 and 
Cnp to a similar extent as the application of the ATX-lysoPLD activity inhibitor HA130 
(Ugt8: HA130, n=3, t-test, p=0.0299; CI994, n=3, t-test, p=0.0176; Tubastatin A, n=3, 
t-test, ns; Cnp: HA130, n=3, t-test, p=0.0382; CI994, n=3, t-test, p=0.0270; Tubastatin 
A, n=3, t-test, ns). To assess the extent to which HDAC1/2 activity may be required for 
the observed ATX-lysoPLD-mediated changes in gene expression, the effect of 
HDAC1/2/3 or HDAC6 inhibition on LPA-stimulated rescue was determined. In 
agreement with a critical role of HDAC1/2, but not HDAC6, the addition of LPA was 
unable to rescue the effect of ATX-lysoPLD inhibition on Ugt8 and Cnp mRNA levels in 
the presence of CI994, but not Tubastatin A (Fig. 2.8B,C) (Ugt8: HA130+CI994+LPA, 
n=3, t-test, p=0.0033; HA130+Tubastatin A+LPA, n=3, t-test, p=0.0373; Cnp, 
HA130+CI994+LPA, n=3, t-test, p=0.0036; HA130+Tubastatin A+LPA, n=3, t-test, 
p=0.0325). It is of note that ATX-lysoPLD inhibition could be observed as early as 2 hrs 
post-application of HA130 (not shown) and was thus fully effective at the time-point of 
HDAC inhibition. Furthermore, no additive or synergistic effects were observed upon 
additional inhibition of HDAC1/2/3 or HDAC6 (data not shown). Moreover, CI994 
(Kraker et al., 2003), tubastatin A (Parab et al., 2015) and LPA (our own data, not 
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shown) have been shown to exert their effects within the first 2 hrs of treatment, thus 
largely excluding a timely separation of their actions. Thus, the above data provide 
strong support for a crucial role of the class I HDAC members HDAC1 and HDAC2 as 
downstream targets mediating the OLG differentiation promoting effect of ATX’s 
lysoPLD activity.  
 
Discussion 
Our data presented here, suggest a modulatory role of ATX during the transition 
from an OLG progenitor to an early stage differentiating OLG as depicted in our 
proposed model shown in Fig. 2.9. In this model, LPA, generated via ATX’s lysoPLD 
activity, activates one (or more) of its cognate G protein-coupled receptors, which are 
referred to as LPA receptors (Choi and Chun, 2013; Chun et al., 2010; Kihara et al., 
2014) and have been found expressed by cells of the OLG lineage (Dawson et al., 
2003; Nogaroli et al., 2009b; Stankoff et al., 2002; Weiner et al., 1998; Zhang et al., 
2014). Activation of the above ATX-LPA axis initiates a downstream signaling cascade 
leading to the activation of HDAC1/2, which in turn mediates histone deacetylation and 
repression of transcriptional inhibitors of OLG differentiation, thereby promoting gene 
expression changes that are associated with the transition from an OLG progenitor to 
an early stage differentiating OLG. ATX has been found to be expressed and secreted 
by OLG progenitors and differentiating OLGs (Figs. 2.4, 2.5 and Fox et al., 2003; Fuss 
et al., 1997; Savaskan et al., 2007) thus suggesting an autocrine signaling mechanism. 
However, and during development, paracrine regulation may also occur via the 
secretion of ATX by cells of the floor plate (Yuelling et al., 2012). Importantly, the 
regulatory mechanism described here appears evolutionarily conserved, at least from 
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zebrafish to rodents.  
In the context of histone deacetylation during the early stages of OLG differentiation, 
it is of note that HDAC1/2 activity has not only been implicated in modulating the 
transition from an OLG progenitor to an early stage differentiating OLG, but also the 
specification of an OLG progenitor from a multipotent neural progenitor cell (Copray et 
al., 2009; Jacob et al., 2011). However, and based on the data shown here, HDAC1/2-
mediated regulation of OLG progenitor specification is unlikely to be modulated by ATX 
and its lysoPLD activity. First, inhibition of ATX-lysoPLD activity was not found to affect 
the expression of nkx2.2.a (Fig. 2.4), which has been described to be upregulated upon 
early developmental loss of HDAC1 activity (Cunliffe and Casaccia-Bonnefil, 2006). 
Second, ATX and its lysoPLD activity were not found to affect the expression of olig2, 
which during OLG progenitor specification has been proposed to be modulated via 
HDAC1/2 activity and upstream of sonic hedgehog signaling (Cunliffe and Casaccia-
Bonnefil, 2006; Ye et al., 2009). Hence, it appears that ATX, via its lysoPLD activity, 
modulates HDAC1/2-regulated gene expression explicitly during a developmental time 
window that coincides with the transition from OLG progenitor to early stage 
differentiating OLG and that likely occurs post-sonic hedgehog-modulated HDAC1/2-
regulated gene expression implicated in OLG progenitor specification. Future work will, 
however, be necessary to more precisely define the relationships between the ATX-LPA 
axis, sonic hedgehog signaling and their downstream effects on HDAC1/2-regulated 
gene expression.  
In general, it is becoming more and more clear that histone acetylation and 
deacetylation events represent dynamic modifications (Peserico and Simone, 2011). 
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Consistent with this notion, histone deacetylation in cells of the OLG lineage has been 
found to be transient and reversible (Shen et al., 2005). In a search for more stable 
repressive histone modifications, marks of trimethylation of lysine residue K9 on histone 
3 (H3K9) have recently been found to coincide with the transition from OLG progenitor 
to differentiating OLG (Liu et al., 2015). Thus, it will be interesting to explore in 
subsequent studies a potential role of the ATX-LPA axis in modulating H3K9 
methyltransferases.  
ATX has been demonstrated to possess two functionally distinct domains, the 
lysoPLD active site and the MORFO domain. Our data presented here, demonstrate 
that ATX’s lysoPLD active site affects epigenetic and gene expression aspects of OLG 
differentiation. In contrast, and based on our previous data, the function of ATX’s 
MORFO domain, as it relates to OLG differentiation, appears restricted to promoting 
cytoskeletal and thus morphological changes (Dennis et al., 2008, 2012; Fox et al., 
2003). This concept that OLG morphogenesis is regulated, at least in part, by 
mechanisms distinct from the ones affecting gene expression is supported by 
previous findings (Buttery and ffrench-Constant, 1999; Ishii et al., 2012; Osterhout et 
al., 1999; Sloane and Vartanian, 2007; Younes-Rapozo et al., 2009). At the same 
time, however, it is also well-known that both of the above stated aspects of OLG 
differentiation occur well-synchronized during development (Bauer et al., 2009; 
Mitew et al., 2014; Wegner, 2008). Taken together, these observations raise the 
exciting possibility that ATX, via the concerted action of its two distinct functional 
activities, may be one of the critical players coordinating gene expression and 
morphological changes during OLG differentiation.  
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The functional effects of ATX’s lysoPLD activity have been well-described to be 
mediated by signaling through a family of G protein-coupled receptors, the so-called 
LPA receptors. To date, there are six receptors that are recognized as bona fide LPA 
receptors, all of which appear to be expressed, at least to some degree, in cells of the 
OLG lineage (Zhang et al., 2014). Notably, LPA1 has long been known to be present on 
OLGs (Dawson et al., 2003; Nogaroli et al., 2009b; Stankoff et al., 2002; Weiner et al., 
1998), and a number of functional roles have been proposed based on tissue culture 
studies. Somewhat disappointingly, Lpar1 knock-out mice have initially not been found 
to display CNS myelin-related pathologies (Contos et al., 2000, 2002). Myelin defects 
were, however, reported in more recent studies analyzing the so-called Málaga variant 
(maLpar1 null mice), a stable variant of the original Lpar1 knock-out mouse strain in 
which defects are more pronounced likely due to interactions of LPA1 with currently 
unknown genetic modifiers (Estivill-Torrús et al., 2008; García-Díaz et al., 2015). In 
maLpar1 null mice, impaired transport of one of the major myelin proteins, namely 
proteolipid protein, was found to be impaired leading to loss of OLGs most likely due to 
stress-induced apoptosis. No deficits in OLG differentiation were noted in these mice. 
Thus, and despite its prominent expression in OLGs, LPA1 appears unlikely to play a 
major role in mediating the ATX-LPA-HDAC1/2 axis described here.  
To our knowledge, null mice have been generated for all currently recognized LPA 
receptors with the exception of LPA6 (Contos et al., 2000, 2002; Lin et al., 2012; Liu et 
al., 2010; Ye et al., 2005). In addition, knock-down studies have been performed in the 
zebrafish and in Xenopus laevis that cover all known bona fide LPA receptors (Geach et 
al., 2014; Yukiura et al., 2011). In neither of the studies have myelin defects been 
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reported. This does not exclude a prominent role of LPA receptor signaling in OLGs but 
rather highlights the complication of functional redundancy and compensation when 
eliminating a single LPA receptor. For example, it has been shown that combined 
knock-down of lpar1 and lpar4 in the zebrafish leads to vascular defects while single 
lpar knock-down has no effect (Yukiura et al., 2011). Similarly, male reproductive 
defects have been observed in triple Lpar1/2/3 knockout mice but not any of the single 
Lpar knockout mice (Ye et al., 2008). In the context of our studies it is interesting that for 
the triple knockout mice no myelin defects have been reported, thus suggesting an 
involvement of at least one of the remaining LPA receptors, namely LPA4, LPA5 and/or 
LPA6. Out of these, LPA4 has been shown to activate PKA via coupling to the 
heterotrimeric G-protein Gαs and increase in cyclic AMP (cAMP) levels (Gardell et al., 
2006). PKA, in turn, has been implicated in regulating HDAC activity via phosphorylation 
(Sengupta and Seto, 2004). While LPA5 was found to not couple to Gαs, its stimulation 
was nevertheless found to be associated with an increase in cAMP levels possibly 
through involvement of G protein βγ subunits (Lee et al., 2006). LPA6 may couple to Gαs, 
however with likely much lower potency than LPA4 (Yanagida et al., 2009a). Clearly, 
more comprehensive analyses will be necessary to dissect the exact roles for each of 
the LPA receptors in the regulation of OLG differentiation and via the ATX-LPA axis. 
Our data presented here, reveal a novel functional role for ATX’s lysoPLD activity, 
namely the promotion of OLG differentiation via an increase in HDAC1/2 activity and 
associated changes in gene expression. In the context of human diseases and in 
particular the major demyelinating disease in human, Multiple Sclerosis (MS), it is 
worth mentioning that ATX mRNA levels have been found reduced within the MS CNS 
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(Raddatz et al., 2014) and that a shift toward a decrease in histone deacetylation has 
been implicated in contributing to the limitations in myelin repair seen in MS (Pedre et 
al., 2011). These findings further support a critical role of ATX in the regulation of CNS 
myelination, and they suggest that misregulation of the ATX-LPA-HDAC1/2 axis may 
contribute to the pathology seen in MS. 
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Figure 2.1. In the developing zebrafish, CRISPR-Cas9-mediated mutagenesis of atx 
leads to a reduction in the mRNA levels for OLG marker genes. A, atx (enpp2) genomic 
structure and CRISPR target sequences. ATG and TGA indicate the locations of the 
translation start and stop sites. Protospacer adjacent motif (PAM) sequences are 
highlighted in red. The sequence encoding T210, the threonine residue shown to be 
obligatory for ATX’s enzymatic activity, is underlined. B,D, Representative images of 
agarose gels showing DNA fragments upon Surveyor nuclease treatment of control 
homoduplexes (c) and control/atx-E2 (B) or control/atx-E7 (D) homo/heteroduplexes. 
Numbers on the left indicate DNA sizes in bp. Arrowheads indicate cleaved PCR 
amplicon fragments at the expected sizes indicative of indel mutations generated by 
genome editing. C,E, Representative images of sequencing traces obtained from 
genomic DNA-derived PCR amplicons from control and Cas9 mRNA/sgRNA injected 
zebrafish embryos. Arrows at the top of each trace indicate the location of the target 
sequence, over and upstream of which a composite sequence trace indicates the 
presence of indel mutations generated by genome editing. F,G, Bar graphs illustrating 
mRNA levels for atx (F) or the OLG marker genes cldnk and plp1b (G) in whole 
embryos as determined by real-time reverse transcription (RT)-qPCR analysis. Control 
(uninjected embryos) values were set to 100% (see horizontal line) and experimental 
values were calculated accordingly. Data shown represent means ± SEM. nsnot 
significant, *p≤0.05, **p≤0.01, ***p≤0.001. H, Representative brightfield images of 
control (uninjected) and Cas9 mRNA/sgRNA injected embryos at 48 hpf. Scale bar: 1 
mm.  
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Figure 2.2. In the developing zebrafish, inhibition of ATX’s lysoPLD activity during early 
stages of OLG differentiation leads to a reduction in the levels of OLG-enriched 
transcripts without apparent effects on the number of olig2-positive cells. A, 
Experimental design. Embryos were treated with the ATX-lysoPLD inhibitors HA130 and 
S32826 at a time point when newly specified OLG progenitors start to differentiate. B, 
Bar graph depicting ATX-lysoPLD activity in whole embryos as assessed by using the 
fluorogenic substrate FS-3. C,D,  Bar graphs illustrating mRNA levels for the OLG 
marker genes cldnk (C) and plp1b (D) in whole embryos as determined by real-time 
reverse transcription (RT)-qPCR analysis. E, Bar graph showing the number of olig2-
positive progenitors in whole embryos as determined through whole mount in-situ 
hybridization. F, Representative extended focus images of whole mount embryos after 
in situ hybridization with a probe specific for olig2. Dorsal views over the hindbrain are 
shown with anterior to the top. Scale bar: 50 µm. G, Representative brightfield images 
of control (vehicle-treated) and ATX-lysoPLD inhibitor treated embryos at 48 hpf. Scale 
bar: 1 mm. For all bar graphs, control (vehicle-treated) values were set to 100% (see 
horizontal line) and experimental values were calculated accordingly. Data shown 
represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 2.3. In the developing zebrafish, inhibition of ATX’s lysoPLD activity during the 
time window when olig2-positive progenitors arise in the hindbrain leads to a reduction 
in the levels of OLG-enriched transcripts without apparent effects on the number of 
olig2-positive cells. A, Experimental design. Embryos were treated with the ATX-
lysoPLD inhibitors HA130 and S32826 during the time window when olig2-positive 
progenitors arise in the ventral hindbrain. B, Bar graph depicting ATX-lysoPLD activity 
in whole embryos as assessed by using the fluorogenic substrate FS-3. C,D, Bar 
graphs illustrating mRNA levels for the OLG marker genes cldnk  (C) and plp1b (D) in 
whole embryos as determined by real-time reverse transcription (RT)-qPCR analysis. 
Note that loss of inhibitory activity as seen for S32826 results in an attenuated effect on 
cldnk and plp1b mRNA levels, thus suggesting that ATX, via its lysoPLD activity, 
regulates OLG differentiation during a critical developmental window. E, Bar graph 
showing the number of olig2-positive progenitors in whole embryos as determined 
through whole mount in-situ hybridization. F, Representative extended focus images of 
whole mount embryos after in situ hybridization with a probe specific for olig2. Dorsal 
views over the hindbrain are shown with anterior to the top. Scale bar: 50 µm. G, 
Representative brightfield images of control (vehicle-treated) and ATX-lysoPLD inhibitor 
treated embryos at 48 hpf. Scale bar: 1 mm. For all bar graphs, control (vehicle-treated) 
values were set to 100% (see horizontal line) and experimental values were calculated 
accordingly. Data shown represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.01, 
***p≤0.001. 
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Figure 2.4. In the developing zebrafish, inhibition of ATX’s lysoPLD activity during early 
stages of OLG differentiation leads to a reduction in HDAC activity within cells of the 
OLG lineage. A, Experimental design using Tg(nkx2.2a:megfp;olig2:dsred2) zebrafish 
embryos, which were treated with the ATX-lysoPLD inhibitors HA130 (10 µM) or 
S32826 (10 µM) at a time point when newly specified OLG progenitors start to 
differentiate. B, Bar graph illustrating the mRNA expression profile under control 
conditions for FACS-isolated mEGFP/DsRed2 double-positive cells as determined by 
real-time reverse transcription (RT)-qPCR analysis. mRNA levels in whole fish were set 
to 100% for each gene individually (marked by the horizontal line) and the values for 
sorted cells were calculated accordingly. C, Bar graph showing the number of 
mEGFP/DsRed2 double-positive cells as determined by FACS analysis. Values for 
vehicle-treated embryos were set to 100% (see control bar) and experimental values 
were calculated accordingly. D,E, Representative single-parameter fluorescence 
histograms (x axis: fluorescence intensity, logarithmic scale; y axis: cell number) 
depicting mEGFP (D) or DsRed2 (E) intensities of mEGFP/DsRed2 double-positive 
cells under control conditions (black line) and upon treatment with HA130 (red line). 
Cells within the area marked by the horizontal line were considered mEGFP (D)- or 
DsRed2 (E)-positive. Note the high purity (100%) of the sorted cell population. F, Bar 
graph depicting sox10 mRNA levels for FACS-isolated mEGFP/DsRed2 double-positive 
cells as determined by real-time reverse transcription (RT)-qPCR analysis. Values for 
vehicle-treated embryos were set to 100% (see control bar) and experimental values 
were calculated accordingly. G, Bar graph depicting HDAC activity as determined by 
using the fluorogenic substrate Boc-Lys(Ac)-AMC. Values for vehicle-treated embryos 
were set to 100% (see control bar) and experimental values were calculated 
accordingly. Data shown in all bar graphs represent means ± SEM. nsnot significant, 
*p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 2.5. In rodent OLG cultures, inhibition of ATX’s lysoPLD activity leads to a 
reduction in the levels of mRNAs encoding OLG differentiation genes and to an 
increase in the level of mRNA encoding the transcriptional OLG differentiation inhibitor 
Egr1. A, Experimental design. Timing of histone deacetylation is marked as described 
by Marin-Husstege et al. (2002). OPC: OLG progenitor. B, Bar graph depicting mRNA 
levels for the OLG differentiation genes Cnp and Ugt8 and the transcriptional inhibitor 
Egr1 as well as Atx as determined by real-time reverse transcription (RT)-qPCR 
analysis. mRNA levels at 24 hrs were set to 100% for each gene and 48 hrs values 
were calculated accordingly. C, Bar graph illustrating ATX-lysoPLD activity as assessed 
by using the fluorogenic substrate FS-3. Control (vehicle-treated) values were set to 
100% (see horizontal line) and experimental values were calculated accordingly. D, Bar 
graph depicting mRNA levels for the OLG differentiation genes Cnp and Ugt8 and the 
transcriptional inhibitor Egr1 as determined by real-time RT-qPCR analysis. Control 
(vehicle-treated) values were set to 100% (see horizontal line) and experimental values 
were calculated accordingly. Data shown in all bar graphs represent means ± SEM. 
nsnot significant, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 2.6. In rodent OLG cultures, inhibition of ATX’s lysoPLD activity leads a 
reduction in HDAC activity. A, Experimental design. Timing of histone deacetylation is 
marked as described by Marin-Husstege et al. (2002). OPC: OLG progenitor. B-D, Bar 
graphs showing HDAC activity as determined by using the fluorogenic substrate Boc-
Lys(Ac)-AMC. Control (vehicle-treated) values were set to 100% (see horizontal line in 
B and control bars in C,D) and experimental values were calculated accordingly. Data 
represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 2.7. In rodent OLG cultures, inhibition of ATX’s lysoPLD activity leads to an 
increase in nuclear histone acetylation at lysine residue 9 of histone 3 (H3K9). A,B, 
Representative confocal images of differentiating OLGs treated with vehicle (control, 
upper panel) or HA130 (lower panel) and immuno-labeled using O4 hybridoma 
supernatants (A,B) and anti-acetyl-histone H3K9 antibodies (A). Nuclei are visualized 
via staining with Hoechst (A,B). Scale bars: 20 µm in A, 100 µm in B. C, Box and 
whisker plot depicting nuclear acetyl-H3K9 levels as assessed by determining 
fluorescence intensities shown in arbitrary units (a.u.). The plot depicts medians and 
quartiles of three independent experiments. Whiskers represent the 10th and 90th 
percentile. ***p≤0.001. D, Bar graph illustrating acetyl-H3K9 levels as assessed by 
Western blot analysis. A representative Western blot image is shown in the inset (upper 
right). For the bar graph, control (vehicle-treated) values were set to 100% (see control 
bar) and experimental values were calculated accordingly. Data represent 
means ± SEM. *p≤0.05 (Student’s t-test).  
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Figure 2.8. In rodent OLG cultures, LPA rescue of ATX-lysoPLD activity inhibition 
requires the activity of class I HDAC members HDAC1 and HDAC2 but not the class II 
HDAC member HDAC6. A, Experimental design. Timing of histone deacetylation is 
marked as described by Marin-Husstege et al. (2002). OPC: OLG progenitor. B,C, Bar 
graphs depicting mRNA levels for the OLG differentiation genes Ugt8 (B) and Cnp (C) 
as determined by real-time reverse transcription (RT)-qPCR analysis. Control (vehicle-
treated) values were set to 100% (see horizontal line) and experimental values were 
calculated accordingly. Data represent means ± SEM. nsnot significant, *p≤0.05, 
**p≤0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
  
			
	
75	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
			
	
76	
Figure 2.9. Proposed model for the role of the ATX-LPA axis in OLG differentiation. 
ATX, which has been found secreted by OLGs throughout the early stages of the 
lineage, generates the lipid signaling molecule lysophosphatidic acid (LPA) via its 
enzymatically active lysoPLD site. LPA, in turn, activates one (or more) of its cognate 
receptors (LPARs) on the surface of OLG progenitors, which leads to the downstream 
activation of histone deacetylase 1 and 2 (HDAC1/2) in the nucleus. Histone 
deacetylation mediates the repression of transcriptional inhibitors of OLG differentiation 
and thereby promotes gene expression changes associated with the differentiation from 
an OLG progenitor (OPC) to an early differentiating OLG (Pro-OLG). Expression 
markers identifying individual stages of the OLG lineage are listed below each OLG 
stage. Markers in black were used in both the zebrafish and rodent studies, while 
markers in light and dark grey are unique for the zebrafish and rodent studies, 
respectively. 
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Chapter 3 
 
 Introduction to Lysophosphatidic Acid (LPA) and their Receptors 
 
Lysophosphatidic acid (LPA)  
Lysophospholipids are phospholipid derivatives originating from cell membranes 
and one of the best studied lysophospholipids is lysophosphatidic acid (LPA). First 
known as a biosynthetic metabolite of cell membrane phospholipids, LPA is now 
regarded as an important regulator for diverse biological functions.	 The molecular 
species of LPA encompass diverse ligands that can vary in length and degree of 
saturation of their fatty acid chain, which is esterified at the sn-1 or sn-2 position of the 
glycerol backbone. The most abundant plasma species of LPA, in humans, is the 16:0 
form, which contains a palmityl chain (Choi et al., 2010a). The term LPA, however, 
commonly refers to the 18:1 species, which is also the most commonly used research 
reagent for LPA signaling studies (Yung et al., 2014). The 18:0 and 18:1 species are the 
most common species found in the spinal cord (Das and Hajra, 1989a; Santos-Nogueira 
et al., 2015). Remaining LPA moieties reported in serum and plasma are 18:2, 16:1 and 
20:4. All known LPA species are synthesized via two major metabolic routes (Fig. 3.1), 
and exhibit different functional effects.  
LPA species are generated by the conversion of membrane phospholipids to 
lysophospholipids, such as LPC, by the action of phospholipase A1 (PLA1), 
phospholipase A2 (PLA2), or PLA1 and lecithin-cholesterol acyltransferase (LCAT), 
depending on the location of synthesis. ATX’s lysoPLD active site is needed to convert 
the lysophospholipids into LPA species (Aoki et al., 2008a; Moolenaar and Perrakis, 
2011). Lysophosphatidyl choline (LPC), the main substrate of ATX’s lysoPLD active 
			
	
78	
site, is by far the most abundant lysophospholipid, in plasma and serum, and is mainly 
found bound to albumin (Croset et al., 2000; Ojala et al., 2006; Tokumura et al., 1999). 
The amount of LPC sufficient for ATX to mediate the conversion to LPA, and 
subsequently activate LPA receptors, is limited to a few micromolars (Jongsma et al., 
2011; Umezu-Goto et al., 2002). Although ATX is the primary LPA producing 
phospholipase in plasma, an alternative, but less common, route of LPA production 
requires the hydrolysis of phosphatidic acid (PA) by the membrane- associated 
phospholipase A1/A2 (PA-PLA1/2) (Aoki et al., 2002, 2008b; Inoue et al., 2011).  
LPA receptors  
The pluripotent, lipid signaling mediator, LPA, exerts its widespread functions 
through the binding and activation of six distinct G protein-coupled receptors (GPCRs), 
which are differentially expressed and show both overlapping and distinct signaling 
properties (Chun, 2013; Chun et al., 2010). In 1996, the first LPA receptor, LPA1 was 
identified in the ventricular zone of the embryonic brain (Hechtet al., 1996; Chun et al., 
2007). LPA1-6 can be divided into two families and are named in the order in which they 
were discovered. The classical receptors, LPA1/Edg-2/vzg-1, LPA2/Edg-4 and 
LPA3/Edg-7, belong to the endothelial differentiation gene (Edg) family, which also 
includes five GPCRs for the lipid mediator sphingosine 1-phosphate (S1P) (An et al., 
1997; Bandoh et al., 1999; Chun, 2013; Hecht et al., 1996). Three additional LPA 
receptors LPA4/ P2Y9/GPR23, LPA5/GPR92 and LPA6/P2Y5/GPR87 are more closely 
related to the purinergic receptor (P2Y) family of GPCRs (Kotarsky et al., 2006; Lee et 
al., 2009a, 2009b; Noguchi et al., 2003; Tabata et al., 2007; Yanagida et al., 2009b, 
2013). These LPARs couple to all four Gα proteins (G12/13, Gq/11, Gi/o, and Gs) and have 
			
	
79	
several converging signaling pathways.  
Albeit with different potencies, all six LPA receptors can be stimulated by 1-acyl-
LPA. LPA3 and LPA6 stand out as they prefer unsaturated 2-acyl-LPA as a ligand, while 
LPA5 exhibits a strong preference for ether-linked 1-alkyl-LPA species (Jongsma et al., 
2011; Williams et al., 2009). Additionally, LPA receptors are expressed in most cell 
types of the nervous system, including neural progenitors, primary neurons, astrocytes, 
microglia, OLGs and Schwann cells (Noguchi et al., 2009).  Due to the complexity of the 
LPAR pathways, overall heterogeneity of subtypes and different expression patterns, 
the effects of LPA are diverse and extensive, regulating many biological functions 
including cell growth, differentiation, survival, motility, and cytoskeletal morphology 
(Choi et al., 2010b; Sano et al., 2002).  
LPA-mediated effects on cells of the CNS  
 
The initial finding outlining that the brain has the highest tissue concentration of 
LPA (Das and Hajra, 1989b), triggered investigative studies of LPA in the CNS. All six 
known LPA receptors are expressed at varying levels in the CNS during development 
and/or postnatal life (Choi et al., 2010a; Fukushima et al., 2001; Lin et al., 2012; 
Noguchi et al., 2009; Pasternack et al., 2009). LPA has been shown to influence myriad 
responses in neurons and glia cell types through its cognate receptors. These receptor–
mediated activities have been identified as important factors in disease states, including 
fetal hypoxia and hydrocephalus (Herr et al., 2011; Yung et al., 2011), neuropathic pain 
(Inoue et al., 2004; Lin et al., 2012; Nagai et al., 2010), ischemic stroke (Li et al., 2008), 
neurotrama (Frugier et al., 2011), neuropsychiatric disorders (Mirendil et al., 2015), 
developmental disorders, Sandhoff disease and MS (Choi and Chun, 2013). 
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With regard to glia cells, astrocytes, microglia and OLGs all express LPA 
receptors. Of particular interest to my studies, LPA1-6 receptors are all expressed on 
OLGs, though at different levels. Through them LPA can initiate a variety of signaling 
cascades in the cell. More specifically, LPA modulates calcium signaling and activates 
the ERK1/2 pathway in OLGs , and can increase MBP expression in differentiating 
OLGs (Nogaroli et al., 2009a). Additionally, LPA plays a role in the cytoskeletal 
maturation of OLGs, as its expression leads to the inhibition of process formation in 
OPCs and increased membrane formation of OLGs, revealing a time dependent role for 
LPA (Dawson et al., 2003; Nogaroli et al., 2009a; Stankoff et al., 2002). Furthermore, 
LPA has been shown to promote OLG cell survival, though these effects were only seen 
in an OLG cell line (Li et al., 2003; Matsushita et al., 2005; Stankoff et al., 2002; Weiner 
and Chun, 1999). 
The LPAR expression profile in astrocytes is quite confusing as cultured 
astrocytes have been shown to express Lpar1-5 (Shano et al., 2008; Sorensen et al., 
2008), however, in vivo, astrocytes appear to express few LPA receptor subtypes aside 
from low levels of Lpar1 (Cervera et al., 2002; Tabuchi et al., 2000). The expression of 
Lpar6 in astrocytes has also yet to be confirmed. Interestingly, LPA has been found to 
stimulate astrocyte proliferation (Shano et al., 2008). Studies investigating LPARs in 
microglia, the resident immune cells of the CNS, found Lpar1 and Lpar3 expression in 
rodents (Möller et al., 2001; Tham et al., 2003), and Lpar1-3 expression in human 
microglia cells lines (Bernhart et al., 2010; Möller et al., 2001).  
LPAR expression can also be seen in neurons. Both Lpar1 and Lpar2 are 
expressed, with Lpar2 more abundantly (Fukushima et al., 2002; Noguchi et al., 2009). 
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Additionally, the expression of Lpar5 in sensory and motor neurons of the spinal cord 
has been linked to pain, whereby Lpar5 null mice appear to have a reduced pain 
phenotype (Lin et al., 2012). Interestingly, LPA promotes cortical neuronal progenitor 
cells (NPCs) to commit to the neuronal lineage via LPA1 signaling (Fukushima et al., 
2007; Kingsbury et al., 2003). In regards to neuronal morphology, LPA can alter the 
actin cytoskeleton and promote microtubule rearrangement (Fukushima and Morita, 
2006; Fukushima et al., 2002), as well as influence the morphology and motility of 
young postmitotic neurons (Fukushima et al., 2002). All in all, LPA, and its cognate 
receptor signaling pathways, plays an integral role in CNS circuitry and development, as 
well as disease pathology, and further investigative studies are needed to uncover the 
multitude of effects brought on by LPA. 
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Figure 3.1. Biosynthesis of lysophosphatidic acid (LPA). The membrane 
phospholipids phosphatidyl choline (PC), phosphatidyl ethanolamine (PE) or 
phosphatidyl serine (PS) get converted into their corresponding lyso-forms by the action 
of phospholipase A1 and A2 (PLA1/2). Autotaxin (ATX) then generates different LPA 
species using the lyso-forms of membrane lipids. Alternatively, PC, PE or PS are 
catalyzed into phosphatidic acid (PA) by phospholipase D (PLD). PLA1/2 then acts on 
phosphatidic acid (PA) and form LPA. The structures of some common human LPAs 
are shown. 
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Chapter 4 
 
The role of LPA6 in Oligodendrocyte Differentiation 
 
(This chapter is in preparation as a manuscript to be submitted to Glia. Samantha 
Spencer, Minh Nguyen and myself contributed to the work reported for this manuscript. 
Samantha Spencer performed the CRISPR/Cas9 injections and Minh Nguyen 
performed process network area and H3K9ac analysis) 
  
Introduction 
 
 Previously, we have shown that the ATX-LPA signaling axis is necessary to 
promote differentiation of OLGs. Since the product of ATX’s enzymatic lysoPLD active 
site, the lipid signaling molecule LPA, is well known to exert its function via the 
activation of one or more of its cognate signaling receptors, the LPA receptors, these 
data suggest a crucial role of LPA receptor signaling in the regulation of OLG 
differentiation and myelination. There are six known G protein-coupled, LPA receptors, 
all of which are expressed on OLGs (LPA1-6). However, loss of function studies have so 
far come up short in providing information regarding their in vivo role in myelination, 
potentially due to the redundant functions among LPA receptors and/or compensation 
upon the genetic deletion of a single receptor (Contos et al., 2000; Contos et al., 2002). 
On the other hand, changes in the molecular mechanisms that govern OLG 
development have not been extensively analyzed in these animals, with the exception 
of Lpar1 KO mice. Transgenic mice carrying a mutated lpar1 gene (maLPA1-null mice) 
exhibit decreased expression of myelin protein MBP, PLP/DM20 and CNPase (Garcia-
Diaz et al., 2015), however, these studies suggest LPA1 plays a role in the later stages 
of OLG development, and not during early OLG differentiation. Our studies, therefore, 
sought to further explore the role of LPARs in OLG differentiation. 
In the studies presented here, we focused on an LPA receptor about which there 
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is still little known, namely, LPA6. LPA6 is the most recently characterized member of the 
LPA receptor family. First identified as an orphan GPCR (Kaplan et al., 1993), activation 
of LPA6 by LPA has been shown to increase intracellular Ca2+ and ERK1/2 
phosphorylation (via Gi/o) and to activate Rho GTPase (via G12/13) (Lee et al., 2009c; 
Pasternack et al., 2008, 2009; Yanagida et al., 2009a). Little is known about the role of 
LPA6 in cellular physiology, except that it is required for human hair growth (Pasternack 
et al., 2008, 2009; Shimomura et al., 2008, 2009).  
After initial investigative studies, we report that LPA6 plays a novel role in OLG 
differentiation. LPA6 is found in differentiating OLGs, both in primary rat cultures as well 
as in the developing zebrafish. LPA6 expression is needed for proper OLG 
differentiation as siRNA mediated down-regulation or CRISPR(cas9) mediated mutation 
of LPA6 reduces the expression of differentiation genes, Cnp and Ugt8, in primary OLGs 
and a myelin specific gene, plp1b, in the developing zebrafish, respectively. 
Additionally, down-regulation of Lpar6 does not appear to affect overall OLG process 
network area. Therefore, the role of LPA6 appears to mediate the gene regulatory, 
rather than the cytoskeletal maturation, portion of OLG development along the lineage. 
Interestingly, down-regulation of Lpar6 did not alter specific epigenetic changes seen 
affected by the ATX-LPA axis and, therefore, may act in an alternative-signaling 
pathway. 
 
Materials and Methods 
Cell culture.  Primary OLG progenitors were isolated from postnatal day 2 (P2) rat 
brains by A2B5 immunopanning and cultured as previously described (Barres et al., 
1992; Lafrenaye and Fuss, 2010; Martinez-Lozada et al., 2014). Plated OLG 
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progenitors were cultured in serum-free proliferation medium (Dulbecco’s modified 
Eagle’s medium (DMEM) containing human PDGF and basic fibroblast growth factor 
(bFGF) (Gemini Bio-Products, Sacramento, CA) for 24hrs, after which cells were treated 
with siRNA reagents in antibiotic/FCS free DMEM containing PDGF/bFGF for 3hrs 
followed by removal of reagents and incubation in antibiotic/FCS free DMEM containing 
PDGF/bFGF for an additional 24hrs before allowed to differentiate in serum-free 
medium (DMEM containing 40 ng/mL tri-iodo-thyronine (T3; Sigma, St. Louis, MO) and 
N2 supplement (Life Technologies, Grand Island, NY); DMEM/T3/N2) over the time 
periods indicated. Typically, at least three independent experiments were performed, 
whereby an independent experiment refers to an experiment in which cells were 
isolated from a separate P2 rat litter at an independent time point (day) and treated 
separately from all other independent experiments.  
CRISPR/Cas9 genome editing. CRISPR target sequences for lpar6a and lpar6b as 
depicted in Fig. 4.2, were identified as described by Wheeler et al., 2015. sgRNAs were 
generated using the cloning-free/short oligonucleotide approach described by Talbot 
and Amacher (2014). Briefly, short-guide oligonucleotides containing a T7 promoter and 
genomic target site were synthesized as described in Wheeler et al., 2015. 1 nanoliter 
of a mixture of Cas9 mRNA (100 ng/µl) and sgRNA (120 ng/µl for lpar6a; 95 ng/µl for 
lpar6b) was injected per one-cell stage zebrafish embryo. Zebrafish were analyzed at 
48 hpf. Brightfield images of whole embryos were taken using an Olympus SZX12 zoom 
stereo microscope (Olympus America Inc., Melville, NY) equipped with an Olympus 
DP70 digital camera system.  
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RNA isolation and real-time RT-qPCR Analysis. For the isolation of RNA from whole 
zebrafish embryos or cultured rodent OLGs, samples were collected and analyzed as 
described in Wheeler et al., 2015. Gene-specific primers were designed and in silico 
tested for specificity using NCBI/Primer-BLAST (Ye et al., 2012). All primers were 
designed to amplify all known splice variants.  
atx/enpp2: forward (5’-CAATGTATGCAGCATTCAAACGAGTG-3’), reverse 
(5’CACCATTTTTCTCACTAGCGTAACG-3’) 
plp1b: forward (5’TGCCATGCCAGGGGTTGTTTGTGGA-3), reverse 
(5’-GGCGACCATGTAAACGAACAGGGC-3) 
cldnk: forward (5’-TGGCATTTCGGCTCAAGCTCTGGA-3’), reverse: (5’-
GGTACAGACTGGGCAATGGACCTGA-3) 
lpar6a: forward (5’-GCGGAGAGGATTGTAACTGCC-3’), reverse: (5’-
TTCGGGCAGTGAGTGACGTT-3) 
lpar6b: forward (5’-ACGGTGGGCTTCCTGATTCC-3’), reverse: (5’-
GACTGATGGTCTCGGGGTGG-3) 
β-actin (actb2)(Buckley et al., 2010) was used as reference gene; eef1a1/1 has been 
assessed as additional reference gene for the analysis of RNA derived from the 
developing zebrafish and no pronounced differences were noted (Yuelling et al., 2010). 
The following unmodified rat gene-specific primer pairs were used:  
Cnp: forward (5’-ATGCCCAACAGGATGTGGTG-3’), reverse 
(5’-AGGGCTTGTCCAGGTCACTT-3’) 
Ugt8:forward (5’-AGGAGCTCTGGGGAGATTGC-3’), reverse 
(5’-TTTGAATGGCCAAGCAGGTCA-3’) 
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Egr1:forward (5’-CCTGACCACAGAGTCCTTTTCT-3’), reverse 
(5’-AAAGTGTTGCCACTGTTGGG-3’) 
Lpar6: forward (5’-GTAAGCGCCAACGGCTCCA-3’),  
reverse (5’-GTAAGCGCCAACGGCTCCCA -3’) 
Pgk1 (as reference gene): forward (5’-ATGCAAAGACTGGCCAAGCTAC-3’), reverse 
(5’-AGCCACAGCCTCAGCATATTTC-3’) 
Pgk1 was used as reference gene due to its previously established expression stability 
in rat OLGs (Nelissen et al., 2010). In addition, Ppia has been assessed as additional 
reference gene for the analysis of RNA derived from differentiating OLG cultures and no 
pronounced differences were noted.  
RT-qPCR reactions with at least 2 technical replicates per sample were performed on a 
CFX96 real-time PCR detection system (BioRad, Hercules, CA) using the iQ SYBR 
Green Supermix (BioRad, Hercules, CA). PCR conditions were as follows: 95°C for 3 
min followed by 40 cycles of 95°C for 15 s, 58°C for 30 s, and 95°C for 10 s. For all 
primer pairs, melting curves were used to ensure specificity. Relative expression levels 
were determined using the ΔΔCT method (Livak and Schmittgen, 2001).  
HDAC activity assay. Rodent OLG progenitor cells were cultured and treated in 
fibronectin coated 96-well plates (1x105 cells/well) and then assayed as described by 
Wheeler et al., 2015.  
siRNA-mediate Gene Silencing. OPCs were transfected with ON-TARGETplus 
siRNA SMARTpools directed against rat Lpar6 (Thermo Fisher Scientific Inc., Pittsburg, 
PA) using Lipofectamine 2000 (Life Technologies Corp., Grand Island, NY). As control, 
an ON-TARGETplus non-targeting siRNA pool (Thermo Fisher Scientific Inc., Pittsburg, 
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PA) was used. Transfection medium containing siRNA-Lipofectamine complexes was 
replaced with serum-free medium (DMEM/PDGF/bFGF) after 3hrs, then the cells were 
cultured for 24hrs before replacing with differentiation medium (DMEM/N2/T3) as well 
as treatment (LPA, HA130 or vehicle) and was then cultured for an additional 24hrs. 
Knockdown of gene expression was assessed by qRT-PCR analysis. 
Immunocytochemistry. For immunocytochemistry using O4 hybridoma supernatants, 
cells were fixed in 4% paraformaldehyde/PBS, nonspecific binding sites were blocked in 
10% FCS/DMEM, and cells were incubated with the supernatant (1:1 diluted in 10% 
FCS/DMEM) overnight. Cells were fixed and in cases of dual staining, permeabilized 
using 0.5% Triton X-100/0.4 M sucrose/PBS and then incubated for 30 min in blocking 
solution (10% FCS/DMEM). Subsequently, cells were incubated overnight with anti-
acetyl-histone H3 (Lys 9), anti- LPA6, anti-Caspase 3 (active (cleaved) form) or anti-Ki67 
antibodies overnight. Primary antibodies were detected using Alexa 488- or Alexa 568-
conjugated secondary antibodies (Life Technologies, Grand Island, NY) and nuclei were 
counterstained using Hoechst 33342 (EMD Millipore, Billerica,MA). For the generation 
of representative images, confocal laser scanning microscopy was used (Zeiss LSM 
700, Carl Zeiss Microscopy, LLC, Thornwood, NY). Images represent 2D maximum 
projections of stacks of 0.5 µm optical sections.  
Nuclear histone acetylation analysis. Cells double-labeled for O4 and acetyl-histone 
H3 (Lys 9) were imaged using confocal laser scanning microscopy (LSM 700 Carl Zeiss 
Microscopy, LLC, Thornwood, NY) as described by Wheeler et al., 2015.   
Cell survival and proliferation analysis. Cells were subjected to immunostaining 
using O4 hybridoma cell supernatants and antibodies specifically recognizing the active 
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(cleaved) form of caspase-3 or the Ki67 antigen. To determine the number of caspase-3 
or Ki67 immunopositive cells, images of four fields per coverslip were taken with a 
20x/0.8 n.a. plan-apochromat objective lens using a confocal laser scanning microscope 
(LSM 700 Carl Zeiss Microscopy, LLC, Thornwood, NY) as described by Wheeler et al., 
2015. 
Isolation of OLG progenitors from zebrafish embryos using fluorescent activated cell-
sorting (FACS). OLG enriched populations extracted from 
Tg(nkx2.2a:megfp;olig2:dsred2) zebrafish embryos were collected as previously 
described by Wheeler et al., 2015.  
Statistical Analysis. To determine significance, GraphPad Prism (GraphPad 
Software, La Jolla, CA) or SigmaPlot (Systat Software, Inc., San Jose, CA) software 
was used. Data composed of two groups were analyzed using the two-tailed Student’s 
t-test or the Mann-Whitney U-test and presented in bar graphs depicting means ± SEM 
or box and whisker plots depicting medians and quartiles. Data compared to a set 
control value lacking variability were analyzed using the one-sample t-test (Dalgaard, 
2008; Skokal and Rohlf, 1995) and presented in bar graphs.  
 
Results  
Down-regulation of Lpar6 leads to a reduction in OLG differentiation genes and 
has no effect on OLG process network area 
During the time of OLG differentiation, OLGs express LPA1-6. To evaluate the role of 
LPA6 individually, primary OPCs, extracted from P2 rats, were transfected with siRNA 
pools specifically silencing Lpar6 expression. Knockdown of gene expression was 
confirmed by qRT-PCR, which revealed a reduction of roughly 50% (Fig. 4.1A). 
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Importantly, down-regulation of Lpar6 was not associated with compensatory up or 
down-regulation of any other receptors (LPA1-5) (Fig. 4.1A). In order to assess the role 
of LPA6 on OLG differentiation, Cnp and Ugt8 gene expression levels were assessed. 
Consequently, down-regulation of Lpar6 led to a reduction in both Cnp and Ugt8 mRNA 
levels (Fig. 4.1B). Interestingly, however, the subsequent down-regulation in OLG 
differentiation genes was not accompanied with an increase in the expression of an 
inhibitor of differentiation, namely Egr1 (Fig. 4.1B). To assess the role of LPA6 in 
morphological maturation of OLGs during differentiation, OLG process index was 
evaluated upon knockdown of Lpar6. Reduction of Lpar6 did not significantly change 
overall OLG process index when compared to control (Fig. 4.1C). Additionally, when 
down-regulating Lpar6, LPA was unable to rescue OLG differentiation genes back to 
control levels, although a slight increase in Ugt8 and Lpar6 expression was noted (Fig. 
4.1D). These effects were not found to be associated with changes in cell survival or 
proliferation as determined by immunostaining using antibodies specifically recognizing 
the active (cleaved) form of caspase-3 or the Ki67 antigen (data not shown). These data 
indicate that LPA6 is needed for proper OLG differentiation and can not be excluded 
from the possible involvement in the ATX-LPA signaling axis. 
In the developing zebrafish, LPA6 promotes myelin gene expression of plp1b 	
To further validate the role of LPA6 in OLG differentiation, we assessed its function in 
the developing zebrafish, an emergent vertebrate model particularly suitable for in vivo 
and developmental research (Best and Alderton, 2008; Fleming et al., 2010). In order to 
examine the role of LPA6, it was necessary to verify the expression of both lpar6a and 
lpar6b, two individual genes produced as a result of a genome duplication (Woods et 
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al., 2000), both in whole zebrafish and OLGs extracted from zebrafish, at 48hpf. To 
obtain an OLG enriched population from the developing zebrafish, we performed 
Fluorescent Activated Cell Sorting (FACS) as introduced in Fig. 2.4., using 
Tg(nkx2.2a:megfp;olig2:dsred2) fish. RNA extracted from FACS sorted OLG enriched 
populations and whole zebrafish, at 48hpf, was used to verify gene expression of lpar6a 
and lpar6b (Fig. 4.2A,B). To assess the role of lpar6a and lpar6b in OLG development, 
we performed the Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/Cas9 genome editing technique. For these studies, we used the same 
codon-optimized Cas9 with nuclear localization signals system as described in Fig. 2.1. 
As shown in Fig. 4.2C-F, injection of guide RNAs against lpar6a and lpar6b genes and 
in vitro transcribed, capped, polyadenylated nls-zCas9-nls RNA into one-cell stage 
zebrafish embryos resulted in the generation of indel mutations over and upstream of 
the CRISPR targeting sequence. These mutations resulted in reduced levels of lpar6a 
and lpar6b mRNA (Fig. 4.2H), an effect that was not observed in uninjected zebrafish. 
Most importantly, the CRISPR/Cas9-mediated reduction in lpar6a and lpar6b 
expression was found associated with a decrease in the transcript levels for the later 
stage OLG differentiation marker proteolipid protein (plp1b) (Fig. 4.2H). As shown in 
Fig. 4.2G, injection of Cas9 mRNA with either of the guide RNAs was not found to be 
associated with changes in the gross morphology of the embryos. The above-described 
data, further support the role of LPA6 in OLG differentiation, and verify its involvement in 
vivo.   
LPA6 promoted progression along the lineage does not alter HDAC activity or 
histone acetylation  
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As previously described, early stages of the OLG lineage are seen to be regulated by 
ATX’s lysoPLD activity, in association with, epigenetic modifications that result in 
increased histone deacetylation (Marin-Husstege et al., 2002; Shen et al., 2005; He et al., 
2007; Shen et al., 2008; Liu and Casaccia, 2010; Takada and Appel, 2010; Swiss et al., 
2011). In order to assess if HDAC activity is affected by the down-regulation of Lpar6, 
siRNA mediated knockdown of Lpar6 was performed on cells that were then subjected 
to a fluorogenic HDAC activity assay. The reduction of Lpar6 did not significantly 
change overall HDAC activity (Fig. 4.3A). It has been previously shown that HDAC 
activity in differentiating OLGs is primarily directed to lysine residues of histone H3, 
including the lysine residue on the tail of histone H3 at position 9 (H3K9) (Swiss et al., 
2011). To assess changes in acetylation at this site, cells treated, as depicted in 
Fig. 4.1, were analyzed by immunocytochemistry, assessing O4+ OLGs with H3K9ac 
nuclear staining, combined with confocal microscopy. Most importantly, siRNA mediated 
down-regulation of Lpar6 did not significantly change the levels of H3K9ac (Fig. 4.3B). 
These findings differ from the epigenetic changes seen regulated by the ATX-LPA 
signaling axis and, thus, highlight LPA6 as a regulator of alternative signaling pathways 
needed for OLG differentiation.  
Discussion 
Differentiation of OPCs into myelinating OLGs encompasses a complex sequence of 
events including cell cycle exit, RNA processing, branching, synthesis of myelin proteins 
and lipids and membranes wrapping around the axon (Raff, 2007; Simons and Trotter, 
2007; Swiss et al., 2011). The mechanisms underlying many of these events are 
attributed to extracellular factors and specific signaling pathways. ATX, specifically 
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through its lysoPLD active site, is one extracellular factor that is needed for proper OLG 
differentiation through its capacity to epigenetically modify the OLG genome. LPA, the 
product of ATX’s lysoPLD active site, is an essential ligand needed to bind its receptors 
on OLGs and activate such signaling cascades. The complexity of this regulation is 
apparent as LPA can bind six different receptors, with converging signaling pathways. 
Most importantly, little is known regarding the role of each receptor in OLG 
development.  Such information is needed to therapeutically target these receptors and 
enhance OLG development pharmacologically. In an effort to understand the signaling 
events governing gene expression changes during OLG differentiation, we examined 
the role of LPA6. The data obtained from these studies reveal that LPA6 plays a novel 
role in OLG gene regulation during differentiation. These studies are the first of their 
kind and further enhance the importance of LPA signaling in OLG development. 
We show for the first time that LPA6 is needed for OLG differentiation. Down-
regulation of Lpar6, and genetic mutation of lpar6a and lpar6b, leads to decreased 
expression of OLG differentiation genes, Cnp and Ugt8, and myelin gene, plp1b, 
respectively (Fig.4.1B; Fig4.2H). These results show a conserved role of LPA6, for which 
OLG differentiation is dependent. Though reduction of Lpar6 decreased the expression 
of OLG differentiation genes, it did not have an effect on the differentiation inhibitor, 
Egr1 (Fig. 4.1B). The expression level of Egr1 is known to decrease as OLG 
differentiation occurs and is followed by the up-regulation of genes involved in lipid 
metabolism and myelination (Swiss et al., 2011). Importantly, Egr1 is a HDAC target 
gene (Swiss et al., 2011), specifically seen regulated by HDAC1/2 (Wheeler et al., 
2015), and acetylation of lysine residues on the tail of histone H3 at position (H3K9ac) is 
			
	
95	
a critical residue that has been linked to the transcription of Egr1 (Kubosaki et al., 2009; 
Tur et al., 2010; Wang et al., 2010). These results are the first to indicate that gene 
expression changes downstream of LPA6 differ from those seen described by Wheeler 
et al., 2015. In this regard, the mechanisms associated with the activation of LPA6 may 
be gene specific and work in conjunction with other signaling events to fine tune the 
genome wide changes needed for proper OLG differentiation.  
Interestingly, LPA added to cells with reduced Lpar6 expression were unable to 
rescue differentiation genes back to control levels, however a slight increase was noted 
in mRNA expression of Ugt8 and Lpar6 (Fig. 4.1D). These results show that LPA6 is 
needed for proper OLG gene expression, although, another LPA receptor may also be 
involved in gene regulation at this time. It is of note that the addition of LPA did not 
affect gene expression levels of Cnp, thus, it is likely that the regulation of different OLG 
differentiation genes is governed by different signaling mechanisms. Nevertheless, 
these data suggest that OLG differentiation requires signaling via the activation of LPA6 
and, as such, highlight a novel role for LPA6. 
Moreover, the effects seen following siRNA mediated down-regulation of Lpar6, 
were primarily changes in gene expression and were independent of morphological 
aspects of OLG differentiation (Fig. 4.1C). Though LPA has been shown to increase 
membrane formation in later stages of OLG development (Nogaroli et al., 2009b), it is 
conceivable that these effects are a result of activation of a single, or a multitude of, 
remaining LPARs. Further analysis on the signaling pathways, led by the activation of 
different LPARs, will help delineate the specific roles they play in OLG development.  
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Our previous studies showed that the ATX-LPA signaling axis activates HDAC1/2 
activity to regulate gene expression changes needed for proper OLG differentiation 
(Wheeler et al., 2015). In order to see if the signaling effects mediated downstream of 
LPA6 were associated with the epigenetic changes previously described, HDAC activity 
was assessed after reduction of Lpar6 expression. siRNA mediated Lpar6 down-
regulation did not alter overall HDAC activity (Fig. 4.3A). This finding outlines the notion 
that LPA6 signaling does not involve HDAC regulation and differs from the ATX-LPA-
HDAC1/2 signaling events. HDAC activity in differentiating OLGs is primarily directed to 
lysine residues of histones H4 and H3 including the lysine residue on the tail of histone 
H3 at position 9 (H3K9) (Swiss et al., 2011). When assessing the acetylation of lysine 9 
on Histone 3 (H3K9ac) in siRNA treated cells when compared to control, no change 
was seen (Fig. 4.3B). H3K9ac is highly regulated by the activity of HDAC1/2, thus, 
without direct targeting of this protein complex, changes in acetylation of siRNA treated 
cells are likely to remain unchanged from control. These data validate the notion that 
signaling via LPA6 does not activate HDAC1/2, and as such, effects the expression of 
differentiation and myelin genes by a pathway different from the one described in 
Chapter 2 (Wheeler et al., 2015). 
Protein kinases have been identified as a bridge of communication between the 
extracellular and intracellular environments (Flores et al., 2008; Fyffe-Maricich et al., 
2011; Guardiola-Diaz et al., 2012; Ishii et al., 2012; Narayanan et al., 2009; Tyler et al., 
2009). With regard to OLGs, mTOR was found to regulate OLG differentiation in vitro 
(Tyler et al., 2009). Acting through its two effector complexes, mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2), mTOR has been linked to the 
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transcription and translation of genes (Laplante and Sabatini, 2013). Interestingly, 
mTOR1 was found to play a major role in OLG differentiation, active myelination, and 
proper myelin compaction on large caliber axons in the CNS (Bercury et al., 2014). As 
signaling pathways involved in OLG differentiation begin to be understood, crosstalk 
between such pathways will be further impacted. Interestingly, pharmacological 
inhibition of the mTOR pathway has the ability to feedback and up-regulate the MAPK 
(mitogen-activating protein kinase) pathway (Carracedo et al., 2008) linking the before 
mentioned PI3K/Akt/mTOR pathway with that of the Ras/Raf/MEK/Erk pathway. 
Importantly, and with regard to OLGs, both major signaling pathways, through 
Akt/mTOR and MEK/Erk1/2, are necessary for full differentiation of OPCs to mature 
OLGs in vitro (Dai et al., 2014). Moreover, LPA6 signaling is known to act through G 
protein-coupled receptors G12/13 and Gi/o (Chun, 2013). Gi/o stands out as it initiates 
protein kinase signaling events including the activation of the PI3K/Akt/mTOR pathway 
and Ras/Raf/MEK/Erk pathways. Taken together, it is plausible that the gene 
expression changes seen with down-regulation or genetic manipulation of LPA6 acts 
through the crosstalk between such signaling pathways. Future studies are needed to 
dissect these signaling events, however, these studies show that it is conceivable that 
the changes in gene expression downstream of LPA6 signaling act, at least in part, 
through protein kinase signaling. 
Cumulatively, LPA6 stands out to be a novel LPA receptor governing gene 
expression patterns during OLG development. The actions of LPA6 appear to be 
conserved across species and display similar characteristics. Interestingly, Xenopus 
embryos were found to express lpar6 and loss of function analysis showed disruption of 
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neural development. Additionally, loss of function of Xenopus lpar6 showed similar 
defects to that of loss of enpp2 (ATX) (Geach et al., 2014). Mutations found in the 
human Lpar6 gene, however, do not show the same neural development phenotype 
(Pasternack et al., 2008; Shimomura et al., 2008, 2009), and LPA6 KO mice remain 
viable (mousephenotype.org). Nevertheless, LPA6 displays a unique role in OLG 
differentiation and future studies will uncover the mechanistic effects of this novel 
receptor.  
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Figure 4.1. In rodent OLG cultures, siRNA mediated down-regulation of Lpar6 
leads to a reduction in the levels of mRNAs encoding OLG differentiation genes, 
but does not change the level of mRNA encoding the transcriptional OLG 
differentiation inhibitor Egr1, or OLG process index. A, Bar graph depicting mRNA 
levels for Lpar1-6 as determined by real-time reverse transcription (RT)-qPCR analysis. 
Control (vehicle-treated) values were set to 100% (see horizontal line) and experimental 
values were calculated accordingly B, Bar graph depicting mRNA levels for the OLG 
differentiation genes Cnp and Ugt8 and the transcriptional inhibitor Egr1 as determined 
by real-time RT-qPCR analysis. Control (vehicle-treated) values were set to 100% (see 
horizontal line) and experimental values were calculated accordingly. C, Box and 
whisker graph depicting process index levels for control and siRNA treated cells as 
determined by immunostaining and morphology analysis. The plot depicts medians and 
quartiles of three independent experiments. Whiskers represent the 10th and 90th 
percentile. D, Bar graph depicting mRNA levels for the OLG differentiation genes Cnp, 
Ugt8 and Lpar6 in siRNA treated cells +/- the addition of LPA, as determined by real-
time RT-qPCR analysis (n=2). Control (vehicle-treated) values were set to 100% (see 
horizontal line) and experimental values were calculated accordingly. Data shown in all 
graphs represent means ± SEM. nsnot significant, *p≤0.05, **p≤0.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
			
	
101	
 
 
 
 
 
 
 
			
	
102	
 
 
 
 
 
 
 
 
 
Figure 4.2. In the developing zebrafish, CRISPR-Cas9-mediated mutagenesis of 
lpar6a and lpar6b leads to a reduction in the mRNA levels for OLG marker gene, 
plp1b. A,B, Representative images of agarose gels showing RNA expression of lpar6a 
and lpar6b in whole fish (A) and FAC sorted OLGs (B). C,E, Representative images of 
agarose gels showing DNA fragments upon Surveyor nuclease treatment of control 
homoduplexes (c) and control/lpar6a (C) or control/lpar6b (E) homo/heteroduplexes. 
Numbers on the left indicate DNA sizes in bp. Arrowheads indicate cleaved PCR 
amplicon fragments at the expected sizes indicative of indel mutations generated by 
genome editing. D,F, Representative images of sequencing traces obtained from 
genomic DNA-derived PCR amplicons from control and Cas9 mRNA/sgRNA injected 
zebrafish embryos. Arrows at the top of each trace indicate the location of the target 
sequence, over and upstream of which a composite sequence trace indicates the 
presence of indel mutations generated by genome editing. G, Representative brightfield 
images of control (uninjected) and Cas9 mRNA/sgRNA injected embryos at 48 hpf. H, 
Bar graphs illustrating mRNA levels for lpar6a, lpar6b and the OLG marker gene plp1b 
in whole embryos as determined by real-time reverse transcription (RT)-qPCR analysis. 
Control (uninjected embryos) values were set to 100% (see horizontal line) and 
experimental values were calculated accordingly. Data shown represent means ± SEM.  
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Fig. 4.3. In rodent OLG cultures, down-regulation of Lpar6 does not effect HDAC 
activity or nuclear histone acetylation at lysine residue 9 of Histone 3 (H3K9). A, 
Bar graphs showing HDAC activity as determined by using the fluorogenic substrate 
Boc-Lys(Ac)-AMC. Control (vehicle-treated) values were set to 100% and experimental 
values were calculated accordingly. Data represent means ± SEM. nsnot significant. B, 
Box and whisker plot depicting nuclear acetyl-H3K9 levels as assessed by determining 
fluorescence intensities shown in arbitrary units (a.u.). The plot depicts medians and 
quartiles of three independent experiments. Whiskers represent the 10th and 90th 
percentile. nsnot significant 
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Chapter 5 
 
Introduction to HIV Neuropathology in the CNS  
 
 
Introduction to HIV 
 
HIV, a member of the lentivirus family, comes in two forms, HIV-1 and HIV-2. 
HIV-2 is mainly found in Western Africa, with some cases arising in Europe and India 
(de Silva et al., 2008), and rarely progresses to AIDS or HAND (HIV Associated 
Neurological Disorders) (Rowland-Jones and Whittle, 2007). Thus, HIV infection 
through HIV-1 predominates as the most common form found worldwide. If HIV infection 
is left untreated, it can take roughly 10-12 years for AIDS to develop, a time period in 
which HIV can cause serious harm to both the immune and nervous system. Over 33 
million individuals are currently infected by HIV (Power et al., 2012) and the CDC 
estimates 50,000 Americans will become infected with HIV each year.  
The single-stranded RNA genome of HIV-1 encodes nine proteins comprising of 
envelope (Env), cor (Gag), polymerase (Pol) and six accessory proteins including Tat 
and Nef. HIV infection is initiated by the binding of the viral envelope protein, gp120 to 
CD4 receptors located on the surface of host cell (Sattentau et al., 1986). This 
interaction triggers a conformational change, which grants the entry of the virus genome 
and proteins. Once the host cell is infected, HIV makes viral DNA using its RNA 
genome template. Newly synthesized viral DNA can then integrate into the host genome 
to form the provirus. Infected cells can either be latent, or actively transcribed to 
produce the virus and viral proteins such as Tat.  
cART (combination antiretroviral therapy), an HIV therapy created in 1996, has 
advanced the longevity of patients suffering from the virus and has had some progress 
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in aiding neurological pathogenesis, but falls short when treating HAND. Roughly 60% 
of the HIV infected population suffers from HAND (Williams et al., 2009). Moreover, 
AIDS remains the most common cause of dementia in non-aged individuals in the US. 
Thus, it is critical that further examination of CNS neuropathology, such as HIV-
associated dementia and moderate cognitive and motor diseases, should be addressed 
so that proper therapies can be given. 
CNS Neuropathology and HIV infected cells 
 As the survival rate and life expectancies for HIV+ patients have increased, so 
has the incidence of HIV neuropathology. HIV can enter the CNS at early stages of 
infection (Kramer-Hämmerle et al., 2005), through penetration of the Blood Brain Barrier 
(BBB) (Bagasra et al., 1996), or by HIV-1 infected macrophages that infiltrate the CNS 
and release the provirus (Merrill and Chen, 1991). Inflammation of the CNS induced by 
HIV-1 infection further disrupts the integrity of the BBB, leading to supplementary HIV-1 
entry and infection (Eugenin et al., 2011). The effect of HIV-1 on neuropathology has 
gained increasing importance as it was reported that up to 70% of AIDS patients 
develop neurological disorders (Jellinger et al., 2000; Maschke et al., 2000). 
Additionally, children exposed to HIV infection were shown to display white matter 
(WM), an area of the brain consisting mostly of glial cells and myelinated axons, atrophy 
(Roy et al., 1992), and adult HIV+ patients demonstrated preferential damage to 
cerebral WM and subcortical brain structures (Jernigan et al., 1993).  
In occurrence with the abnormal appearance of WM and brain inflammation seen 
in HIV infected patients, there is an increase in both microgliosis and astrogliosis (Esiri 
et al., 1991). Infected microglia have been shown to secrete pro-inflammatory cytokines 
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and chemokines in addition to HIV viral proteins, such as Tat, that exhibit toxicity to both 
myelin and OLGs (Herbein et al., 2010; Sui et al., 2004; Tyor et al., 1992). Viral 
proteins, such as Tat and gp120, can induce the production of toxic factors, including 
ROS, (Chauhan et al., 2003; Hurley et al., 2003; King et al., 2006; Lipton, 1998; Nath 
and Geiger, 1998) from infected glial cells in addition to further stimulating viral 
replication and production.  
OLGs, the myelin producing cells of the CNS, are very vulnerable to HIV 
infection. Though lacking the expression of CD4, it has been reported that 
galactosylceramide (previously introduced, UGT8, is the enzyme responsible for its 
synthesis), expressed on the surface of OLGs can serve as an alternative receptor 
mediating HIV infections (Albright et al., 1996; Harouse et al., 1991; Yahi et al., 1992). It 
has not been concluded, however, that OLGs are in fact directly infected by HIV. 
Nevertheless, it is apparent that OLGs can be injured by HIV infection as hyperplasia of 
OLGs has been found in AIDS patients (Gyorkey et al., 1987) and, interestingly, HIV 
induces activation of the death pathways, p53 and BAX in OLGs (Jayadev et al., 2007). 
Accordingly, the effects of HIV on the CNS are quite significant with infection resulting in 
progressive atrophy to WM areas alongside glial cell reactivity and infection, and toxic 
factor release. A better understanding of the mechanisms that lead to injury in the CNS 
will help predict future therapies that, when used in conjunction with cART, will prolong 
survival, mental cognition and motor capabilities for patients.  
HIV-1 Tat 
 Tat is an HIV viral protein that is essential for efficient viral transcription and 
replication. It is synthesized at both early and late stages of viral replication and has a 
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strong tendency to adhere to the surface of nearby cells. Tat is known to express a CCF 
motif which can mimic the CC-chemokines that attract CCR2, CCR3, and CXCR4 
expressing glial cells (Cardona et al., 2006). The mRNA of the Tat protein consists of 
two coding exons, the first encoding amino acids 1-72, and the second encoding amino 
acids 73-101. In most research laboratories working with Tat, such as the laboratories in 
which we conducted Tat related studies, a recombinant truncated version of amino 
acids 1-86 is used.  
The cellular responses induced by Tat expression appear to be robust as it can 
bind to many different receptors and cell surface markers. Tat can bind to chemokine 
receptors, reportedly leading to increased intracellular calcium levels, as well initiate 
iGluRs activation of the PLC, protein kinase C (PKC) and Gi/o pathway, leading to IP3-
dependent calcium release (Albini et al., 1998; Power et al., 1998; Song et al., 2003). In 
machrophages, Tat-induced calcium signaling results in the production of pro-
inflammatory cytokines and chemokines (Puri and Aggarwal, 1992), further promoting 
inflammation. Microglia are also strongly affected by Tat as they appear to display a 
decrease in cAMP levels needed to induce expression of neuroprotective substances as 
well as an increase in their production of free radicals (Aloisi et al., 1999).  
Other glial cells that fall victim to Tats influence are astrocytes. Tat activates 
astrocyte production of pro-inflammatory cytokines and chemokines, further promoting 
astroglial inflammatory responses (El-Hage et al., 2008; Zou et al., 2011). Additionally, 
Tat has been reported to cause an increase in free radical and ROS production in OLGs 
leading to process retraction and apoptosis (Fernández-Gamba et al., 2012; 
Rathnasamy et al., 2011). Though there is limited research on the effects of Tat on OLG 
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development and myelination, patients exhibiting symptoms associated with HAND 
display both motor and cognitive impairments that can be linked to WM injury in the 
CNS. It is imperative that we fully understand the dimensions in which HIV-1 and its 
viral proteins, such as Tat, inflict on the CNS to cause such impairments. It is of upmost 
importance to investigate the role of Tat on the development of the myelinating cells of 
the CNS, OLGs, in an effort to repair its function and WM injuries seen in HIV infected 
patients. 
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Chapter 6 
 
HIV-1 Tat Modulates ATX lysoPLD Activity and Oligodendrocyte Differentiation 
 
(This chapter was submitted as a paper in ASN Neuro in April of 2016. Dr. Patrick Zou 
and myself equally contributed to the work reported for this manuscript)  
 
Introduction 
Neurocognitive complications are frequently reported in HIV+ patients. Although 
combined anti-retroviral therapy (cART) effectively blocks HIV replication in the central 
nervous system (CNS) and profoundly decreases the incidence of severe 
neurocognitive impairments, such as HIV-associated dementia, ~50% of the HIV-
infected population still develop various forms of milder neurocognitive deficits, 
collectively called HIV-associated neurocognitive disorders (HAND) (Ellis et al., 2007; 
McArthur et al., 2010). White matter injuries in HIV-infected patients are commonly 
observed, and have been shown to correlate to HAND pathogenesis (Filippi et al., 2001; 
Archibald et al., 2004; Pfefferbaum et al., 2007). Although cART can reduce the viral 
load in the cerebrospinal fluid (CSF) to below detectable levels, its effect is limited with 
regard to white matter damage and HAND (Yilmaz et al., 2006). This implies that toxic 
factors released by previously infected CNS cells may inflict more damage than the 
virus itself.  
One candidate factor for HIV-induced white matter injury is the HIV-1 viral protein 
transactivator of transcription (Tat), which was originally discovered as a key component 
for efficient transcription of the HIV genome. Tat has been shown to be continuously 
expressed and secreted by infected CNS cells, and can be detected in the CSF (Wang 
et al., 2014) of HIV patients, even with cART (Johnson et al., 2013). Previously, we 
have reported that Tat significantly decreases immature OLG viability (Zou et al., 2015). 
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Importantly, Tat exposure also reduced the extensive networks formed by fine, 
branching processes that are typical for OLGs at this stage, suggesting Tat may also 
inhibit immature OLG differentiation.  
OLG development has been extensively studied and well characterized both in 
vivo and in vitro. Newly formed oligodendrocyte progenitor cells (OPCs) migrate to their 
targeted destination to differentiate into pre-myelinating OLGs that will ultimately evolve 
into mature OLGs and myelinate axons. It is also well established that OLG 
differentiation is controlled by the fine-tuning of both intrinsic factors, such as 
transcriptional control and epigenetic regulation, and extracellular signals, including 
growth factors and mitogens (Zuchero and Barres, 2013; Mitew et al., 2014). One 
extracellular protein that has been shown to play a significant role in OLG development 
is Autotaxin (ATX), also known as ENPP2, phosphodiesterase-1α/ATX, or 
lysophospholipase D (lysoPLD), which is predominantly expressed and secreted by 
OLG lineage cells (Zhang et al., 2014), and has been shown to play an important role in 
OLG development. Previous studies in our lab have shown that ATX, via two functional 
domains, promotes OLG differentiation along the lineage. The first domain, the 
modulator of OLG remodeling and focal adhesion organization (MORFO) domain, was 
found to promote the morphological maturation of OLGs (Dennis et al., 2005). The 
second domain is an enzymatic lysoPLD-active site that generates the lipid signaling 
molecule lysophosphatidic acid (LPA) (Tokumura et al., 2002; Umezu-Goto et al., 2002; 
Nakanaga et al., 2010); it has been shown to promote OLG differentiation and 
myelination by epigenetically regulating the expression of OLG differentiation genes 
(Wheeler et al., 2015). 
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Since both Tat and ATX affect immature OLGs, we hypothesized that Tat inhibits 
OLG differentiation by interfering with the ATX-LPA signaling pathway. Our studies 
shown here demonstrated that 18 hr Tat treatment led to a reduction in the process 
network and OLG differentiation genes, Ugt8 and Cnp, expression. Although LPA by 
itself did not affect OLG morphology, it protected OLGs from Tat-induced process 
retraction, and rescued gene expression down-regulated by Tat. Tat treatment also 
decreased ATX lysoPLD activity in vitro. Co-immunoprecipitation, using biotin-
conjugated Tat and V5-tagged ATX, revealed a potential physical interaction between 
Tat and ATX, which may account for the reduced ATX lysoPLD activity in the presence 
of Tat. Together, these results strongly suggest that, in addition to its effects on OLG 
processes, Tat may physically bind to ATX, inhibiting ATX lysoPLD activity, and down-
regulate LPA signaling. Thus, Tat-ATX interactions have the potential to interfere with 
OLG differentiation and also to block the protective effects of LPA on OLG process 
morphology. Disrupting interactions between ATX and Tat may be a potential 
therapeutic strategy for protecting HIV patients from white matter injury.  
 
Materials and Methods 
 
All animal procedures were performed strictly in compliance with protocols reviewed 
and approved by the Virginia Commonwealth University Institutional Animal Care and 
Use Committee (IACUC). 
Pharmacological compounds. Lysophosphatidic acid (LPA; 18:1; Sigma, St. Louis, 
MO) was dissolved in DMEM containing 0.1% fatty acid-free bovine serum albumin. 
Recombinant Tat1-86 and biotin-conjugated Tat (ImmunoDx, LLC Woburn, MA) were 
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dissolved in distilled water. In the experiments involving pharmacological compounds, 
vehicle control refers to the solvent that is used to dissolve the compounds.  
ATX-lysoPLD activity assay. ATX-lysoPLD activity was determined using the 
fluorogenic assay previously described (Ferguson et al., 2006; Wheeler et al., 2015). 
Concentrated (40x) conditioned medium, obtained via centrifugal filters (EMD Millipore, 
Billerica, MA), from primary OLG cultures treated with vehicle control or Tat for 18hrs 
and grown in phenol-red-free DMEM were incubated with 2.5 μM FS-3 substrate 
(Echelon Biosciences Inc., Salt Lake City, UT) for 4 hr at 37°C. Alternatively, 
concentrated (40x) conditioned medium from untreated primary OLG cultures grown in 
phenol-red-free DMEM were incubated with vehicle control or Tat (100nM) and 2.5 μM 
FS-3 substrate (Echelon Biosciences Inc., Salt Lake City, UT) for 4 hr at 37°C. Increase 
in fluorescence with time was measured at an excitation wavelength of 485 nm and an 
emission wavelength of 520 nm using a PHERAstar multimode microplate reader (BMG 
LABTECH Inc. Cary, NC.). 
RNA isolation and real-time RT-qPCR analysis. Isolation of RNA from control and 
treated OLGs were performed as previously published (Wheeler et al., 2015).  
The following unmodified mouse gene-specific primer pairs were used:  
Cnp:  
forward (5’-ATGCCCAACAGGATGTGGTG-3’),  
reverse (5’-AGGGCTTGTCCAGGTCACTT-3’) 
Ugt8:  
forward (5’-AGGAGCTCTGGGGAGATTGC-3’),  
reverse (5’-TTTGAATGGCCAAGCAGGTCA-3’) 
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Atx:  
forward (5’- GACCCTAAAACCATTATTGCTAA-3’),  
reverse (5’-GGGAAGGTGCTGTTTCATGT -3’) 
Lpar1:  
forward (5’- GCCACCTGGCTGCTGCAGA -3’),  
reverse (5’-GTGTCGATGAGGCCCTGCCG -3’) 
Lpar2:  
forward (5’- CTGTTCAGCCGCTCCTACCTGG -3’),  
reverse (5’-GGCAGCTGACGTGCTCTCTGCCATAG -3’)  
Lpar3:  
forward (5’- ACGAGCTTCGTCCCCGTCCA -3’),  
reverse (5’-ACGAGCTTCGTCCCCGTCCA -3’) 
Lpar4:  
forward (5’-GCCTTGGTACGTTCCCAAGCCATT-3’),  
reverse (5’-AGTTGCAAGGCACAAGGTAATCGGG -3’) 
Lpar5:  
forward (5’-GGGACTAGAGGGGAGCTCACCGAA-3’),  
reverse (5’- TAGCCTCTGGCTGGTGGCATCCTAG-3’) 
Lpar6:  
forward (5’-GTAAGCGCCAACGGCTCCA-3’),  
reverse (5’-GTAAGCGCCAACGGCTCCCA -3’) 
Pgk1: (as reference gene):  
forward (5’- ATGCAAAGACTGGCCAAGCTAC-3’),  
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reverse (5’-AGCCACAGCCTCAGCATATTC -3’) 
RT-qPCR reactions with at least 2 technical replicates per sample were performed on a 
CFX96 real-time PCR detection system (BioRad, Hercules, CA) using the iQ SYBR 
Green Supermix (BioRad, Hercules, CA). PCR conditions were as follows: 95°C for 3 
min followed by 40 cycles of 95°C for 15 s, 58°C for 30 s, and 95°C for 10 s. For all 
primer pairs, melting curves were used to ensure specificity. Relative expression levels 
were determined using the ΔΔCT method (Livak and Schmittgen, 2001). 
Western Blot. Concentration of proteins extracted from cultured OLGs or brain 
tissues were determined using a BCA protein assay kit (ThermoFisher Scientific, 
Waltham, MA). Equal amounts of protein samples were loaded on a Criterion precast 4-
20% gradient SDS gel (Bio-Rad, Hercules, CA), electrophoretically separated, and 
probed with antibodies specific to 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase) 
(Abcam, Cambridge, MA). Bound primary antibodies were detected with appropriate 
IRDye secondary antibodies (1:3000, Li-COR, Lincoln, NE), and imaged using an 
Odyssey Imager (Li-COR). Protein bands were quantified using Li-COR image studio 
software. 
Cell culture. Immature murine OLGs were cultured as previously described (Zou et 
al., 2015). In brief, primary mixed glial cells isolated from brains of postnatal day 0 - 2 
mouse pups irrespective of sex (CD-1, Charles River Laboratory, Wilmington, MA) were 
plated in Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Technologies, Carlsbad, 
CA) supplied with fetal bovine serum (10%, Thermo Scientific Hyclone, Logan, UT), 
glucose (6 g/L, Sigma, St. Louis, MO), Sodium Bicarbonate (0.13%, Life Technologies), 
Penicillin/Streptomycin (1x, Life Technologies). Culture medium was refreshed every 
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other day. At day 8, O2A/glial progenitor cells were collected from the mixed cultures 
and re-plated on poly-L-lysine coated 12-well plates or cover slips, at a density of 
250,000 cells/well or 15,000 cells/cover slip, and incubated in DMEM supplied with 
CNTF (10 ng/ml, Peprotech, Rocky Hill, NJ), NAC (5 μg/ml, Sigma) and triiodothyronine 
(15 nM, Sigma) for 2 days before further experiments. 
Repeated measure paradigm. Repeated measurements of the morphology of 
individual OLGs were performed as previously published (Zou et al., 2011). In brief, 
OLGs were cultured in 12-well plates for 2 days before treatment with vehicle or 100 nM 
Tat. Culture plates were then transferred to the environmental chamber (37°C, 5% CO2) 
of a Zeiss Axio Observer Z1 system (Carl Zeiss Microscopy, LLC, Thornwood, NY). 
Individual OLGs were randomly selected, and imaged hourly for 18 hrs. Images were 
analyzed using the Zeiss Axiovision 4.8 software. 
Immunostaining. O4 immunostaining was performed on live, unfixed cells. All other 
immunostaining was performed after cells were fixed with 4% paraformaldehyde. 
O4 monoclonal antibodies [1:20, grown from hybridoma cells in our lab (Knapp and 
Hauser, 1996)] was applied at room temperature for 15 min. Goat anti-mouse IgM-Cy3 
(1:1000, Millipore, Billerica, MA) was used to probe bound O4 antibodies. All LPA 
receptor antibodies [Anti- LPAR1 (Abcam), LPAR2 and LPAR3 (Santa Cruz, Dallas, 
TX), LPAR4 (Alomone labs, Hadassah Ein Kerem, Israel), and LPAR6 (Acris, San 
Diego, CA)] were applied at 1:1000 at room temperature for 1 hr, and corresponding 
secondary antibodies were conjugated to Alexa 488 (1:2000, Life Technologies) were 
used as secondary antibodies. The cell nucleus was stained with the Hoechst 33342 
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dye (1:2000, Life Technologies). Images were taken on a confocal microscope (Zeiss 
LSM 700, Carl Zeiss, Thornwood, NY) and processed using Zeiss Zen 2010 software. 
Co-immunoprecipitation. Dynabeads Protein G (1.5 mg/50 μl, Life Technologies) 
was first mixed with primary antibodies (5 μg): non-specific mouse IgG, mouse anti-V5, 
and rabbit anti-biotin, respectively (all from Abcam), and washed three times with PBS 
at room temperature. Concentrated supernatant from a COS-7 cell line (500 μl) was 
mixed with 5 μg biotin-conjugated Tat, and added to the Dynabeads-bound primary 
antibodies and gently rocked overnight at 4°C. The next day, Dynabeads (with bound 
proteins) were washed three times at room temperature with PBS before being 
collection and then resuspended in loading buffer (2x Laemmli buffer, Bio-Rad), heat 
denatured (95°C, 5 min) and loaded (40 µl/sample) to a 4 – 20% SDS-PAGE precast 
gel (Bio-Rad) for Western blotting. 
 
Results 
 
Tat-induced decrease in immature OLG process networks, is reversed by LPA 
An earlier study reported that immature OLGs exposed to HIV-1 Tat show 
significantly decreased viability in vitro (Zou et al., 2015). In addition, surviving cells 
exhibit abnormal morphology, indicating that the differentiation of these cells is 
disrupted. To investigate the effect of Tat on the morphology of differentiating OLGs in 
more detail, immature OLGs at 2 days in vitro were treated with vehicle or Tat for 18 hrs 
before morphological analysis was performed. Compared to vehicle-treated OLGs, Tat 
treatment led to a loss of fine, branched processes in as little as early as 4 hrs and this 
continued throughout the 18 hr experimental period (Fig. 6.1). Statistical analysis from 4 
			
	
118	
independent experiments (≥ 30 cells/treatment group) showed a significant decrease in 
process network in Tat treated OLGs (Fig. 6.2). 
Since LPA signaling has been shown to promote expression of genes involved in 
OLG differentiation (Wheeler et al., 2015), we examined whether LPA could reverse Tat 
induced reduction of the OLG process network. As shown in Fig. 6.2, the addition of 1 
or 10 μM LPA does not affect the process network of OLGs. However, when added 
concurrently with Tat, LPA completely blocked Tat-induced process retraction, thus 
revealing a protective role of LPA against Tat-mediated effects on OLG process 
network.   
The effect of Tat to down-regulate Cnp and Ugt8 expression is reversed by LPA 
The lysoPLD activity of ATX has been reported to regulate OLG gene expression 
(Wheeler et al., 2015). Thus, we investigated whether gene expression in immature 
OLGs was also affected. As seen in Fig. 6.3A, 18 hr Tat-treatment significantly 
decreased the expression of the OLG differentiation genes Cnp and Ugt8. Interestingly, 
Tat treatment did not alter Atx gene expression. Since the main function of ATX 
lysoPLD activity is to produce the lipid signaling molecule LPA, we next examined 
whether LPA could rescue the expression of genes down-regulated by Tat. The addition 
of LPA completely rescued the expression of Cnp and Ugt8, but did not have any 
significant effect on Atx expression (Fig. 6.3B). In addition, protein expression data from 
Western blot analysis verified that Tat treatment decreased CNP expression, which was 
reversed by the addition of LPA (Fig. 6.3C).  
Expression of LPA receptors is not affected by Tat treatment  
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Since the effects of Tat on immature OLG morphology and differentiation gene 
expression can be rescued by LPA, we hypothesized that Tat interferes with the LPA 
signaling pathway. To assess the LPA receptors (LPARs) expression profile in our 
system, we performed immunostaining with antibodies specific to different LPARs in our 
2 days in vitro immature OLGs. Results revealed the presence of LPA1-4 and LPA6 on 
O4+ OLGs (Fig. 6.4A). To assess whether Tat alters LPAR expression, qRT-PCR was 
performed on 18 hr Tat- or vehicle- treated OLGs. Our results showed that Tat 
treatment had no effect on LPA1-6 gene expression on immature OLGs (Fig. 6.4B).  
Tat decreases ATX lysoPLD activity 
Since Tat did not affect the expression of LPARs in immature OLGs, we next 
examined whether Tat disrupts LPA production. Extracellular LPA is predominantly 
produced by the lysoPLD activity of ATX, which converts lysophosphatidylcholine (LPC) 
to LPA by removing its choline group (Aoki et al., 2008). Thus, we assessed whether 
Tat treatment alters ATX lysoPLD enzymatic activity in OLGs. Immature OLGs were 
treated with vehicle or Tat for 18 hr before supernatant was collected for the ATX 
lysoPLD activity assay. OLGs treated with Tat showed significantly lower ATX lysoPLD 
activity in the supernatant during the 4 hr assay (Fig. 6.5A). The reduction of lysoPLD 
activity was seen as a steady inhibition that led to a ~10% overall decrease across all 
assay time points (Fig. 6.5B).  
Physical interaction between Tat and ATX decreases ATX lysoPLD activity  
 Since Tat treatment did not alter Atx expression in OLGs, we next assessed 
whether the reduced Atx lysoPLD activity was mediated by an interaction between Tat 
and ATX. Vehicle or Tat was added to the supernatant collected from untreated primary 
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OLG cultures immediately before ATX lysoPLD activity was assessed. In this 
experimental paradigm, which bypassed any potential effect on cells, Tat directly and 
significantly decreased ATX lysoPLD activity (Fig. 6.6A). We next hypothesized that 
decreased ATX lysoPLD activity might be the result of a physical interaction between 
Tat and ATX. To test this hypothesis, we performed co-immunoprecipitation using 
biotin-conjugated Tat and V5-tagged ATX collected and concentrated from the 
supernatant of a stably transfected COS-7 cell line (Dennis et al., 2012). As seen in Fig. 
6B, V5-tagged ATX was detected in anti-biotin precipitates and vice versa, suggesting a 
physical interaction between ATX and Tat. As a control for non-specific binding, neither 
V5-tagged ATX nor biotin-conjugated Tat was detected in precipitates collected using a 
mouse IgG1 monoclonal isotype control (Fig 6.6B, bottom panel). It has been previously 
reported that cell-associated ATX, compared to secreted ATX, migrates slower during 
SDS-PAGE due to differences in glycosylation (Jansen et al., 2005). Since we used 
high density cultures of adherent cells to obtain cell culture supernatants of high ATX 
concentration, the higher molecular weight ATX band (MW ~ 125 kDa) seen in Fig. 6.6B 
likely represents cell-associated ATX derived from floating and/or damaged cells.  
Discussion 
White matter injury is frequently reported in HIV+ patients at all stages 
(Gongvatana et al., 2009; Zhu et al., 2013; Ragin et al., 2015). The mammalian adult 
CNS has been known to maintain a population of OLG precursor cells, which migrate to 
the lesion site upon injury and differentiate into myelinating OLGs to replace the injured 
OLGs and regenerate lost, damaged myelin (Polito and Reynolds, 2005; Kang et al., 
2010; Zuchero and Barres, 2013). Hence, it is interesting that white matter injury 
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persists when HIV RNA is undetectable in the cerebrospinal fluid (Yilmaz et al., 2006; 
Ragin et al., 2015). Our studies here showed that HIV-1 Tat, which is continuously 
secreted by infected CNS cells, even in the absence of viral replication, inhibits the 
lysoPLD activity of ATX, possibly via a potential physical interaction. The interaction 
between Tat and ATX not only attenuates OLG differentiation, but also disrupts the 
protective effects of LPA on OLG process morphology. Thus, targeting the interaction 
between Tat and ATX may be a therapeutic strategy to promote recovery of white 
matter injury in HIV patients.  
OLG lineage cells are targets of HIV-1 Tat. Proliferation and migration of OLG 
precursor cells, viability of immature OLGs, morphology, and myelin-like membrane 
production of mature OLGs have all been reported to be disrupted by Tat both in vivo 
and in vitro (Hahn et al., 2012; Zou et al., 2015). Our initial experiments found that 
immature OLGs that survived 18 hr Tat treatment exhibit a decrease in process network 
(Fig. 6.1). Although LPA by itself does not promote process outgrowth, it protects OLG 
process network from Tat-induced damage (Fig. 6.2). Previously, we have reported that 
early OLG differentiation is regulated by epigenetic mechanisms downstream of the 
LPA signaling pathway (Wheeler et al., 2015). Consistently, gene expression studies 
and Western blot analysis showed that OLG differentiation genes, Utg8 and Cnp, were 
down regulated by Tat (Fig. 6.3). This Tat-induced down regulation of OLG 
differentiation genes were also rescued with the addition of LPA (Fig. 6.3), strongly 
supporting our hypothesis that Tat affects OLG differentiation by interrupting the LPA 
signaling pathway. Additionally, Atx gene expression in OLGs treated with Tat and/or 
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LPA was not significantly different from control (Fig. 6.3), suggesting the LPA rescue of 
Cnp and Ugt8 gene expression was not attributed to an increase in Atx expression.  
There are six bona fide LPARs, all of which are found on OLGs, with LPAR1 
being the most abundantly expressed (Zhang et al., 2014). Our experiments showed 
that 18 hr Tat exposure did not affect the expression of any LPAR gene in OLGs. Thus, 
the finding that LPA rescues both Tat-induced down regulation of OLG differentiation 
genes Ugt8 and Cnp (Fig. 5), and the decrease of OLG process networks (Fig. 6.2), 
strongly indicates that Tat might alter LPA production rather than LPAR expression.  
In the CNS, LPA is predominantly produced by the lysoPLD activity of ATX. 
Although Tat did not affect Atx gene expression, supernatant collected from Tat-treated 
OLGs showed significantly decreased ATX lysoPLD activity. Since physical interactions 
between proteins may lead to an altered conformation and function, we hypothesized 
that Tat interacts with ATX, thus inhibiting its lysoPLD activity and production of LPA. 
Our experiments showed that ATX lysoPLD activity was significantly decreased when 
Tat was added directly to the supernatant collected from untreated OLGs. Further, when 
biotin-conjugated Tat was added to the supernatant collected from a COS-7 cell line, 
that stably expresses V5-tagged ATX, the two proteins were precipitated together. 
These results strongly implicate that Tat, by binding to ATX, inhibits ATX lysoPLD 
activity and LPA production. The crystal structures of Tat and ATX reveal that both 
proteins contain cysteine-rich domains, indicating the possibility of forming 
intermolecular disulfide bonds (Tahirov et al., 2010; Nishimasu et al., 2011; Gu et al., 
2014). It is worth mentioning that the V5-tagged ATX used in the co-
immunoprecipitation was collected from the supernatant of a stably transfected cell line. 
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Thus, the concentration of ATX cannot be effectively determined, and may exceed the 
physiological concentration of ATX in vivo. Additionally, both Tat and ATX have been 
reported to physically interact with integrin receptors (Hausmann et al., 2011; Urbinati et 
al., 2012), introducing the possibility that the binding between Tat and ATX may require 
participation of other components. Further studies are required to better characterize 
the affinity and stoichiometry of the ATX-Tat interaction, as well as whether this 
interaction requires additional adaptor proteins. Alternatively, it is reported that Tat1-72 
and Tat1-86 can efficiently enter certain cells via endocytosis (Mann and Frankel, 1991). 
It is also thus conceivable that Tat enters the cell and interferes with the secretion of 
ATX, leading to decreased ATX lysoPLD activity in Tat-treated OLGs. In brief, the study 
reported here can be summated by our proposed working model (Fig. 6.7). The viral 
protein Tat, via its proposed interaction with ATX’s lysoPLD active site, reduces the 
expression of OLG differentiation genes and interrupts the protective role of LPA on 
OLG morphology. 
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Figure 6.1: HIV-1 Tat decreases immature OLG process networks. Sample phase 
contrast images of immature OLGs treated with vehicle- or 100 nM Tat at 0, 2, 4, 6, 12 
and 18 hr. While normal growth was observed in vehicle-treated OLGs, Tat treatments 
leads to decreased process network, especially after 4 hr.  
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Figure 6.2: LPA protects OLGs from Tat-induced process retraction.  (A) 
Representative images of Vehicle-, Tat-, LPA- and Tat + LPA- treated OLGs shown by 
O4+ immunostaining (Scale bar = 10 μm). (B) OLGs treated with 100 nM Tat showed 
significantly decreased process network at 18 hr. LPA at 1 or 10 μM rescued the 
decreased OLG process network induced by 100 nM Tat. LPA by itself at both 
concentrations has no effect on OLG process network. (*** p<0.001 vs. 100 nM Tat; 
One-Way ANOVA followed by post-hoc Bonferroni’s test, N=4 individual experiments, ≥ 
30 cells were counted for each N). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
			
	
128	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
			
	
129	
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: OLG differentiation genes are down-regulated with Tat treatment. (A-
B) Quantitative RT-PCR gene expression analysis of vehicle, Tat and LPA treated 
immature OLGs. (A) Immature OLGs treated with Tat for 18 hr showed decreased 
expression of Ugt8 and Cnp. Tat treatment has no effect on expression of Atx. (B) Tat-
induced decrease of Ugt8 and Cnp expression can be rescued by adding LPA to 
culturing medium. Current addition of Tat and LPA also has no effect on Atx expression. 
(C) Western blot showed that 18 hr Tat treatment decreases protein expression of Cnp 
in immature OLGs, which can also be reversed by LPA (*: p<0.05 vs. Control. For Fig. 
3A & 3B: student’s t-test, N=5; For Fig 3C. One-Way ANOVA followed by post hoc 
Bonferroni’s test, N=4 individual experiments).  
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Figure 6.4: Expression of LPA receptors are not affected by Tat treatment. (A) 
Immunostaining showing LPA1-4 and LPA6 are found on O4+ immature OLGs at 2 div 
(days in vitro) (Scale bar = 10 µm). (B) qRT-PCR gene expression data showing LPA1-6 
expression in OLGs is not altered by Tat treatment. The mean value for vehicle-treated 
OLGs was set to 100% (horizontal line) and values for Tat-treated cells were calculated 
accordingly. (student’s t-test; N=4 individual experiments).  
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Figure 6.5: Tat decreases ATX lysoPLD activity. ATX lysoPLD activity assay was 
performed using supernatant collected from 18 hr Tat- or vehicle-treated primary 
immature OLGs. (A) Tat-treatment significantly decreases overall lysoPLD activity. (B) 
The mean value of the lysoPLD activity of supernatant from vehicle-treated OLGs was 
set to 100% (horizontal line). Treat cells with Tat leads to ~10-15% drop of lysoPLD 
activity at all time points examined [*: p<0.05 vs. control; Two-way ANOVA (Tat, Time) 
followed by post-hoc bonferroni’s test, N=5 individual experiments]. 
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Figure 6.6: Physical interaction of TAT and ATX alters ATX activity. (A) Adding Tat 
to the supernatant collected from untreated primary OLG cultures significantly 
decreased the ATX lysoPLD activity when compared with control [* p<0.05, vs. Control; 
Two-way ANOVA (Tat, Time) followed by post hoc Bonferroni’s test, N=4 individual 
experiments]. (B) Concentrated supernatant collected from a stably transfected Cos7 
cell line that secrets V5-tagged ATX was mixed with biotin-conjugated Tat, and 
immunoprecipitated (IP) with antibodies specific to V5 (left panels) or biotin (right 
panels) and processed for Western blot (WB) for biotin (bottom panels) or V5 (top 
panels), respectively. Mouse IgG has no known specificity was used as negative 
control. While nothing was detected from msIgG precipitates, V5-tagged ATX was 
detected in anti-Biotin precipitates, and vice versa.  
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Figure 6.7: Proposed model for effects of Tat on immature OLG differentiation. Tat 
interacts with ATX, decreasing its lysoPLD activity and subsequent LPA production. 
Changes in LPA prevent the protective ability of LPA towards Tat-induced retraction of 
OLG process network area and the differentiation promoting ability to regulated OLG 
genes, Ugt8 and Cnp.  
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Chapter 7 
 
Final Conclusions 
 
 
In the CNS, OLGs repeatedly wrap their membranes around axons to form a highly 
compacted multilayered myelin sheath to ensure proper signaling in the CNS. The 
importance of the myelin sheath becomes apparent in diseases where it is injured or its 
function is impaired such as in MS and WM associated injuries found in HIV+ patients. 
In such cases, a better understanding of OLG differentiation is necessary to further 
recognize how to stimulate repair under pathological conditions. Focal areas of 
demyelination characterize MS in the CNS and cells with the potential to myelinate have 
been found present within MS lesions, however, remyelination remains inefficient, likely 
due to a block in OLG differentiation within the context of the lesioned CNS environment 
(Chang et al., 2002b; Kuhlmann et al., 2008c; Wolswijk, 2002). Additionally, there is WM 
atrophy and OLG impairment in the brains of HIV+ infected individuals (Sarma et al., 
2014; Sclafani et al., 1997). In general, OLG differentiation requires changes in gene 
expression. Current knowledge underlying these molecular mechanisms is limited and 
represents a major hurdle in identifying therapeutic targets suitable for stimulating OLG 
differentiation and myelination under conditions as they are found in MS and HIV+ 
infection. Thus, the focus of the experiments outlined in this dissertation was to 
characterize a novel molecular mechanism governing changes in gene expression as 
they occur during OLG differentiation, i.e. mechanisms mediated by the extracellular 
protein ATX. In investigating this novel mechanism, additional roles of ATX were also 
revealed. The data obtained bring new knowledge to the field and will aid in the full 
understanding of how to stimulate repair of the myelin sheath after injury. 
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In the context of the demyelinating disease, MS, ATX mRNA and protein levels have 
been found reduced (Comabella and Martin, 2007), thus suggesting that promoting 
OLG differentiation under such pathological conditions may require the activation of the 
molecular mechanisms mediated by ATX. In this regard, ATX plays an important role in 
initiating the signaling pathways regulating gene expression changes during OLG 
differentiation. Specifically, these changes are mediated through the activity of its 
functionally active domain, the lysoPLD active site. More mechanistically, ATX’s 
lysoPLD activity regulates HDAC1/2 activity and gene expression. Such a 
differentiation-promoting role of ATX via its lysoPLD active site and via activation of 
HDAC1/2 is supported by data in which the inhibition of ATX’s lysoPLD activity by 
HA130 and S32826 both decreased overall HDAC activity, seen in vivo and in vitro 
(Figs. 2.4,6), and increased histone acetylation of lysine 9 on Histone 3 (H3K9ac) (Fig. 
2.7). Conversely, OLGs treated with LPA, the enzymatic product of ATX’s lysoPLD 
activity, showed an increase in HDAC activity (Fig. 2.6D). Furthermore, inhibition of the 
lysoPLD active site kept expression levels of Ugt8 and Cnp down-regulated and 
maintained elevated Egr1 expression, thus inhibiting progenitor cells from differentiating 
(Fig. 2.5D). In the zebrafish, genetic manipulation of atx, as well as specific inhibition of 
the lysoPLD active site, led to a reduction in both cldnk and plp1b expression (Figs. 
2.1,2,3). In support of the hypothesis that HDAC1/2 activation is downstream of the 
ATX-LPA signaling cascade, inhibiting HDAC1/2, but not HDAC6, kept OLG 
differentiation genes, Ugt8 and Cnp down-regulated and in a progenitor state; an effect 
that could not be rescued by the addition of LPA (Fig. 2.8B,C). Thus, LPA, formed via 
the lysoPLD active site of ATX, is essential in OLG differentiation as it enhances 
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HDAC1/2 activity and ultimately regulates the gene expression changes needed for 
proper OLG development (Fig. 2.9).  
Although several extracellular signaling molecules, ATX included, are known to 
be essential for OLG differentiation (Mitew et al., 2014), the intracellular regulators are 
poorly understood. With regard to the data outlined in Chapter 2, the mechanism(s) by 
which the ATX- LPA axis activates HDAC1/2 activity, needed for OLG differentiation, 
has yet to be discovered. Previously, it has been reported that LPA induction of HDAC 
activity is blocked by inhibiting receptor activation with pertussis toxin (Ishdorj et al., 
2008). The A-protomer of pertussis toxin ADP-ribosylates the α subunits of 
heterotrimeric Gi/o proteins, resulting in the receptors uncoupling from the Gi/o proteins. 
The uncoupling of GPCR from the Gi/o proteins disrupts the communication between the 
receptor and the effector signaling cascades (Mangmool and Kurose, 2011). All current 
LPA receptors couple to Gi/o (Chun, 2013). Thus, the inability of LPA to activate HDAC 
activity through Gi/o, reveals the possible involvement of signaling pathways initiated by 
Gi/o in OLG differentiation. Although LPA6 signals through Gi/o, data outlined in Chapter 
4 reveal the unlikelihood that this receptor activates HDAC1/2 signaling during OLG 
differentiation. It is possible, however, that the signaling pathways, downstream of LPA6 
and the ATX-LPA signaling axis, converge and together mediate gene expression 
changes. Interestingly, LPA also failed to induce HDAC activity when LPA1 expression 
was reduced by siRNA (Ishdorj et al., 2008). These findings, together with the maLPA1-
null mice studies, in which LPA1 plays a role in the later stages of OLG development, 
and not during early OPC differentiation (Garcia-Diaz et al., 2015), proves it unlikely that 
activation via LPA1 stimulates HDAC1/2 activity during OPC differentiation. 
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Nonetheless, these experiments provide insight to possible signaling pathways linking 
the ATX-LPA axis to HDAC1/2 regulation of gene expression changes needed for OLG 
differentiation. Key players seen in the converging signaling cascades downstream of 
LPA receptors are protein kinases.  
Signaling via protein kinases acts to connect the extracellular environment to the 
intracellular environment. As diverse protein signaling cascades are initiated via the 
activation of LPARs/Gi/o, it is possible that activation of HDAC1/2 is a result of protein 
kinase activity. Interestingly, hyperphosphorylation of HDAC1 and HDAC2 leads to a 
slight, but significant, increase in deacetylase activity (de Ruijter et al., 2003). HDAC1 
has been reported to be phosphorylated by casein kinase 2 (CK2), cAMP-dependent 
protein kinase, and protein kinase G(Cai et al., 2001). HDAC2, however, is 
phosphorylated uniquely by protein kinase CK2 in vitro (Tsai and Seto, 2002). Thus, 
CK2 presents itself as an interesting protein kinase involved in the regulation of both 
HDAC1 and 2. Though initially considered to be a “constitutively active” protein, it is now 
understood that activated Akt can phosphorylate CK2 (Nguyen and Mitchell, 2013). 
Additionally, CK2 has been recorded to physically associate with Akt (Guerra, 2006), 
phosphorylate Akt on Ser129 (Di Maira et al., 2005), contribute to Akt activation (Di 
Maira et al., 2009), and interact with Akt within Wnt/β-catenin signaling (Ponce et al., 
2011). In association with Akt, activation of the PI3K/Akt/mTOR pathway has recently 
been shown to trigger phosphorylation of HDAC1 in breast cancer cells (Citro et al., 
2015). Interestingly, the PI3K/Akt/mTOR pathway is one of the signaling pathways 
initiated by Gi/o activation. As such, activation and interaction of the PI3K/Akt/mTOR 
pathway with CK2 may contribute to the regulation of HDAC1/2. This hypothesis, 
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however, will need further examination to pinpoint the exact mechanisms leading the to 
epigenetic changes initiated via the ATX-LPA axis observed during OLG differentiation. 
Targeting individual LPA receptors, and the signaling pathways by which they alter 
gene expression, is a conceivable approach to trigger differentiation of OLGs.  Thus, a 
better understanding of the functions of individual LPA receptors involved in OLG 
differentiation are needed. In researching the effect of the under-investigated LPA6 in 
OLG differentiation, it was found that LPA6 is critically involved in the regulation of OLG 
differentiation genes, Cnp and Ugt8, in vitro (Fig 4.1) and myelin gene, plp1b, in vivo 
(Fig. 4.2). Though initially seen to parallel results seen when inhibiting the lysoPLD 
domain of ATX, and revealing a potential receptor downstream of the ATX-LPA axis, it 
was later revealed that gene expression changes induced by down-regulation of Lpar6 
somewhat differed from those that are epigenetically modulated.  
Taking a closer look, the signaling events of the ATX-LPA-HDAC1/2 axis and those 
downstream of LPA6 appear to have different effects on OLG gene regulation. 
Reduction of Lpar6 expression by roughly 50%, maintained the down-regulated 
expression of OLG differentiation genes, Ugt8 and Cnp (Fig. 4.1B), however, the 
expression of Cnp did not reach the same level of down-regulation as seen when 
inhibiting the lysoPLD active site (Fig. 2.5D). Most intriguingly, down-regulation of Lpar6 
did not have an effect on the expression of OLG differentiation inhibitor, Egr1 (Fig. 
4.1B), whereby, inhibition of the lysoPLD active site caused Egr1 expression to remain 
elevated (Fig. 2.5D). Of utmost importance is the data revealing that the down-
regulation of Lpar6 does not effect HDAC activity (Fig. 4.3). In line with these findings, 
no change was found in the acetylation of lysine 9 on Histone 3 (H3K9ac) in siRNA 
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treated cells compared to control (Fig. 4.3). The data further exemplify the differences in 
signaling through the ATX-LPA-HDAC1/2 axis and through LPA6.  
One factor that remained consistent was the finding that following the inhibition of 
ATX’s lysoPLD active site and by the siRNA mediated down-regulation of Lpar6, 
primary changes were found in gene expression and were independent of 
morphological aspects of OLG differentiation. Neither treatment had a significant effect 
on the process morphology of OLGs (Supp. Fig. 8.1;Fig.4.1C). As OLGs develop along 
the lineage, alterations in both gene expression and cytoskeletal maturation are seen. 
The studies outlined in this dissertation reveal that both the ATX-LPA-HDAC1/2 and 
LPA6 signaling pathways influence immediate gene expression changes in OLG 
differentiation rather than directly mediating cytoskeletal changes. It is plausible, 
however, that changes in morphology could result as a consequence of the changes in 
gene expression.  
The discrepancies seen between targeting the lysoPLD active site and LPA6 were 
initially hypothesized to be the result of experimental timing differences. In this context, 
experimentation using siRNA prolongs the time in which OLGs are exposed to mitogens 
(in order to ensure proper knockdown of the gene) and though the time frame from 
mitogen removal remains consistent, it is plausible that subsets of these OPCs are 
differentiated. It is understood that there is a short time window in which HDAC1/2 play 
a crucial role in the differentiation phase of OLG development. Data outlined in this 
dissertation further confirms this role and links it to the extracellular signaling of LPA, by 
way of ATX’s lysoPLD active site. It is conceivable, however, that if siRNA experiments 
targeted a subset of OPCs that were past the differentiation stage, differences would be 
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seen in gene expression and could underlie the variances seen in Cnp and Egr1 
expression levels. To address this idea, Egr1 expression was analyzed following the 
same experimental timeline seen in siRNA experiments, whereby OLGs were subjected 
to mitogens for an additional 24hrs before treatment with HA130 (ATX lysoPLD active 
site inhibitor). Egr1 expression remained up-regulated (Supp. Fig. 8.2), as was seen 
previously in Chapter 2, thereby dispensing the experimental timeline as a confounding 
factor contributing to the changes seen between the ATX-LPA-HDAC1/2 and LPA6 
pathways.  
An alternative, and more plausible, hypothesis elucidating divergent gene 
expression patterns, is notion that signaling events downstream of LPA6 differ from the 
ATX-LPA-HDAC1/2 pathway, in that they do not activate epigenetic players. LPA6 
exerts its effects through the activation of Gα12/13 and Gαi/o (Chun, 2013). Though many 
signaling pathways are found downstream of Gα12/13 and Gαi/o, recently the 
PI3K/Akt/mTOR pathway has been shown to play a role in OLG development and 
myelination (Flores et al., 2008; Narayanan et al., 2009; Sherman et al., 2012). 
Specifically, mTOR, a serine threonine protein kinase, regulates OLG differentiation in 
vitro (Tyler et al., 2009). mTOR exists in two functionally distinct complexes, mTORC1 
and mTORC2, which are more classically known to be associated with the regulation of 
translation, but have recently been found to play a role in the  regulation of gene 
transcription (Bercury et al., 2014; Cunningham et al., 2007; Laplante and Sabatini, 
2013). While there is a tight balance between the activity of mTORC1 and mTORC2 in 
OLG differentiation, it has recently been found that signaling through mTORC1 is critical 
for the regulation of OLG differentiation and myelination (Bercury et al., 2014). 
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Interestingly, ablation of Raptor, a protein component of mTORC1, reduced both protein 
and gene expression levels of CNP and PLP in the corpus callosum and spinal cord 
(Bercury et al., 2014). Though UGT8 was not analyzed in these studies, reduction of 
CNP and PLP, seen with the loss of mTORC1, parallels the reduction in Cnp and plp1b 
found by down-regulation or genetic manipulation of LPA6. Additionally, Raptor has 
been shown to physically bind to and regulate how YY1 binds to gene promoters 
(Cunningham et al., 2007). This finding is particularly interesting with regard to OLGs, 
because YY1 has been shown to be essential for OLG progenitor differentiation (He et 
al., 2007). 
Furthermore, multiple signaling pathways are often coordinately regulated by 
extensive crosstalk and the pharmacological inhibition of the mTOR pathway can  
feedback to up-regulate the MAPK (mitogen-activating protein kinase) pathway 
(Carracedo et al., 2008). These studies link the PI3K/Akt/mTOR pathway with that of the 
Ras/Raf/MEK/Erk pathway. In evaluating the crosstalk between these two pathways 
(both found downstream of Gαi/o), Dai et al., 2014 found that both major signaling 
pathways, through Akt/mTOR and MEK/Erk1/2, are necessary for full differentiation of 
OPCs to mature OLGs in vitro. Though these studies primarily focused on the 
expression of MBP, it does not exclude the possibility that these signaling events are 
initiated by the activation of LPA6. As previously discussed, the PI3K/Akt/mTOR 
pathway plays a role in the phosphorylation of HDAC1 (Citro et al., 2015), and there is 
reason to hypothesize that protein kinases play a role in the epigenetic changes 
regulated by the ATX-LPA axis. Though LPA6 does not appear to activate HDAC 
activity, as seen regulated by the ATX-LPA axis, it is plausible that there is crosstalk 
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between the two signaling pathways that regulate overall gene expression changes 
needed for proper OLG differentiation. Taken together, there are many implications that 
protein kinase signaling, downstream of Gi/o, play a role in OLG differentiation and 
further studies revealing a possible association with LPA6 and the ATX-LPA axis will 
further elucidate the importance of LPA signaling in OLG development.  
In brief, it is unlikely that the ATX-LPA-HDAC1/2 axis acts through LPA6 to activate 
the epigenetic changes needed for proper OLG differentiation. It is plausible, however, 
that LPA6, works in conjunction with the ATX-LPA-HDAC1/2 signaling cascades to fine 
tune gene expression changes needed for proper development. It is also conceivable 
that the activation of LPA6, by LPA, is a result of an alternative, LPA-producing source. 
ATX has been shown to be dispensable for hair follicle morphogenesis (Grisanti et al., 
2013) and LPA6 is essential for the maintenance of human hair growth (Pasternack et 
al., 2008, 2009). The ligand, LPA, needed to stimulate LPA6 for hair growth, however, it 
not a product of ATX, but rather by PA-PLA1 (Inoue et al., 2011). Thereby, we cannot 
rule out the possibility that other sources of LPA may stimulate LPA6 in OLG 
differentiation.  
 ATX is involved in a wide range of physiological mechanisms including, but not 
limited to, lymphocyte homing (Knowlden and Georas, 2014), hyperoxic lung injury 
(Nowak-Machen et al., 2015), cancer motility (Jankowski, 2011) and the formation of the 
vasculature by vasculognesis and angiogenesis (Kleger et al., 2011). The role of ATX is 
becoming more evident as further research is conducted, however, a great deal of 
information is yet to be uncovered regarding this extracellular protein. Studies present in 
this dissertation display one of the newest discoveries regarding ATX, its subsequent 
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interaction with HIV-1 viral protein Tat. As seen in chapter 6, Tat has a negative effect 
on the differentiation of OLGs, both by down-regulating OLG differentiation genes and 
causing process retraction (Fig.6.1,2,3). As Tat is considered a “sticky” protein that 
binds many receptors, it was initially suspected that Tat binds LPA receptors and alters 
their expression. To our surprise, Tat had no effect on the expression of LPA1-6 (Fig. 
6.4). Looking further, the addition of LPA, formed via ATX’s lysoPLD domain, was able 
to rescue the effects of Tat on OLG mRNA expression and protected OLGs against Tat 
induced process retraction (Fig. 6.2,3). Thus, implying that Tat interferes with LPA 
signaling, which as outlined in this dissertation, is now known to play a large role in OLG 
differentiation. Rather than binding to LPA receptors on OLG, the negative effects of Tat 
are a result of a protein-protein interaction with ATX that results in the reduction of 
ATX’s lysoPLD activity (Fig.6.5,6). Hence, Tat released in HIV-1 individuals limits the 
protective properties of ATX lysoPLD active site on OLG differentiation and could 
attribute to the WM injuries seen in infected patients. These data provide another novel 
role of ATX in pathological conditions found in the injured CNS and exemplifies the 
importance of this protein in OLG differentiation.   
To conclude, the data outlined in this dissertation, reveal novel molecular 
mechanisms, that are mediated by ATX and LPA6, and are critically involved in the 
regulation of OLG differentiation; providing insight into innovative therapeutic targets 
suitable for stimulating remyelination under pathologic conditions such as those found in 
MS as well as HIV+ patients (Fig. 7.1). These studies are the first of their kind revealing 
the importance of the understudied LPA6 in OLG differentiation, a finding that could lead 
to the creation of novel therapeutic drugs. Additionally, ATX was found to interact with 
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the viral protein, Tat, a unique discovery that may lead to future breakthroughs 
pinpointing the increasingly important role of ATX in glial biology. Further investigation 
into the epigenetic pathways that regulate OLG gene expression, LPAR expression and 
signaling, as well as ATX-Tat interactions may reveal important information regarding 
development that can be used when developing and testing future therapeutic 
approaches.   
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Figure 7.1. Schematic cartoon representing effects of ATX’s lysoPLD active site in 
development and pathology. Development: LPA, formed via the lysoPLD active site 
of ATX binds to one or more of the LPA receptors, LPA1-5, on OLGs, to activate 
HDAC1/2 and regulate gene expression changes needed for OLG differentiation. LPA 
signaling through LPA6 likely acts through a different signaling pathway(s) (possibly 
through Akt/mTOR and/or MEK/Erk1/2) to regulate gene expression changes. LPA 
formed via PA-PLA1 may be the ligand for LPA6 signaling. Pathology: LPA acts as a 
protectant against HIV-Tat induced decreases in process network area of OLGs. LPA 
can also rescue the effect of HIV-Tat on OLG differentiation genes. At the same time, 
HIV-Tat can block the generation of LPA by negatively affecting ATX’s lysoPLD activity. 
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Chapter 8 
Supplemental Figures, Data and Protocols  
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Supplemental Figure 8.1: Inhibition of ATX’s lysoPLD active site does not change 
overall process network area of OLGs. Box and whisker plot depicting process 
network area of OLGs for HA130 treated cells as determined by immunostaining and 
morphology analysis. The plot depicts medians and quartiles of three independent 
experiments. Whiskers represent the 10th and 90th percentile.  
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Supplemental Figure 8.2. Egr1 remains up-regulated with HA130 treatment after 
72hr. Bar graph depicting mRNA levels for transcriptional inhibitor Egr1 as determined 
by real-time reverse transcription (RT)-qPCR analysis. OLGs were treated with 
mitogens for 48hr before the addition of HA130 or DMSO control for an additional 24hr. 
Control (DMSO-treated) values were set to 100% and experimental values were 
calculated accordingly. Data shown represent means ± SEM. *p≤0.05. 
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Supplemental Figure 8.3. LPA1-4 inhibitor can be rescued by LPA, but not at the 
same magnitude as seen with rescue of the ATX lysoPLD active site alone. A. 
Timeline depicting when cells were removed from mitogens and treated. B. Box and 
whisker plot depicting Ugt8 mRNA gene expression of OLGs treated with BrP-LPA 
(Inhibitor of LPA1-4) or HA130 (ATX lysoPLD Inhibitor) +/- the addition of LPA as 
determined by qRT-PCR analysis. The plot depicts medians and quartiles of three 
independent experiments. Whiskers represent the 10th and 90th percentile. Control 
(DMSO-treated) values were set to 100% and experimental values were calculated 
accordingly. Data shown represent means ± SEM. #p≤0.05, *p≤0.05. 
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Figure 8.4: The effect of TAT on ATX lysoPLD activity has regional differences. 
(A-F) Tat expression was induced for 10 days before animals were sacrificed and 
different regions of the mouse brain were dissected. (A-C) ATX lysoPLD activity in 
proteins extracted from whole brain, midbrain or frontal cortex were not affected by 10-
day Tat expression. (D-E) In hippocampus or striatum, expression of Tat for 10 days 
significantly increases ATX lysoPLD activity. (F) ATX lysoPLD activity was significantly 
decreased by 10-day Tat expression in cerebellum. (G-I) Astrocytes from whole brain, 
hippocampus and cerebellum were cultured and treated with 100 nM Tat. ATX lysoPLD 
activity from astrocytes of all three areas was increased with Tat exposure. [A-F: *,&: 
p<0.05 vs. Tat-; G-I: * p<0.05 vs. Control; Two-way ANOVA (Tat, Time) followed by 
post-hoc Bonferroni’s test, N=3]. 
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A2B5 Immunopanning for Oligodendrocytes 
   
Preparation of A2B5 plates: (10 pups/150mm plate) 
  
• Obtain 3 Falcon 150 x 15mm (non tissue culture) plates and put a line on the side of 
the plate with a sharpie (will help to ensure all areas of plate are washed) 
• Prepare IgM (-20° freezer in purple box reading IgM) in 50mM Tris/HCL (pH 9.5). 
Add 12.5ml IgM to dish followed by 25ml Tris HCL (1x). Make sure the liquid covers 
the entire bottom of the dish. 
• Put in 4°C T.C. Fridge O/N– keep sterile!! If a shorter time is needed, incubate in 
37°C for 2-3hrs 
• Remove (do not wash) IgM and replace with A2B5 supernatant media (-80° freezer 
on bottom left, place in water bath to defrost and centrifuge 1.5 X 1,000 for 3 min). 
• Add A2B5 with 30ml pipette, 10ml for each plate. Then add 10ml of DMEM/Ab/FCS 
to each plate. 
• Incubate O/N at 4°C 
  
Set Up 
 
• Remove plates from 4°C and wash 2x with PBS (sterile) and incubate 37°C/CO2 
until required 
• Obtain sterilization pouch filled with scissors and scalpel and filter paper pouch from 
the bottom drawer of the bench (with the microscope on top). 
o Big Scissor- cut the heads from the body 
o Middle Scissor- remove brain from skull 
o Small Scissor- remove meninges and mince in HANKS solution 
• Obtain filter (blue- 40 micron) from the top drawer of the bench with the microscope 
on top 
• Put 5 50ml tubes in hood (one for digestion, two for washing and two to hold mixed 
glia that will be given to Dr. Cabral’s lab) 
• Put DNase on ice and put trypsin in the water bath 
• If using coverslips: put coverslips in ethanol and then sterile water and let them dry 
in the hood on white filter paper (middle drawer of bench in the middle of T.C.) 
• UV everything in hood for about 10 min while getting the pups (5th floor rat room) 
  
Procedure: 
 
• Go to fifth floor to get pups, make sure to bring a box down to the animal room. 
• Weigh pups on the T.C. scale and record weight 
• Remove heads from pups using big scissor and put bodies in a plastic bag. Put 
heads on a petri dish on ice. 
• Extract brains (whole) from P2-P4 pups Cut from the brain stem up to the nose, 
open skull and extract the whole brain. Place the brain on filter paper, remove the 
cerebellum, and carefully drag the brain along the paper to remove excess blood. 
Once clean place and mince in 60mm petri dish containing 5ml HANKS (T.C. fridge). 
Use a razor blade to further mince the brains. Wash plate with HANKS – final 
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volume + 10ml. 
• Add minced brains to a 50ml tube- using the extra HANKS to obtain every cell. 
• Add enzymes (2.5mL trypsin and 100ml DNAse I) incubate for 15 min at 37°C (swirl 
around every 5 minutes), stirring every 5min. 
• Add fibronectin (human) to coverslips or wells. 1:10 dilution. Place in incubator for at 
least 30 minutes. 
• Discard of paper towel and carcases in the freezer in T.C. 
• Wash scissors with water and then D.I. water and lay on paper towel. 
• Inactivate enzymes: add equal volume DMEM/10% FCS to cells taken from water 
bath 
• Centrifuge cells at 1.2 x 1000 rpm for 3 min. Pour off supernatent, unless giving the 
astrocytes to another lab. 
• Re-suspend pellet in 10ml DMEM/FCS.  Aspirate with 16g, big (x5) and 22g, small 
(x3) needles to achieve single cell suspension. Needles are found on the bottom 
drawer of T.C. bench with microscope on top. Syringes are above the weigh station- 
10ml volume. 
• Increase volume of cell suspension. If you have three plates, add to final volume of 
30ml, then add 30ml again for 10ml on each plate. Plate out evenly among panning 
plates (Mix 1 cell:1 media with DMEM/FCS per plate) 
• Incubate 30 min at 37°C/CO2 
• Then, remove/discard media (mostly containing unwanted astrocytes and glial cells) 
• Wash plates 2x with 1X PBS (discard washes) 
• Wash cells off plates (x2) with 10mL DMEM/FCS.  Check on microscope to ensure 
majority of cells are removed from plate. About 10 washes/quarter, physically force 
the cells off the dish and into the media. 
• Collected cells: pass through FALCON 40mm cell strainer (top drawer of bench 
with microscope on top- blue), centrifuge and re-suspend in 10mL 
• Differential adhesion: 10 min at 37°C/CO2 on non-TC (not cell star, 1 on ice and 1 
in hood) 100mm dish. 
• Fibronectin Removal- during the 10 minute incubation, remove fibronectin from the 
plates and add 50ul of PBS for a total of 2 washes. Leave in PBS until add media. 
• Make Media- Make sure to use FCS free media and add T3,N2, PDGF or bFGF. 
• Collect media and count cells- vacuum out media and add 1ml FCS free media. 
• Get a microcentrifuge tube and put 18ul of trypan blue in the tube. This dye will go 
into cells that are dead. Then add 2ul of the resuspended pellet in 1ml of your 
desired media. Take about 10ul of the dye and cells and put into cell counter. Count 
all squares at the top left, right, lower left and right. 
• Plate out cells: (1-5x104 /well/100ml) in 24 well cluster plate 
• Incubate for 30 min (minimum) at 37°C/CO2 in DMEM/FCS 
• Add 400ml media/well and incubate overnight (O/N) 
  
Medium- T3, N2- TC working aliquots box 
   bFGF and PDGF in -20°- things that make oligos proliferate box 
   T.C.- DNase- bottom right rack (-20°) 
   Trypsin- bottom left rack (-20°, 15ml tube) 
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 Preparation of zebrafish embryos for FACS  
 
*Need a negative control (non-fluorescent embryos) for setting the FACS machine 
*Do not use more than ~150 embryos per tube (50-60 is best)  
*Works for 48hpf, 72hpf and 4dpf zebrafish 
 
1. Dechorionate embryos and place in 1.5mL eppendorf tubes 
2. Anesthetize with MESAB (Tricaine) 
3. De-yolk embryos in 100uL calcium-free Ringer’s solution; pipette up and down 
with 200uL pipette (x20-50 depending on how many embryos in tube) 
4. Let sit on ice for 2min 
5. Spin down (quick spin), remove liquid and wash with 1X PBS (x2) 
6. Prepare 1mL (per number of tubes needed) of trypsin-EDTA 0.25% + 5mg/mL 
collagenase + 100uL DNase.  Will need separate tubes for different samples or if 
have a very large number of embryos.  (Have also used 500uL volume and 
seems to work fine) 
7. Add 200uL of trypsin/collagenase/DNase mix to each tube of embryos and 
aspirate with 20-gauge needle in a 1mL syringe (x10); add the remaining 800uL 
of solution and aspirate again with 20-gauge needle (x5) 
8. Incubate in 30C water bath for 15min. At end of 15min aspirate again with 26-
gauge needle (x5-10).  Aspirate more if needed. 
9. Spin at 3000rpm for 2min in +4 centrifuge, remove liquid and wash with 1mL ice-
cold 5%GS/PBS then spin again. Note when removing liquid from tube: If pellet is 
very snotty and begins to suck up immediately, collect snotty pellet and put in a 
new tube then empty the rest of liquid and put pellet back into original tube and 
wash.   This part can be tricky so be careful to not discard pellet. 
10. At end, re-suspend pellet in 500uL ice-cold 5%GS/PBS and aspirate with 26-
gauge needle (x5-10).  If using multiple tubes, divide the 500uL 5%GS/PBS 
volume between tubes, aspirate, then combine into one tube at end with a final 
volume of 500uL). If first time doing protocol, verify that method has worked by 
running through a 40um cell strainer. 
11. Collect cells from sorter in 500uL Trizol for RNA extraction or lysis buffer for 
protein extraction.  
12.  
Collagenase type 2 (Worthington 4174): Fisher # NC9870009 
Trypsin-EDTA 0.25% (1x) (Gibco) Invitrogen # 25200-056 
DNase I, type II Sigma D4527 
Calcium-free Ringer’s solution (recipe from the zebrafish book) 
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Acetyl-Histone 3-Lysine 9 (H3K9ac) Staining of OLGs 
 
04+ 
1. Fix with 4% Para for 10min (40µl) 
2. Wash with PBS 3X5min (80µl) 
3. Block with Media >30min 
4. Primary Ab- 04 (make sure to spin down before add to cells) (60µl), leave overnight 
at 4°C 
5. Wash with PBS 3X5min (80µl) 
6. Add secondary Ab at a dilution of 1:250 for 1hr RT (IgM 488) 
7. Wash with PBS 3X5min (80µl) 
  
Acetyl Histone 3 Lysine 9 
1. Optional fix with 4% Para for 10min 
2. Wash with PBS 3X5min (80µl) 
3. Permeabilize with 1%/0.4M Sucrose/1XPBS for 10 min (important step to make sure 
Ab can penetrate cell)  
4. Wash with PBS 3X5min (80µl) 
5. Block with media > 30min (50-60ul) 
6. Add H3K9ac Ab at 1:400 O/N at 4°C 
7. Wash with PBS 3X5min (80µl) 
8. Add secondary Ab at a dilution of 1:250 for 1hr RT (Alexa Fluor Anti Rb) 
9. Wash with PBS 3X5min (80µl) 
  
Hoechst 
1. Add Hoechst Stain for 10 min (50µl) 
2. Wash with PBS 3X5min (80µl) 
  
*Add vectoshield to slides and place coverslip on top. Use clear nail polish to seal the 
edges. 
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Protein Assay  
 
1. Add 100ul Total Cell Extract Buffer + 2AB- Protease + Phosphatase Inhibitor 
Cocktail (1:100) (per 1X106 cells) to each well  
 
Total Cell Extract Buffer 
 
Reagent Volume (250ml) Volume (100ml) 
20mM Hepes pH 7.0 5mL (1M) 2mL (1M) 
150mM NaCl 4.38g (2.19) 1.75g (0.86) 
10mM KCL 2.5mL (1M) 74mg (1mL-1M) 
1mMMgCl2 250ul (1M) 20mL 
20%Glycerol 50ml (1M) 1mL 
1% Triton X-100 2.5ml  
 
2. Plate on ice and rock for 2 min  
3. Use scraper to remove cells from plate 
4. Spin down  
5. Diluting Samples-  
a. 10xà 2.5µl sample + 22.5µl of PBS 
b. 5x à 5.0µl sample + 20µl of PBS 
6. ABS Reagents 
 
Tube Vol. BSA Vol. 1X BSA Final 
Stock 300ul (stock) - 2000 
A 375 (stock) 125µl (1:4) 1500 
B 325 (stock) 325µl (1:2) 1000 
C 175 (A) 175µl (1:2) 750 
D 325 (B) 325µl (1:2) 500 
E 325 (D) 325µl (1:2) 250 
F 325 (E) 325µl (1:2) 125 
G 100ul (F) 400µl (1:5) 25 
Blank - 25 - 
 
a. Amount= Samples (ex. 6) X 2= 12 
b. BSA= 9 X 3 = 27 
c. Total= 39, add another to make 40  
d. 200ul of ABC reagents/well= 200µl X 40= 8000µl 
e. A= 25 (.25 x 8000 = 2.0 X 2= 4.0ml) 
f. B =24 (.24 x 8000 =1.920 X 2 = 3.840ml) 
g. C=1 (.1 x 8000 = 80 x 2 = .160ml) 
h. Total of 50 parts or 8mls in a 15ml tube, vortex and wait to react. 
i. Add 200µl to BSA first and samples last.  
7. Make plate 
a. BSA samples- start from left to right: Stock, A,B,C,D,E,F,G,Blank. Add to 
first three wells. Add 25µl of BSA  
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b. Diluted samples- start from left to right and in 4th and 5th rows. Add 25ul of 
sample 
8. Incubate at 37°C in dark room for 1hr 
9. Leave at RT for 15 min 
10. Measure concentration on Pherastar under protein assay protocol 
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IP Lab Data Analysis for Acetyl Histone 3 Lysine 9 Stain 
` 
 
Image Analysis 1 
Username: Fuss lab  
Password: 0825 
 
Image Analysis 2 
Username: Babette 
Password: oligo 
 
1. Obtain picture from the Q drive convert pictures to tif from Zen software. Open—
File---Export—Save to Natalie Preetha folder 
2. Convert the picture to .tif by opening ZEN and export  the picture in .tif 12 bit and 
then save 
3. Note units of measurements-pixel dimensions under scaling x  
4. Under IP Lab open .tif file 
5. Analyze- define XY units. Set 1 pixel=0.106 micrometers-add name or scroll 
down to find AcetylH3.  
6. Analyze-set acetyl H3 –uncheck calibration bar 
7. Analyze-segmentation-Blue 
8. segment color-magenta set min- ~840covers nucleus w/o holes and max-4094 
(threshold applied to each image in the same way)  
9. Math-split color channels-RGB – can use this to determine min/max 
10. Enhance – edit color table-monochrome may be easier to view 
11. Red-min-264 
12. Analyze- Segmentation- Component- 
a. blue min-840 AND Red min-264 
b. For NOT- select AND reverse 
c. Must have blue and red checked- should now give a magenta color over 
nucleus. 
13. Analyze-Measure Segments-magenta segment-gives average intensity and area 
of RBG 
14. To remove oligos that you do no want to be analyzed use the eraser tool  
15. Set measurements-sum, min, max, mean, shape for area, limit-to filter out 
16. Measurement options-erase failing criteria 
a. include interior holes 
b. include a side and vertical margin (left+top) 
c. outline-number 
17. Max number-can have a limit 
18. Analyze –measure segments ROI- gives table which gives individual 
19. Sort by Area under set neasurements-3 
20. Qualify segments-Magenta segments-table summarizes  -gives average 
21. Open multiple images  
22. Edit-transfer attributes of original image-length units transfer to all or specific 
image 
			
	
166	
23. Analyze-segmentation-done 
24. Analyze-quantify segments-summary will be added to same table 
25. If need to erase non oligodendrocytes: Use erase tool-double click to choose 
pixels and then quantify 
26. Click on X to export table to excel 
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ATX lysoPLD Activity Assay 
 
1. For fish studies using protein extracted from whole zebrafish: 
Prepare samples: 
• Dechorionate zebrafish and anesthetize with MESAB (at least 100μL/mL) 
• Quick wash embryos with 1x PBS (ensure they are anesthetized! – may take 
a couple of minutes) 
• Remove yolk sacs: 
• Suspend fish in ice-cold Ringer’s solution (116mM NaCl; 2.9mM KCl; 1.8mM 
CaCl2; 5mM HEPES, pH 7.2) + 1mM EDTA + protease inhibitors 
• Pipette up and down with 200μl pipette ~10x-30x; liquid will become cloudy 
• Quick spin to collect fish at bottom of tube 
• Wash with ice-cold Ringer’s solution, quick spin, remove then add more 
Ringer’s solution (x3) until solution is clear and can see fish (they should look 
thin and stringy due to removal of yolk sac-can check under microscope to 
see if most of yolk has been removed) 
• Quick spin and remove solution 
• Quick wash with 1X PBS then add 1X PBS at ~1μl/embryo + protease 
inhibitor 
• Homogenize with electronic pestle (~3sec/10μL) and spin 10,000rpm for 3min 
at +4°C 
• Transfer supernatant to fresh 1.5mL tube (keep homogenate on ice at all 
times!!) 
• Measure concentration with nanodrop “Protein A280”; Aliquot, label tubes and 
store at -80C 
2. For all OLG samples, you must obtain OLG supernatant in PHENOL-FREE 
media. Spin down the supernatant to concentrate protein levels. Make sure you 
start the activity assay with the same amount in all conditions. Do not dilute 
samples from tissue culture- there is already a small amount of ATX being 
secreted  
3. Make master mixes for each sample (triplicates) in separate eppendorf 
tubes (all reagents multiply by 3.3) 
• Dilute samples in 1xPBS to a final volume of 115.5μL (35μL x 3.3):  
100μg/100µL x 3.3 = 330μg total 
• Do not forget to include a blank: 1X PBS only (no sample) 
• Dilute FS-3 substrate from stock solution of 1 mM (in 1XPBS) to 50 µM in 
reaction buffer (stock for assay) (Echelon L-2000) 
• Working FS-3 concentration can vary from 0.5 to 5 µM. 
• We currently use 2.5μM final in a volume of 5μL per reaction x 3.3 = 16.5μL 
per sample master mix 
• (New FS-3 should be reconstituted to a stock concentration of 1mM in 1X 
PBS, not dH2O!) 
4. In a black 96 well plate (Corning #3991), pipette the following reagents per well 
(done in triplicates). Be sure to add FS-3 last! 
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Volume Volume (x3.3) Reagent [Stock] [Final] 
35μL 115.5μL Sample + 1X PBS   
10μL 33μL FAF-BSA 10 mg/mL 1 mg/mL 
50μL 165μL Rxn Buffer   
5µL 16.5µL FS-3 substrate 50 µM 2.5 µM 
 
5. Read samples in the PHERAstar - Set to 37°C (turn on incubator in PHERAstar 
several minutes before reading to allow to warm up). Incubation time can vary 
depending on enzyme activity and concentration.  
Settings: 
• Protocol name: ATX Activity Assay – Fluorescence (Do not change settings 
so can compare different runs) 
• Excitation = 494nm / Emission = 520nm  
• Cycle time: 600sec (10 min); Number of flashes per well: 10 
• Focal height and gain have already been set on this machine for this type of 
plate and samples, do not change! 
• Focal height: 5.0mm; Gain: 110 (set to 20% maximum so signal will not 
saturate) 
6. Incubator will not shut off on its own.  After the run is over, take the plate out and 
shut off incubator because if plate left in overnight, all wells will evaporate into 
machine! 
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RNA extraction from whole zebrafish 
 
 
1. Dechorionate zebrafish embryos and transfer to a 1.5mL tube 
 
2. Anthesthetize with MESAB (42uL/mL system water) and wait ~5-10min – check 
that fish are no longer swimming around by inverting tube a few times **All steps 
involving Trizol should be performed in fume hood!** (Trizol is located in 4C 
refridgerator) 
 
3. Remove system water and add ~200uL Trizol and homogenize with electronic 
pestle for a few seconds until embryos are in solution (be careful with 
homogenizer and make sure Trizol does not spill out of tube) (Note: can store 
homogenized embyros in Trizol at -80C if cannot finish protocol) 
 
4. Add 300uL more of Trizol and vortex to completely mix – total volume = 500uL.  
Incubate samples at RT for 5min 
 
5. Add 100uL of chloroform.  Cap tubes securely and shake vigorously by hand for 
15sec and incubate at RT for 2-3min 
 
6. Centrifuge at 12,000xg for 15 min at 4C.  Mixture will separate into a lower red 
(phenol/chloroform phase), a white interphase and a clear aqueous phase. RNA 
is located in this top aqueous phase (volume is ~60% of total volume) 
 
7. Transfer aqueous phase only to a new tube and precipitate RNA by adding 
250uL isopropanol.  Incubate at RT for 10min and spin at 12,000xg for 10min at 
4C (The RNA will form a gel-like pellet on side of tube) 
 
8. Remove supernatant and wash pellet with 500uL 75% ethanol.  Mix sample by 
vortexing 
 
9. Centrifuge at 7500xg for 5min at 4C 
 
10. Remove as much supernatant as possible without disturbing RNA pellet and let 
air dry for 5-10min (leave caps open) 
 
11. Elute in RNase-free dH2O (~20-100uL dH2O) 
 
12. Measure concentration on nanodrop label tubes and store at -80C 
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Image Analysis  
Username: Fusslab 
Password: 0825 
Software: IP lab 
Q drive for pictures 
Dennis_VCU script for analysis- don’t save anything to the script 
 
1. Get image (TIF) of interest from Q drive. Make sure to take only one cell with one 
nucleus. Always take pictures that were taken with 40X magnification.  
2. Free hand the region of interest using the dotted tool. Trace around the cell, 
leaving out anything not connected to the cell. 
3. Go to the MATH tab and split color channels. Keep under RGB, and get rid of 
blue. 
4. Click RUN- segmentation. 
5. Create own threshold, mask to select the processes, and move min slider back 
and forth.  
6. Receive measurement results: sum of the threshold value, mean/area 
7. The top number is the network area and the bottom is the process index 
8. * If you have a big gap- it may count as 2 cells and give 4 numbers. If you know 
that it is part of the same cell, you can add the numbers.  
9. Go back to the free hand tool and draw around the cell body, make sure the 
nucleus is covered. 
10. With receive 2 numbers- make sure they are the same! Subtract the cell body 
from the whole cell measurement.  
11. * If the cell body is below 50- the program will not be able to measure it. 
12. Go to FILE- EXPORT-EXCELL 
13. Put Measurement Results in sheet 1 of excel. 
 
Jameel EZ- enable macros  
 
1. Set cursor to A1-column 1 (blank) 
2. Tools- MACRO-MACROS-RUN 
3. Take 4 numbers and put horizontally 
4. Highlight all horizontal numbers  
5. Use the filter cone, drop down menu and get rid of the blanks 
6. Copy 1st three columns 
7. Clear contents and paste into H2 
8. NA/PI/Cell Body 
9. Copy formula from old experiment  
10. NA PI complexity- take average from each column and paste values in column O. 
11. Normalize to control cells  
12. The average of the normalized cells should all equal 100. 
13. Highlight three column: net area/ proc are/ complexity and the avg/ NA norm/PI 
norm/NC 
14. Go back to treated cells and copy 
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15. Take the average and this number is compared to 100 (control) 
16. Never want number to be 0. 
17. Take figures and go to sigmaplot and measure standard error, etc.  
18. Use about 30-35 cells per experiment and have an N of at least 3, may need 4 
or 5.  
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